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Existing warfarin dosing methods do not accurately predict warfarin 
maintenance doses for patients in the lower or upper quartile of dose 
requirements. It was argued that this is related to the use of the international 
normalised ratio (INR) as a sole marker of anticoagulation for warfarin dose 
individualisation. The overarching premise of this thesis was that the 
coagulation proteins are on the causal path from warfarin dose to INR response 
and that a measure of coagulation protein response in addition to the INR will 
be helpful in the prediction of future anticoagulant response. The aim of this 
thesis was to apply pharmacometric methods to understand the coagulation 
kinetics underpinning the warfarin dose response and to introduce a new 
perspective to the prediction of anticoagulant response to warfarin. 
A joint model was developed to quantify the influence of warfarin on all 
six vitamin K-dependent coagulation proteins (factors II, VII, IX, X, and proteins 
C and S) simultaneously. The full correlation structures that exist between 
parameters at the individual level and between residual errors of different 
coagulation proteins were accounted for. Of all the coagulation proteins 
considered, factor VII was found to have the shortest degradation half-life and 
will therefore be the first to reach a new steady-state following a perturbation 
introduced by warfarin. 
Subsequently, the influence of coagulation proteins and their interactions 
on the INR was explored based on simulations from a mechanistic coagulation 
network model. A sensitivity analysis revealed that INR is most sensitive to 
factor VII and an isobologram analysis demonstrated that the presence of more 
than one coagulation protein deficiencies is redundant for INR effect. It was 
proposed that factor VII is the most influential on the INR and that the use of 
factor VII as a marker of anticoagulation (in addition to the INR) may improve 
the prediction of the anticoagulant response.   
A factor VII-based method for the prediction of anticoagulant response to 




coagulation network model. The prediction method was shown to be associated 
with minimal bias and its use was illustrated using data from one typical 
simulated patient and two real patients supporting a proof-of-principle. 
Finally, a framework for systematic evaluation of model assumptions was 
developed. In particular, a flowchart was proposed to evaluate assumptions 
based on the impact and the probability of assumption violation. The 
assumptions underpinning the pharmacometric analyses presented in this thesis 
were evaluated and used to illustrate the utility of the proposed framework. 
 In this thesis, both the top-down and bottom-up pharmacometric analyses 
were applied to explore the coagulation kinetics underpinning warfarin dose 
response. Standard methods such as population analysis, model simulations, 
isobologram analysis, and sensitivity analysis were employed. A heuristic 
model-order reduction method was experimented and seemed to work well 
although generalisation of the method to other settings requires prospective 
testing.   
The work conducted in this thesis offered a new perspective on the 
prediction of anticoagulant response. The next step would be to extend the 
current method to the prediction of warfarin maintenance dose. This would 
require setting up and evaluating a dose individualisation algorithm (perhaps 
Bayesian) that incorporates a factor VII-INR bivariate response variable. Last but 
not least, a framework for systematic evaluation of assumptions was proposed. 
An important future step would be to apply the framework to a series of other 
settings to fully explore the utility and robustness of the framework to different 
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1.1. Introduction to the thesis 
Warfarin is the mainstay oral anticoagulant therapy that is indicated for the 
treatment and prevention of thomboembolic disease. The physiological response 
to warfarin is a reduction in the concentrations of functional vitamin K-
dependent coagulation proteins (factors II, VII, IX, X, and proteins C and S) that 
leads to a prolonged clotting time and is usually monitored clinically using the 
international normalised ratio (INR). Sub-therapeutic INR is associated with 
increased clotting risk while supra-therapeutic INR carries a significant risk of 
major bleeding events [1]. The safe and effective use of warfarin is therefore 
dependent on maintaining the INR within a narrow therapeutic range.  
The goal of warfarin dose individualisation is to predict the warfarin 
maintenance dose that will keep the steady-state INR (𝐼𝑁𝑅𝑆𝑆) within this range. 
Several tools, usually with an underpinning model, have been developed to aid 
warfarin dose selection in the clinic. Despite a significant body of literature in 
this area, prediction of anticoagulant response and warfarin maintenance dose 
in patients remain inaccurate [2-7]. This highlights the difficulty in choosing an 
optimal warfarin maintenance dose for individual patient where it requires a 
quantitative understanding of warfarin dose response while accounting for the 
inherent variability between and within patients.  
The work conducted in this thesis involves the application of 
pharmacometric methods to understand warfarin dose response. 
Pharmacometrics is the science of quantitative pharmacology. It involves the 
development and application of mathematical and statistical models to (1) 
describe, understand, and predict the pharmacokinetics (PK) and 
pharmacodynamics (PD) of a drug; (2) quantify the variability between and 
within patients as well as the uncertainty in predictions; (3) rationalise decision 
in the drug development process and optimisation of drug therapy in routine 
clinical setting; and (4) design studies to generate data for inferential purposes.   
Pharmacometric analysis has an inherent utility in dose individualisation. 
It is unique in that it allows the partitioning and quantification of variability 
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between and within patients. Variability between patients may be predictable 
due to dependence of PK or PD process on individual characteristics while the 
remaining variability are unexplained and assumed random. Understanding the 
variability between patients and its effect on dose requirements is useful to 
rationalise dosing decisions and to tailor the dosing regimen to suit the needs of 
a specific patient. Indeed, this provides the basis for warfarin dose 
individualisations in clinical practice where patient characteristics (e.g. 
concomitant drugs) [8-16] and measures of anticoagulant response (e.g. INR) [12, 
17, 18] are used to predict the between-patient differences in warfarin dose 
response. From a practical perspective, because the pharmacometric approach to 
analysis is based on population data (and not solely on data from any one 
particular patient), it has an innate ability to cope with sparse data that are 
typically generated during routine patient care [19-21].   
The reason for the poor predictive performance of available warfarin 
dosing tools is not fully understood [5]. It is probable that empirical models (e.g. 
those using a linear function [12, 22-25]) underpinning these dosing methods are 
too simple to accommodate the complexity of the coagulation system. 
Importantly, it is believed that much of the issues with the poor predictive ability 
of existing tools relate to the use of INR, a blunt estimate of coagulation that is a 
composite of multiple coagulation proteins, as a sole marker of anticoagulant 
response to guide warfarin dosing [12, 17, 18, 22, 23, 25-30]. 
The overarching premise of this thesis is that a measure of coagulation 
protein in addition to the INR will better inform the prediction of anticoagulant 
response and warfarin dose requirement. This was argued and rationalised 
based on the full causal path of warfarin dose response from warfarin dose, 
warfarin PK, warfarin PD, coagulation proteins’ response, coagulation network 
response to the INR response. Here, due to the its downstream location on the 
causal path, INR response is a conglomerate measure of the variability in all of 
the upstream components. Then, in theory, inclusion of the coagulation protein 
response will provide a signal from the system that lies causally between 
warfarin concentration and INR response and as such will be helpful in 
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delineating the different sources of variability in anticoagulant response and in 
elucidating the dose response relationship of warfarin. A choice of a coagulation 
protein that is particularly sensitive to warfarin and also influential on the INR 
would be appropriate.  
To this end, pharmacometric models that vary in the level of mechanistic 
detail were developed and applied in this thesis. In the first stage, a semi-
mechanistic, compartmental model was developed to quantify the time course 
of warfarin influence on factors II, VII, IX, and X, and proteins C and S 
simultaneously. Subsequently, a fully-mechanistic model of the coagulation 
network [31], which includes components of in vivo coagulation and in vitro 
blood coagulation tests (e.g. INR), was used to explore the effect of coagulation 
proteins and their interactions on the INR in order to identify a sensitive and 
influential coagulation protein for the prediction of anticoagulant response. This 
involves testing hypotheses and what-if scenarios via simulations from the 
model that are otherwise not permissible within standard experimental 
framework due to (1) the complex interactions between components of the 
coagulation network; (2) the different orders of magnitude in the rate of change 
and turnover rate of coagulation components; and (3) the fact that the act of 
drawing a blood sample can itself activate the coagulation system. In the 
development of a method for the prediction of warfarin anticoagulant response, 
a heuristic model reduction method was employed in which a statistical model 
was used to approximate the fully-mechanistic model such that all responses of 
interest were captured over an appropriate span of the input-output 
relationship. In doing this the statistical model is considerably simpler than the 
full mechanistic model and is amenable to manipulation for clinical application, 
particularly the potential for Bayesian forecasting. Finally, this work culminates 
in the development of a framework to explore and formalise model-based 
assumptions and limitations. This final component is critical in formally 
addressing the model-based components of this thesis that underpin the 
proposed method for the prediction of warfarin anticoagulant response. 
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1.1.1. Aims of the thesis 
The aim of this thesis was to apply pharmacometric methods to understand 
the coagulation kinetics underpinning the warfarin dose response and to 
introduce a new perspective to the prediction of anticoagulant response to 
warfarin. There were four specific objectives: 
1. To develop a model to quantify the relationship between warfarin and 
vitamin K-dependent coagulation proteins (Chapter 2), 
2. To explore vitamin K-dependent coagulation proteins as drivers of the 
anticoagulant response (Chapter 3),  
3. To develop a coagulation protein-based method for the prediction of 
anticoagulant response to warfarin (Chapter 4), and 
4. To develop a framework for evaluating assumptions intrinsic to a 
pharmacometric model (Chapter 5). 
1.1.2. Overview of the introduction 
The introduction is divided into four sections: 
1. Section 1.2 Pharmacometrics (a brief overview of models, types of models, 
and model-building approaches),   
2. Section 1.3 Modelling drug concentrations and responses, 
3. Section 1.4 Modelling physiological systems, drug concentrations, effects, 
and responses, and 
4. Section 1.5 Warfarin and anticoagulant response.   




The term pharmacometrics was first coined by Benet and Rowland, the 
editors of the Journal of Pharmacokinetics and Biopharmaceutics in 1982 [32]. 
The field of pharmacometrics has enjoyed rapid advances in the past 20 years. 
This is attributable to successful application of pharmacometrics to various 
stages of the drug development process, from drug discovery (e.g. identification 
of drug target) through preclinical development (e.g. dose selection for first-in-
human clinical trial) to clinical development (e.g. establishment of drug safety 
profile) to regulatory approval (e.g. labelling requirements) and post-marketing 
studies and optimisation (e.g. dose optimisation for special populations).  
In clinical practice, pharmacometric analysis provides a useful means for 
dose individualisation by partitioning and quantification of (predictable or 
unpredictable) variability in dose-concentration-response relationships between 
and within patients. Understanding the variability between patients and its 
effect on dose requirements is useful to rationalise dosing decisions and to tailor 
the dosing regimen (dose, dosing frequency, and dosing time of a drug) to suit 
the needs of a specific patient. Indeed, this forms the basis of dose 
individualisations in clinical practice for drugs that exhibit a narrow therapeutic 
window and large between-subject variability in dose-concentration-response 
relationships. In this setting, patient covariates (e.g. renal function) and / or 
response measures (i.e. markers of effect of a drug) that are predictive of future 
responses to drug are typically used for dose individualisations. This allows the 
patient to derive the most benefit from medicines use while minimising the risk 
of adverse drug effects to the patient.    
Models are an integral part of pharmacometric analysis. In the following 
sections, different types of pharmacometric models and model-building 
approaches are outlined.     
  




A model is a construct that represents a simplified version of the reality.   
For instance, a globe is a model of the earth. A globe is a miniature non-working 
version of the earth. Typically, it contains details such as geographic coordinate 
systems (longitude and latitude) and representations of land masses and water 
bodies, boundaries of countries, topographies, et cetera. An example in the 
context of pharmacometrics is a compartmental PK model. The compartmental 
structure of these models provide a framework to describe key PK processes: 
absorption, distribution to tissues, metabolism, and elimination of drugs. The 
compartments do not necessarily relate to a true physiological space but 
represent a simplified and abstract version of a (complex) physiological system 
that provides an adequate description of the observed time course of drug 
concentrations. A detailed description of compartmental PK model is provided 
in Section 1.3.1.1.   
Pharmacometric analyses are underpinned by mathematical models to 
describe the relationship between input variables (e.g. drug doses) and output 
variables (e.g. drug concentrations and system responses). The general form of a 
mathematical model is given as follows:  
 
𝒚 = 𝒇(𝜽, 𝑿) + 𝜺 
Equation 1.1 General form of a mathematical model. 
 
Here, the input variables 𝑿(𝑛 × 𝑝) are related to the output variables 𝒚(𝑛 × 1) by 
a mathematical function, 𝒇(𝑛 × 1), which contains a set of unknown constants 
termed parameters, 𝜽(𝑝 × 1), and residual unexplained error that is given as 𝜺(𝑛 ×
1). Note that in this thesis, matrices are capitalised and both matrices and vectors 
are written in bold font.  
Besides characterising a given input-output relationship, a mathematical 
model can be applied to learn about the underlying system, to generate and test 
hypotheses, to answer what-if questions, and to make predictions about future 
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instances involving the system (e.g. future patients). Practical applications 
dictate that models must be simple enough for practical use while capturing 
important aspects of the relationships of interest to the level of detail that is 
sufficient for the intended purpose. Models are therefore not meant to reflect all 
of reality – a point well made by George Box, who is considered one of the great 
statistical minds of the 20th century, in his widely quoted remark that [33]:  
 
“Essentially, all models are wrong, but some are useful”. 
George E. P. Box (statistician, 1918-2013) 
 
1.2.2. Empirical versus mechanistic models 
A simplistic view of pharmacometric models is that they are either 
developed based on data (empirical models) or mechanisms (mechanistic models). 
It is important to note a continuum of possibilities between fully-empirical and 
mechanistic models and that it is vital to consider the intended use of the model 
when choosing between model types during the model development process.    
The development of an empirical model is driven by data and the principle 
of parsimony. An empirical model is (in theory) the simplest model that provides 
an adequate description of the data at hand. Note here that the mechanisms, be 
it the pharmacology or the biology, from which the data arose are not necessarily 
accounted for and as such empirical models typically have poor predictive 
performance when extrapolating to new conditions [34]. Prominent examples of 
empirical model are models that are based on parsimonious use of polynomials 
or exponentials. The 𝐸𝑚𝑎𝑥  model (Section 1.3.1.2), which is ubiquitous in 
pharmacology research, is also arguably empirical if it is applied to data out of 
the receptor binding context. A simple clinical example of an empirical model is 
shown in Equation 1.2 where INR is modelled as an empirical function of factors 
II, VII, X, protein C, and the prothrombin fragment (F1+2) [35]. In this example, 
the model provides an adequate fit to the INR data. However, the linear nature 
Chapter 1: Introduction  
11  
 
of the model and the inclusion of protein C are unlikely to be consistent with 
known physiology of blood coagulation underpinning the INR test.   
 
𝐼𝑁𝑅 = 𝜃1 ∙ 𝐼𝐼 + 𝜃2 ∙ 𝑉𝐼𝐼 + 𝜃3 ∙ 𝑋 + 𝜃4 ∙ 𝑃𝐶 + 𝜃5 ∙ (𝐹1 + 2) 
Equation 1.2 An empirical model for the INR [35]. 
 
Semi-empirical models are derived by incorporating components of 
essential prior information regarding the underpinning pharmacology and 
biology to the model [36, 37]. Typical examples of semi-empirical models are 
compartmental PK models (see Section 1.3.1.1), which are developed to 
characterise the time course data of drug concentrations by considering the 
different PK processes (absorption, distribution, metabolism and elimination of 
drugs) but do not necessarily delve into specifics of the physiological 
mechanisms involved. Semi-mechanistic models, on the other hand, contain 
greater level of mechanistic detail and address missing knowledge of the system 
by heuristic imputation of empirical functions. For the purpose of this thesis, 
empirical, semi-empirical, and semi-mechanistic models are collectively referred 
to as top-down models. A detailed description and examples of top-down models 
is provided in Section 1.3.    
At the other end of the spectrum, mechanistic models are developed fully 
based on mechanisms and generally only utilise data for model calibration and 
validation. In contrast to top-down models, mechanistic models are not 
necessarily bound by the principle of parsimony and are therefore generally 
more complex with respect to model structure and the number of parameters. 
Looking beyond the model complexity, mechanistic models contain valuable 
systems information, allow for extrapolation and prediction of future data, and 
are inherently useful to improve our understanding of complex physiological 
systems considering that hypotheses can be generated and tested within the 
simulation framework to explore what-if scenarios. Prominent examples of 
mechanistic model are those under the banner of quantitative systems 
pharmacology (QSP) models (see Section 1.4.1). In this thesis, mechanistic 
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models are referred to as bottom-up models. Details and examples of bottom-up 
models are available in Section 1.4.     
In this thesis, both top-down and bottom-up models are utilised to 
understand the coagulation kinetics underpinning the warfarin dose response. 
Chapter 2 outlines the development of a top-down, compartmental model to 
quantify the observed time course of warfarin dose and effect on vitamin K-
dependent coagulation proteins. Chapter 3 describes the use of a bottom-up QSP 
model of the coagulation network [31, 38], which includes mechanistic 
components of in vivo coagulation and in vitro blood coagulation tests, to explore 
coagulation proteins as drivers of the INR. This is followed by Chapter 4, which 
details the development of a coagulation protein-based method for the 
prediction of anticoagulant response to warfarin. Here, a heuristic model-order 
reduction technique in which an empirical approximation to the QSP was 
developed. Finally, in Chapter 5, a framework for evaluating assumptions 
intrinsic to a top-down or bottom-up pharmacometric model is proposed.     
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1.3. Modelling drug concentrations and responses 
Understanding, quantifying, and predicting drug concentrations and 
effects is of pivotal importance to both drug development and dose 
individualisation in clinical practice. Here, the expected drug concentrations and 
responses for a given dose, the time course of desired and adverse effects, and 
the associated variability between and within patients relate to the PK and PD 
properties of the drug [39]. In this thesis, a drug effect is distinguished from a 
system response. A drug effect relates to primary drug action or the influence of 
the drug on some components of the system, for instance, enzyme inhibition or 
target inactivation, whereas a response is mediated by the system and could 
include a measurable marker of a drug effect. Then, warfarin’s inhibitory action 
on vitamin K epoxide reductase (VKOR) and the influence on coagulation 
protein concentrations are examples of drug effect. On the other hand, INR 
represents a response from the coagulation network where various zymogens, 
activating enzymes, and cofactors work in concert that culminates in a stable clot 
formation. In this section, basic principles of PK and PD as well as common top-
down models employed to characterise drug concentrations and responses are 
introduced. This is followed by a description of the statistical methods used for 
the development of these top-down models.       
1.3.1. Models for drug concentrations and responses 
1.3.1.1. PK models 
PK is a discipline within pharmacology that relates the given dose(s) of a 
drug to the time course of drug concentrations in the body. The PK properties of 
a drug is governed by absorption, distribution, metabolism, and excretion of the 
drug. These four processes are abbreviated to ADME.  
The goal of a PK model is to describe and predict the time course of drug 
concentrations in a physiological matrix, most often, the plasma drug 
concentrations. The plasma drug concentrations (𝐶) at a given time after dose (𝑡) 
can be modelled as a function of the administered dose (𝐷) and 𝑡 via a vector of 
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parameters, 𝜽𝑷𝑲(𝑝𝑃𝐾 × 1). The error in the prediction of 𝐶 is denoted as 𝜀𝑃𝐾. The 
general mathematical form of a PK model is given in Equation 1.3.      
 
𝐶 = 𝑓𝑃𝐾(𝐷, 𝑡, 𝜽𝑷𝑲) + 𝜀𝑃𝐾(𝑡) 
Equation 1.3 General mathematical form of a PK model. 
 
Common PK parameters of interest include clearance (𝐶𝐿 ), volume of 
distribution (𝑉), and derived parameters such as the first-order elimination rate 
constant ( 𝑘 =
𝐶𝐿
𝑉
). 𝐶𝐿  is a proportionality constant that relates the rate of 
elimination to the drug concentration. It represents a measure of the functional 
capacity of the physiological system for drug elimination. 𝑉, on the other hand, 
relates to the extent of drug distribution and is influenced by body structure and 
composition. For drugs administered extravascularly, the bioavailability (𝐹) and 
the first-order absorption rate constant (𝑘𝑎), or similar rate parameter, are also of 
interest.  
PK models are typically constructed using compartments. In 
compartmental modelling, the complex physiological system is reduced to a 
finite number of compartments to characterise drug disposition (distribution 
and elimination). A compartment represents a hypothetical space that consists 
of a group of tissues that display similar kinetic profiles. It is important to note 
that a compartment does not necessarily represent a true physiological space and 
specific tissues that make up a compartment are unknown. 
The number of compartments for a PK model of a drug relates to the 
disposition kinetics of the drug (not input process) and is typically guided by the 
observed time course of drug concentrations. One of the simplest and most 
commonly applied PK models is the one-compartment model with first-order 
absorption and elimination (see panel a, Figure 1.1). Here, the drug distribution 
occurs so rapidly that it appears as if it is an instantaneous process. Then, when 
absorption and distribution are completed, the plasma drug concentrations will 
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exhibit a mono-exponential decline and will appear linear on the logarithmic 
scale (see panel b, Figure 1.1).  
For this model, the rate of change of the amount of drug in the depot (𝐴1) 
and in the central compartment (𝐴2) after administration of a defined dose (D) 




= −𝑘𝑎 ∙ 𝐴1;      𝐴1𝑡=0 = 𝐹 ∙ 𝐷 
𝑑𝐴2
𝑑𝑡







Equation 1.4 ODEs for a one-compartment PK model with first-order absorption and 
elimination. Here C represents the concentration in the central compartment. 
 
Solving the above-mentioned ODEs for the central compartment gives the 
corresponding closed-form, algebraic solution: 
 
𝐶 =
𝐹 ∙ 𝐷 ∙ 𝑘𝑎






𝑉 𝑡 − 𝑒−𝑘𝑎𝑡) 
Equation 1.5 Closed-form solution for a one-compartment PK model with first-order 
absorption and elimination. 
 
 




Figure 1.1 Compartmental models. Panel a shows the schematic of a one-compartment 
PK model with first-order absorption and elimination. Panel b shows the corresponding 
time course of plasma drug concentrations (D = 10 units, F = 1, ka = 2 h-1, CL = ln 2 
L/h, V = 1 L). Panel c shows the schematic of a two-compartment PK model with first-
order absorption and elimination. Panel d shows the corresponding time course of plasma 
drug concentrations (D = 10 units, F = 1, ka = 2 h-1, CL = 3 L/h, V1 = 1 L, k12 = 0.5 h-1, 
k21 = 0.25 h-1).  
 
In a two-compartment model, an additional compartment is included to 
account for the relatively slow drug distribution into some tissues which is 
usually termed the peripheral compartment (see panel c, Figure 1.1). The resulting 
time course of plasma drug concentrations will show a biphasic decline on the 
semi-logarithmic scale where a distinct phase driven predominantly by the 
distribution process is visually apparent (see panel d, Figure 1.1). In practice, it is 
rare for more than three compartments to be needed to empirically characterise 
the plasma PK profile for a drug.  
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Finally, the mathematical functions and structure of the compartmental 
models may be modified to account for different modes of drug administration 
or more complex ADME processes, for instance, absorption lag, target-mediated 
drug disposition, drug interactions, autoinduction and autoinhibition. 
1.3.1.2. PD models 
PD is a discipline within pharmacology that relates the drug concentrations 
to the observed pharmacological effects. The goal of a PD model is to describe 
and predict the drug effects (𝐸) based on given concentrations of a drug (𝐶) via 
a vector of parameters, 𝜽𝑷𝑫 (𝑝𝑃𝐷 × 1). The error in the prediction of 𝐸 is denoted 
as 𝜀𝑃𝐷. The general mathematical form of a PD model is given in Equation 1.6.   
 
𝐸 = 𝑓𝑃𝐷(𝐶, 𝜽𝑷𝑫) + 𝜀𝑃𝐷(𝐶)  
Equation 1.6 General mathematical form of a PD model. 
 
Drug effects are underpinned by classical receptor theory [40-42]. In this 
thesis, receptor ligands will be discussed in the context of drugs. These terms 
will therefore be used interchangeably. Reversible binding of the drug to a 
receptor is governed by the law of mass action [41]. At equilibrium, the 
concentration of drug-receptor complex (𝐶𝑅) depends on drug concentration (𝐶) 
and the equilibrium dissociation constant of the drug for the receptor (𝐾𝐴), which 
is a reciprocal measure of affinity. Because the system has a finite number of 
receptors, receptor binding is limited by the total concentration (or capacity) of 
available receptors in a system (𝑅0). Receptor binding can be suitably described 
by using a hyperbolic function, which is typically used to characterise capacity-
limited processes:  
 




Equation 1.7 Receptor binding model. 
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The relationship between receptor occupancy (i.e. 𝐶𝑅 from Equation 1.7) 
and drug effect (𝐸) can be described by using a proportionality constant known 








Equation 1.8 Intrinsic activity model. 
 
Here, 𝐸𝑚  represents the maximum effect in a system. Substitution of the 
expression for 𝐶𝑅  from Equation 1.8 into Equation 1.7 and upon further 
simplification, gives the standard hyperbolic function, the 𝐸𝑚𝑎𝑥 model, which is 
one of the most frequently used PD models in pharmacology research:   
 




Equation 1.9 The Emax model. 
 
Here, 𝐶50 is the drug concentration that elicits half-maximal effect and is equal 
to 𝐾𝐴 (for the case where the effect is directly linked to receptor binding). 𝐸𝑚𝑎𝑥 is 
the maximum effect of the drug and is given by 𝐸𝑚𝑎𝑥 = 𝛼 ∙ 𝐸𝑚. Drugs with 𝛼 = 1 
and 𝛼 = 0.4  are therefore capable of eliciting 100% and 40% of system’s 
maximum effect, respectively. In the 𝐸𝑚𝑎𝑥  model, the magnitude of the drug 
effect depends positively on the drug concentration. However, the relationship 
between drug concentration and effect is nonlinear (see Figure 1.2) and as such 
doubling the concentration will not result in doubling of drug effect. The drug 
effects will eventually asymptote to a maximum effect (𝐸𝑚𝑎𝑥) despite increasing 
concentrations. 
 




Figure 1.2 The concentration-effect relationship for an Emax model. In this model, Emax = 
100 and C50 = 0.15 units/L.   
 
One of the major drawbacks of the 𝐸𝑚𝑎𝑥  model, which assumes that the 
drug effect is directly proportional to receptor occupancy [40], is that it does not 
consider the chain of events between receptor binding and emergence of drug 
effect (see Figure 1.3). Importantly, the intrinsic activity model is not 
generalisable to all settings, for instance, it does not explain the receptor reserve 
phenomenon where stimulation of only a fraction of the whole receptor 
population evokes an apparent maximal effect [43].  
It was proposed that, in general, two sequential steps, receptor binding 
followed by signal transduction, are required for a drug to elicit an effect (see 
Figure 1.3) [42, 43]. However, the signal transduction process is typically not 
experimentally accessible and as such the exact functional form of the signal 
transduction model that relates receptor occupancy to drug effect cannot be 
determined based on bioassay data of the effects of the drug. 
 




Figure 1.3 Schematic of drug effect. The drug binds to the receptor to induce a 
conformational change in the receptor. A signal or stimulus is generated. The signal 
provokes a series of biochemical reactions that results in the observed drug effect.   
 
It has been shown mathematically that the function resulting from two (or 
more) hyperbolic functions in sequence is also a hyperbolic function [43, 44]. 
Then, given that the drug-receptor binding is hyperbolic (Equation 1.7) and that 
the final concentration-effect relationship observed is commonly hyperbolic, it 
can be deduced that the black box function for signal transduction is necessarily 
hyperbolic. For brevity, the signal transduction model and details of its 
derivation are not shown. A comprehensive description can be found in the 
landmark paper published by Black and Leff [43]. Substitution of the derived 
(empirical) signal transduction model in the receptor binding model (Equation 
1.7) gives the operational model [43]:      











Equation 1.10 Operational model. 
 
Here, 𝜏 is a measure of transduction efficiency of 𝐶𝑅. The operational model can 




 and 𝐶50 =
𝐾𝐴
𝜏+1
. It is evident that 𝐸𝑚𝑎𝑥  and 𝐶50  are inherently 
correlated via parameter 𝜏 and that 𝐶50  is mathematically bounded to be less 
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than or equal to 𝐾𝐴  assuming no change in receptor sensitivity (e.g. due to 
tolerance) over the course of the experiment.  
An extension to the basic 𝐸𝑚𝑎𝑥 model is the sigmoidal 𝐸𝑚𝑎𝑥 model (Equation 
1.11), which includes the estimation of an empirical exponent (𝛾) to modify the 
slope of the concentration-effect curve at half-maximal effect (see Figure 1.4).  
 






Equation 1.11 The sigmoidal Emax model. 
 
Note here that the standard 𝐸𝑚𝑎𝑥 model is a special case of the sigmoidal 𝐸𝑚𝑎𝑥 
model when 𝛾 = 1. In theory, 𝛾 has its basis in cooperativity of ligand binding to 
allosteric sites of the same receptor and it itself represents the number of drug 
molecules binding per receptor (hence supposedly an integer) [45]. However, in 
modelling practice, 𝛾  is often found to achieve non-integer values and its 
inclusion is typically driven by data. In this case, 𝛾  is an empirical shape 
parameter and theoretical interpretation of 𝛾 is generally not possible.   
 
Figure 1.4 The concentration-effect relationship for a sigmoidal Emax model. γ refers to 
the shape parameter. In this model, Emax = 100 and C50 = 0.15 units/L.   
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1.3.1.3. PKPD models 
The PK model that describes the time course of drug concentrations 
(concentration versus time) can be substituted into a PD model that predicts the 
concentration-effect relationship (effect versus concentration) to give the time 
course of drug effects (effect versus time). The general mathematical form of a 
pharmacokinetic-pharmacodynamic (PKPD) model is given in Equation 1.12.       
 
𝐸 = 𝑓𝑃𝐷(𝑓𝑃𝐾(𝐷, 𝑡, 𝜽𝑷𝑲), 𝜽𝑷𝑫) + 𝜀𝑃𝐾𝑃𝐷(𝑡) 
Equation 1.12 General mathematical form of a PKPD model. 
 
Here, the drug effect (𝐸) is a function of time (𝑡) and is dependent on the dose 
(𝐷), vector of PK parameters 𝜽𝑷𝑲(𝑝𝑃𝐾 × 1), and PD parameters 𝜽𝑷𝑫(𝑝𝑃𝐷 × 1). The 
error in the prediction of 𝐸(𝑡) is denoted as 𝜀𝑃𝐾𝑃𝐷.  
PKPD models can be broadly divided into two types according to the 
temporal differences between drug concentrations and effects: (1) immediate 
effects models and (2) delayed effects models.  
1.3.1.3.1. Immediate effects models 
When using an immediate effects PKPD model, it is assumed that the drug 
effect is directly linked to the drug concentration and as such there is no time lag 
between PK and PD. As a result, the PD profile reflects the shape of the PK profile 
and at each time point, the magnitude of drug effect relates positively with the 
drug concentration, for instance, the maximum effect is achieved at the time 
when the drug concentration is at its maximum (panel a, Figure 1.5). Here, since 
PK is linked directly to PD, drug concentration alone is sufficient to describe PD. 
It follows that the PD models presented in Section 1.3.1.2 (e.g. the 𝐸𝑚𝑎𝑥 model) 
can be used to characterise the immediate effects of a drug and that no further 
modification to the model structure is required. However, with few exceptions 
(e.g. binding of unfractionated heparins to thrombin), drug effects are delayed 
in relation to the plasma drug concentrations in reality.   
  




Figure 1.5 The time course of drug concentrations and effects. Panel a shows immediate 
effects. Panel b displays delayed effects relative to drug concentrations (e.g. maximal 
drug effect occurs after the peak plasma concentration). The drug concentrations were 
generated using a one-compartment model with first-order input and output. The drug 
stimulates the production of a physiological intermediate and the delay is attributable to 
the turnover of the intermediates. Both models were generated using D = 10 units, F = 
1, ka = 1 h-1, CL = ln 2 L/h, V = 1 L, Emax = 100, and C50 = 2.5 units/L. The delayed 
effects model has two additional parameters: Rin = 1 unit/h and kout = 0.003 h-1.  
 
1.3.1.3.2. Delayed effects models 
In this setting, drug effects appear delayed in relation to the drug 
concentrations (panel b, Figure 1.5). There are various mechanisms for delayed 
effects including distributional delay to the site of drug action, slow dissociation 
of the drug from the receptor, and mediation of pharmacological responses by a 
physiological intermediate. Integration of the delay mechanism into the PKPD 
model is important for accurate characterisation, prediction, and extrapolation 
of the time course of drug effects (e.g. the onset, intensity, and duration). 
Distributional delay is usually accounted for using an effect compartment model 
and the delay caused by slow dissociation of the drug from the receptor is 
considered by the inclusion of a non-equilibrium receptor binding model. Neither 
the effect compartment model nor the non-equilibrium receptor binding model 
were used in the work presented in this thesis. For a description of these models 
refer to Gabrielsson 2012 [46], Rosenbaum 2016 [47], and Al-Sallami 2009 [39].    
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The mechanism of action for many drugs involves either stimulation or 
inhibition of the production or degradation of a physiological intermediate. 
Often, the turnover of these physiological intermediates is the rate-limiting step 
for the drug effects to be observable. For instance, warfarin inhibits the 
production of vitamin K-dependent coagulation proteins but its effect on the 
coagulation proteins is not immediately evident until existing coagulation 
proteins were degraded. The time course of observed response is then dependent 
on the degradation half-life of the coagulation protein. Delay due to the turnover 
of a physiological intermediate can be accommodated by the inclusion of a 
turnover model [48, 49]. There are two components to a turnover model: (1) 
synthesis of the physiological intermediate and (2) degradation of the 
intermediate. It is usually assumed in a turnover model that: (1) the precursor 
pool for the physiological intermediate is abundant and hence, the synthesis of 
the intermediate is independent of the precursor concentration i.e. a zero-order 
input process; and (2) the degradation of the physiological intermediate is a first-
order process. Taken together, the rate of change of a physiological intermediate 








Equation 1.13 The turnover model. 
 
Here, 𝑅𝑖𝑛 is the zero-order rate of synthesis, 𝑘𝑜𝑢𝑡 is the first-order degradation 
rate constant, and 𝐼𝑡=0 is value of the physiological intermediate at equilibrium 
when the rate of synthesis equals to that of degradation.  
A drug can either inhibit or stimulate the synthesis or the degradation of a 
physiological intermediate which provides the four model constructs used to 
describe these mechanisms (see Table 1.1) [48, 49]. The choice of either Model I, 
II, III, or IV should align with the mechanism of drug action. For instance, in 
Chapter 2, Model II (inhibition of synthesis) was deemed appropriate to describe 
warfarin’s inhibitory action on the production of functional vitamin K-
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dependent coagulation proteins. Another example is the use of Model IV 
(inhibition of degradation) to characterise physostigmine’s inhibitory action on 
the degradation of acetylcholine.  
At a single dose level, the time course of drug effects of Models I, II, III, and 
IV may be indistinguishable from that of an effect compartment model and 
therefore data in isolation of mechanistic insight should not be used to define the 
PKPD link. However, the time to maximum drug effect (𝑡𝐸,𝑚𝑎𝑥) of these models 
appear to increase with dose (Figure 1.6). On the contrary, in the effect 
compartment model, the 𝑡𝐸,𝑚𝑎𝑥  remains constant with dose (not shown). The 
difference in dose-𝑡𝐸,𝑚𝑎𝑥 relationship is an important characteristic that is useful 
for distinguishing delayed effects that arise from distributional delay or from 
drug action on the turnover of a physiological intermediate.  
 
Table 1.1 Four basic models to represent drug action on the turnover of a physiological 
intermediate of interest. EC50 is the drug concentration that elicits half-maximal 
stimulatory effect. Emax is the maximum stimulatory effect of the drug. IC50 and Imax are 
the inhibitory counterparts of EC50 and Emax.  
Model ID Mechanism Model 




= 𝑅𝑖𝑛 (1 +
𝐸𝑚𝑎𝑥 ∙ 𝐶
𝐸𝐶50 + 𝐶








= 𝑅𝑖𝑛 (1 −
𝐼𝑚𝑎𝑥 ∙ 𝐶
𝐼𝐶50 + 𝐶








= 𝑅𝑖𝑛 − 𝑘𝑜𝑢𝑡 (1 +
𝐸𝑚𝑎𝑥 ∙ 𝐶
𝐸𝐶50 + 𝐶








= 𝑅𝑖𝑛 − 𝑘𝑜𝑢𝑡 (1 −
𝐼𝑚𝑎𝑥 ∙ 𝐶
𝐼𝐶50 + 𝐶









Figure 1.6 The time course of drug effects for the four basic models used to represent 
drug action on the turnover of a physiological intermediate of interest. The drug effects 
were simulated from a one-compartment model (with first-order input and output) that 
is linked to a turnover model via one of the four models described in Table 1.1. Panels a, 
b, c, and d relate to Model I (stimulation of synthesis), II (inhibition of synthesis), III 
(stimulation of degradation), and IV (inhibition of degradation), respectively. Three 
different dose levels were simulated: D = 10 mg (blue line), D = 100 mg (black line), and 
D = 1000 mg (red line). In these models, F = 1, ka = 100 h-1, CL = 14 L/h, V = 20 L, Rin 
= 10 units/h, kout = 0.2 h-1, Emax = 5, EC50 = 1 mg/L, Imax = 1, and IC50 = 0.1 mg/L. E 
represents drug effect and tE,max is the time to maximum drug effect.   
  
1.3.1.4. KPD models 
Both PK and PD data are required for the development of a PKPD model. 
For practical reasons or by means of study design, there may be few or no drug 
concentration data available for analysis, for instance, in phase III clinical trials 
and in routine clinical practice. Hence, a class of general models, the kinetic-
pharmacodynamic (KPD) model, that is built solely on dose-effect-time data was 
introduced [50-53]. A schematic of a typical KPD model is shown (panel b, Figure 
1.7) and is compared and contrasted to a PKPD model (panel a, Figure 1.7).   





Figure 1.7 Schematic of the structure of a PKPD model example (panel a) and a KPD 
model example (panel b). Note the absence of PK samples necessitates the assumption of 
a PK model structure for KPD modelling.     
 
In contrast to a PKPD model, where the drug concentrations (𝐶) are used 
as driver of PD effects (Equation 1.9), standard KPD model uses the elimination 
rate of the drug (𝐸𝑅) to drive the PD dynamics (Equation 1.14) [50]. 
 




Equation 1.14 The drug effect driven by the elimination rate of the drug. 
 




𝐴50 = 𝑉 ∙ 𝐶50 
Equation 1.15 Relationships between C50, EDK50, and A50. 
 
Here, 𝐸𝐷𝐾50  is a conglomerate solution of 𝐶50  and 𝐶𝐿  (Equation 1.15) and it 
represents the drug elimination rate that gives half-maximal effect. 
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Alternate parameterisation of a KPD model, where the PD effect is driven 
by the amount of drug in the body (𝐴), had been proposed. Essentially, this 
parameterisation can be thought of as a simplification of the 𝐸𝐷𝐾50 
parameterisation by factoring out the influence of 
𝐶𝐿
𝑉
 (Equation 1.15) to give: 
 




Equation 1.16 The drug effect driven by the drug amount in the body. 
 
Here, 𝐴50  is a composite of 𝐶50  and 𝑉  (Equation 1.15) and it represents the 
amount of drug in the body that gives half-maximal effect.    
KPD analysis has been successfully applied to modelling a wide range of 
therapeutics [54-58]. In particular, the 𝐸𝐷𝐾50 parameterisation is widely applied 
[54, 59, 60] but from a theoretical viewpoint, how the elimination rate could drive 
PD is not pharmacologically intuitive and likely to be inconsistent with classical 
receptor theory underpinning drug effects. Furthermore, in 𝐸𝐷𝐾50 
parameterisation where 𝐸𝑅 =
𝐶𝐿
𝑉




introduced and enforced mathematically, which means that estimation of 𝐸𝐷𝐾50 
will always be dependent on 
𝐶𝐿
𝑉
 and may therefore lead to potential numerical 
instability during the estimation process. In this thesis, a KPD model was used 
to characterise the observed time course of warfarin dose and anticoagulant 
response. See Chapter 2 for a detailed description.   
PK and PD data provide considerable insight into both the PK and PD 
aspects of a drug. However, in the absence of PK data, an imputation of the PK 
model structure is required. In the case of a misspecification in the PK model 
structure, parameter estimates (e.g. 𝐴50, 𝑘𝑜𝑢𝑡) may be biased and random-effects 
parameters (e.g. variance of between-subject variability [ 𝜔2  in NONMEM® 
parlance])  may be inflated although it is possible for the goodness-of-fit of the 
KPD model to appear robust to the misspecification [58, 61].  
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Due to the absence of PK data, parameter estimation for KPD models 
requires special consideration. Some KPD model parameters may not be 
structurally identifiable i.e. an infinite set of parameter values results in the same 
output (PD predictions) even given perfect input-output conditions (dose-effect-
time data) [62-65]. This was explored and reported in Chapter 2. In addition, in 
the setting of imperfect input-output data, some KPD model parameters may not 
be able to be estimated with reasonable precision i.e. not deterministically 
identifiable [66, 67]. Here, the use of a wider dose range, different route of 
administrations, and more intensive PD sampling may alleviate some of the 
deterministic identifiability issues.  
1.3.2. Statistical methods 
In pharmacometrics, top-down models are usually developed using the 
nonlinear mixed-effects approach in order to characterise the observed 
concentration and / or response data for a set of individuals. This approach is 
based on a hierarchical structure where typically, two levels of hierarchy are 
considered; (1) at the level of the within-subject effects (i.e. a model for the data) 
and (2) at the level of the between-subject effects (a model for the individuals). 
More levels of hierarchy may be specified as required. The nonlinear mixed-
effects approach to model development will be introduced followed by a 
description of the estimation methods commonly used. A more detailed and 
technical description of nonlinear mixed-effects modelling and estimation 
methods is provided by Davidian and Giltinan 1995 [20], Lavielle 2014 [21], and 
Bonate 2011 [19].       
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1.3.2.1. Models for the data  
The first level in the model hierarchy describes the structural model that is 
used for all individuals, where each individual is allowed to have different 
parameter values, and also includes a statistical model for residual errors i.e. the 
residual unexplained variability (RUV). Assuming additive error, observations of 
the 𝑖th individual, 𝒚𝒊, can be described by the general function: 
 
𝒚𝒊 = 𝒇(𝒕𝒊, 𝜷𝒊) + 𝜺𝒊 
𝜺~𝑖𝑖𝑑 𝑁(0, 𝜎2). 
Equation 1.17 Model for the observations of the ith individual. 
 
Here, the model describes the systematic and random variation associated with 
observations of individuals. Systematic variation is characterised through the 
mathematical function 𝒇(𝑛𝑖 × 1)  that is dependent on time, 𝒕𝒊(𝑛𝑖 × 1) , and a 
vector of parameters, 𝜷𝒊 ( 𝑝 × 1 ). Random variation, on the other hand, is 
represented by an assumption on the RUV, 𝜺  (i.e. 𝜺𝒊  for all individuals). It 
describes how observations are distributed around the values predicted by the 
model. RUV may arise due to various factors including process noise (e.g. error 
in recorded sampling time or dose), measurement noise (e.g. assay error), 
moment-to-moment variability, and model misspecification (e.g. “All models are 
wrong”). Most often, it is assumed that: (1) 𝜺 have a mean of zero, (2) 𝜺 are 
uncorrelated, (3) 𝜺 have common variance 𝜎2 and are identically distributed for 
all time points and covariates, and (4) 𝜺 are normally distributed. Taken together, 
elements of 𝜺 are independent and identically distributed (iid) from a normal 
distribution with a mean of zero and a variance of 𝜎2 . If these assumptions 
appear to be violated (e.g. non-normality), a transformation of the 𝜺 space (via 
transformation of 𝒚 [i.e. 𝒚𝒊 for all individuals] or 𝜺 itself) can be considered to 
avoid assumption violation and to provide an apparent distribution that is useful 
for modelling the available data. An example is the Box-Cox transformation 
function (𝜻) that transforms 𝒚 via a suitably fixed or estimated parameter 𝜆 to 
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account for non-normality in the distribution of 𝜺 (Equation 1.18). Note here that 
logarithmic transformation is a special case of Box-Cox transformation when 𝜆 =





 , 𝜆 ≠ 0 
𝑙𝑛 𝒚 , 𝜆 = 0
 
Equation 1.18 Box-Cox transformation. 
 
In this thesis, because all vitamin K-dependent coagulation proteins were 
assayed in the same blood sample, part of the assay error and all of the process 
error will be correlated across different coagulation proteins for the same sample. 
A correlation structure for 𝜺  of different coagulation proteins (termed L2 
correlation in NONMEM® parlance) was introduced to the model (Chapter 2).   
1.3.2.2. Models for the BSV 
The second level in the model hierarchy describes the between-subject 
variability (BSV) in the individual parameters 𝜷𝒊 . Part of the BSV may be 
predictable. The predictability may arise from factors internal (e.g. phenotypic 
and genotypic characteristics) or external (e.g. extracorporeal drug removal, 
drug formulation, interacting drugs) to the individual. The remaining BSV are 
unexplained (e.g. yet to be understood influences of the genome) and assumed 
random. To account for these possibilities, a model for the dependence of 𝜷𝒊 on 
systematic and random components is required:     
 



























Equation 1.19 Model for the parameters of the ith individual. 
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Here, 𝜷𝒊 is modelled as a function, 𝝍(𝑝 × 1), of typical value of parameters, 𝜷 
(𝑝 × 1), covariates, 𝒙𝒊(𝑥 × 1), and unexplained random effects, 𝜼𝒊(𝑝 × 1). It is 
usually assumed that 𝜼 (i.e. 𝜼𝒊 for all individuals) is normally distributed with a 
variance-covariance given by 𝛀(𝑝 × 𝑝). Because physiological parameters have a 
natural lower boundary of zero, an exponential model that constrains the 
parameter estimates to only positive values is usually used to describe BSV 
(Equation 1.20).  
 
𝛽𝑖 = 𝛽 ∙ 𝑒
𝜂𝑖 
Equation 1.20 Exponential model for a parameter of the ith individual that can only 
take on positive values. 
 
1.3.2.3. Software and estimation methods 
Within the pharmacometric community, the most commonly used 
nonlinear mixed-effects modelling software program is NONMEM® (ICON 
Development Solutions, Ellicott City, MD, USA). In this thesis, the first-order 
conditional estimation (FOCE) (with interaction) method was implemented in 
NONMEM® for parameter estimation (see Chapter 2). Other parameter 
estimation methods, such as the first-order (FO) method, Laplacian method, 
expectation-maximisation (EM) method, and the stochastic approximation 
expectation maximisation (SAEM) method, are also available. A technical 
description of these estimation methods can be found elsewhere [19, 21, 68, 69]. 
For nonlinear mixed-effects models, the FO, FOCE, and Laplacian methods 
estimate the population parameters using a maximum likelihood (ML) type 
approach. The likelihood is defined as the probability of the data (𝒚) arising from 
a particular structural model, given a set of parameter values (𝜷, 𝛀, and 𝜎2). 
Unfortunately, in the nonlinear mixed-effects modelling framework it is not 
possible to compute the likelihood for the population model in closed form due 
to the nonlinear way in which the random effects enter the model.  It is necessary, 
therefore, to linearise the model around the random effects in order to compute 
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the expectation and variance of the likelihood. The gradient based ML methods 
in NONMEM are therefore based on a linearisation process.   
The FO method linearises the nonlinear mixed-effects model using a first-order 
Taylor series expansion around the expected value of zero for all elements of 𝜼 
and 𝜺 [68]. More recent estimation methods, FOCE and Laplacian methods, are 
developed around the marginal likelihood (rather than the nonlinear mixed-effects 
model itself) [69]. In these methods, the conditional probability distribution 
function of 𝜼 (conditioned on 𝛀) is linearised using the Taylor series expansion 
to give an approximate closed form solution to the marginal likelihood function. 
Here, both the FOCE and Laplacian methods differ from the FO method in that 
the Taylor expansion uses the expectation of the empirical Bayes estimate (EBE) 
of 𝜼, denoted as ?̂?. Here, the EBEs are obtained using an empirical maximum a 
posteriori (MAP) like estimation based on the present estimate of population 
parameters i.e. 𝜷, 𝛀, and 𝜎2 (prior information) and individual observed data 
(posterior information). Note that the prior information is also based on the 
individual’s data and hence this is not strictly a Bayesian (or MAP) technique. 
Whereas the FOCE method uses a first-order Taylor series expansion, the 
Laplacian method offers a more accurate approximation by using a second-order 
expansion around the EBE of ?̂? [69]. 
Finally, population parameters, 𝜷, 𝛀, and 𝜎2, are estimated simultaneously 
using the ML estimated method where value of parameters that maximise the 
likelihood of the data are taken as the final parameter estimates, denoted as ?̂?, 
?̂?, and ?̂?2. 
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1.4. Modelling physiological systems, drug concentrations, effects, and 
responses 
PK, PD, and PKPD modelling are based on a reductionist approach where 
a component of a system is observed and analysed in isolation of the whole 
system in order to provide insights into system behaviour [70, 71]. The 
reductionist approach to modelling, although convenient, and often works in the 
setting from which it was developed, it does not account for the complex 
interplay between the underpinning components and as such it may have poor 
predictive performance when used to extrapolate.  
1.4.1. QSP model and its application 
In the past decade, there has been a growing interest in QSP models. While 
PKPD models approximate the underlying physiological system using (often) 
simple mathematical functions (e.g. 𝐸𝑚𝑎𝑥  model [Equation 1.9] and turnover 
models [Equation 1.13]), QSP models represent a more holistic approach to 
representing and understanding the system (see Figure 1.8). A QSP model 
typically includes a coherent mathematical representation of key physiological 
connections and system dynamics and also a quantitative characterisation of the 
PK and PD of a drug of interest that are consistent with the current state of 
knowledge [72]. With the added description of the underpinning biology, QSP 
model provides a rational basis to understand how a response is elicited within 
a system following a perturbation introduced by a drug thereby offering a 
complete description of the causal path of the dose and response of a drug 
(Figure 1.8). It is important to note here that Figure 1.8 represents a 
generalisation of the causal path between the dose of a drug and system 
response. The generalisation may not be strictly accurate or hold across all 
instances, drugs, or models. For example, in contrast to that suggested by Figure 
1.8, population PD models may contain a system response component. 




Figure 1.8 Causal path of the dose of a drug and system response. PK relates drug dosing 
to concentration. PD links drug concentration to receptor occupancy and drug effect. 
QSP is unique in that the biological system underpinning a response is considered in 
addition to the PK and PD of the drug. The same figure is reproduced and explained in 
the context of warfarin in Figure 1.15. 
                
It is worth noting that QSP models are usually thought of as an extension 
of classical pharmacology and an area of application of systems biology. This 
was aptly described by Berger and colleagues that: “systems pharmacology involves 
the application of systems biology approaches, combining large-scale experimental 
studies with model-based computational analyses, to study drug activities, targets, and 
effects” [73]. A QSP model that has found a niche in relating drug pharmacology 
to the physiological system can thereby be distinguished from systems biology 
that describes a broader quantitative study of any biology. 
QSP models provide a natural framework to account for both drug-specific 
(e.g. affinity of a drug to its target) and tissue-specific (e.g. transporter density) 
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properties for a comprehensive description of a drug’s pharmacology. For this 
reason, QSP models have important potential for applications in the drug 
development process and clinical setting. The models can be used to test 
conjectures, generate hypotheses, and assess what-if scenarios regarding a drug 
and system of interest via simulations from the model, for instance, to identify 
new drug targets, biomarkers, or mechanisms that underpin drug effects and 
systems responses in addition to testing alternative dosing regimens. The ability 
of QSP models in testing hypotheses is a relatively new construct. Recent work 
conducted by Shivva et al. [74] developed a QSP model to assess mechanisms of 
gastrointestinal absorption of ketones. This model included knockout variants 
within the systems model (e.g. knockout of absorption process or site) in order 
to determine the most likely influence on the plasma profile. Another example is 
the successful application of a bone biology model [75] by the Food and Drug 
Administration (FDA) to identify the need for further dose optimisation of a 
recombinant human parathyroid hormone in the long-term treatment of 
hypoparathyroidism in order to address the safety concerns for hypercalciuria. 
Additionally, QSP models may be applied to guide future research, for example, 
in evaluating if the study design allows observation of important changes in 
safety and efficacy markers of interest. Finally, and probably most importantly, 
the development of the QSP model itself is helpful in both enhancing the drug 
development teams’ level of system knowledge as well as identifying knowledge 
gaps particularly relating to biomarkers. This is important for a true 
understanding of the system and acknowledgement of the limitations attached 
to the model for effective model use and future refinement.    
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1.4.2. Model development 
In general, there are six stages of QSP model development [72]: 
1. identification of needs and formulation of goals,  
2. determination of model scope,  
3. representation of biology, 
4. calibration or estimation of model parameters using data from reference 
subjects, 
5. exploration of knowledge gap and variability, and 
6. application and refinement of model. 
For simplicity, the above six stages of QSP model development are presented as 
unidirectional, although in practice, this is rarely the case. The model 
development process is complex and often involves multiple learn and confirm 
cycles where the structural model may be tested, falsified, reduced, or expanded. 
Because the works reported in this thesis are based on application and not 
development of a QSP model, QSP model development is only briefly 
introduced here. Emphasis will be placed on representation of the biology and 
mathematical formalism of a QSP model, which are essential to facilitate 
understanding and use of a QSP model.       
1.4.2.1. Representing the biology 
In the QSP framework, necessary biological details are usually prioritised 
over the principle of parsimony. Consequently, QSP models tend to be complex 
with (potentially) a vast number of states and parameters. Finding an optimal 
granularity that is the level of detail in which the system and the drug of interest 
are represented in order for a QSP model to be useful, is notoriously difficult and 
is dependent on various factors including (1) the need for the model, (2) the 
amount of available information on the system and the drug of interest, as well 
as (3) availability of collaborators [76]. 
Need: The need for a QSP model typically arises from a set of high priority 
problems or questions that cannot be answered by using standard modelling 
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methodology. Here, a necessary step to QSP model development is the 
specification of a feasible modelling goal after considering and understanding 
the problem context. Subsequently, this will be used in combination with 
available data and knowledge to identify a suitable scope for the model.  
Prior knowledge: The development of a QSP model requires integration of 
diverse data, existing knowledge, educated guesses, and hypotheses into a single 
coherent mathematical framework. To this end, a thorough review of literature 
is usually conducted and sometimes, expert opinions are sought regarding the 
drug and the target or system in which the drug acts in order to arrive at a QSP 
model structure (sometimes termed model topology) that is consistent with the 
current state of knowledge. Of particular interest in the search for information, 
are the structure (connections and interactions of components or sub-systems) of 
the system, mechanisms of the drug of interest, relevant parameter values as well 
as physiological and pathophysiological conditions for components of the 
system, which are of appropriate amplitude scales at, for example, molecular, 
cellular, tissue, organ, or sub-system level.  
Most often, the information identified are heterogeneous due to variation 
in experimental conditions, assay methods, species (human versus animal), and 
the rigor in which the experiments were conducted. It is therefore necessary to 
carefully screen, select, and document available information for inclusion into 
the model. Additionally, competing hypotheses may be identified and 
imputation of model structure may be made based on assumptions. These 
uncertainties in model structure should be addressed and appropriately 
documented. Should the need arise, these uncertainties should be revisited and 
the QSP model updated according to the current state of evidence. 
Collaborators: An extensive collaborative network is important for the 
development and application of QSP model. Long-term partnership with wet 
laboratories, clinics, hospitals, drug development project teams, and experts in 
the field of interest allow continual generation of new data and mechanistic 
insights that will be helpful for model refinement for effective model use. 
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1.4.2.2. Mathematical formalism 
ODEs are the most widespread formalism of QSP models [70]. In ordinary 
differential equation modelling, the quantity in a state of interest is modelled as 
a continuous variable over time with relationships and dynamics within- and 
between-states defined by mathematical functions and real-valued parameters.  
In the ODE setting, each state is represented by an ODE that contains two 
general types of rate expressions as building blocks: (1) rate of input and (2) rate 
of output. Different mechanisms of input (e.g. exogenous input, natural 
production, formation reaction) and output (e.g. natural degradation, complex 
formation) can be accounted for using mathematical functions. For instance, in 
Equation 1.21, output of 𝐴 via diffusion, which is governed by the law of mass 
action and is therefore a first-order process, is characterised using a linear 
function whereas output of 𝐵 that is transporter-dependent is described using 
the Michaelis-Menten equation. Finally, in the representation of the rate of 
change of the quantity in a state, the ODE subtracts the sum of output rate from 




= −𝑘 ∙ 𝐴;     𝐴𝑡=0 = 𝐴0 
𝑑𝐵
𝑑𝑡
= 𝑘 ∙ 𝐴 −
𝑉𝑚𝑎𝑥
𝐾𝑀 + 𝐵
∙ 𝐵;     𝐵𝑡=0 = 0 
Equation 1.21 ODE describing conversion of A to B via a first-order process and 
saturable elimination of B. 
 
For QSP model development and application, the physical quantity in each 
of the states in the model over time are of primary interest. This requires solving 
the systems of ODEs. In some cases, the ODE systems can be expressed in exact 
closed forms then a solution can be obtained algebraically. However, QSP models 
usually do not have algebraic solutions due to the recursiveness (causing 
nonlinearity) of the system that leads to dependence of an input or output 
function on the state itself. For example, 𝑘 ∙ 𝐴 of Equation 1.21 is amenable to 
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algebraic representation, which allows simplification of the equation to 
Equation 1.22, whereas 
𝑉𝑚𝑎𝑥
𝐾𝑀+𝐵
∙ 𝐵 part of the equation is nonlinear in response 









∙ 𝐵;     𝐵𝑡=0 = 0 
Equation 1.22 Simplification of Equation 1.21. 
 
The time-stepping procedures are numerical techniques for computing 
solutions to the ODE by conditioning the next step solution on the immediate 
previous time point. The Euler’s method (Equation 1.23) is one of the simplest 
and it forms the basis to construct more complex methods for solving systems of 
ODEs [77]. Briefly, starting from a known initial value (𝑦𝑛), the Euler’s method 
uses the tangent line equation given by the ODE i.e. 𝑓(𝑡𝑛, 𝑦𝑛) =
𝑑𝑦
𝑑𝑡
 and a small 
time step size (ℎ) to approximate successive point (𝑦𝑛+1) on the solution curve of 
the ODE. The solution from one time point is then advanced to the next time 
point and the process is continued iteratively until the desired vector of solutions 
(𝑦0, 𝑦1, ⋯ , 𝑦𝑛, 𝑦𝑛+1) is obtained.   
 
𝑦𝑛+1 ≈ 𝑦𝑛 + ℎ ∙ 𝑓(𝑡𝑛, 𝑦𝑛) 
Equation 1.23 Euler’s method for solving ODEs with a given initial value 
 
The Euler’s method may require specification of a very small ℎ  to obtain 
reasonably accurate solutions, which typically leads to an exaggerated increase 
in computation time. For this reason, higher order methods such as the Runge-
Kutta methods [77, 78] that adapt ℎ according to the ODE model gradients are 
generally preferred for better numerical accuracy and computational efficiency. 
Finally, in systems where there is a large difference in the rate constants among 
the ODEs which may cause rapid variation in the solutions, stiff time-stepping 
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solvers may be required. In MATLAB® (The MathWorks Inc., Natick, 
Massachusetts, USA), ode45 and ode15s functions are commonly used for non-
stiff and stiff systems, respectively. A technical explanation of these numerical 
methods and detailed description of the aforementioned ODE solvers can be 
found elsewhere [79, 80].     
In contrast to PKPD models, parameters for QSP models are almost always 
not estimated but heuristically calibrated by modellers based on single or 
multiple input-output relationship(s) of interest. In QSP models, some or most 
parameters are not known a priori and due to model complexity, they are often 
not identifiable (definition of identifiability is provided earlier in Section 1.3.1.4). 
Then, with a flat likelihood surface with respect to the parameter(s) of interest, 
the driving force for the parameter search diminishes for (traditional) derivative-
based optimisation methods (e.g. gradient method and the Newton’s method). 
For more effective exploration of parameter space, stochastic optimisation 
methods (e.g. simulated annealing and SAEM method) can theoretically be 
considered [81]. However, it is important to note that QSP models are generally 
not amenable for estimation purposes even if all unidentifiable parameters are 
fixed [76, 82]. This is because fixing a parameter may bias other parameters in 
the system then when a large number of parameters are fixed, the bias 
compounded within the system may be so huge that it renders the model 
unusable for its intended purpose. 
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1.4.3. Coagulation network model 
In this thesis, a QSP model of the coagulation network, which was 
developed by Wajima and colleagues [31] and later updated by Gulati and peers 
[38], was applied to explore the kinetics of coagulation proteins as driver of the 
INR (see Chapter 3) and subsequently, to derive a coagulation protein-based 
method for the prediction of anticoagulant response to warfarin (see Chapter 4). 
A schematic of the QSP coagulation network model is shown in Figure 1.9.  
  
 
Figure 1.9 Schematics of the coagulation network model [31]. APC represents activated 
protein C, AT-III antithrombin-III, CA contact activator, DP degradation product, F 
fibrin, Fg fibrinogen, II factor II, IIa thrombin, K kallikrein, P plasmin, PC protein C, Pg 
plasminogen, Pk prekallikrein, PS protein S, TAT thrombin-antithrombin complex, TF 
tissue factor, TFPI tissue factor pathway inhibitor, Tmod thrombomodulin, VK vitamin 
K, VKH2 vitamin K hydroquinone, VKO vitamin K epoxide, XF cross-linked fibrin.      
 
The model accounts for various subsystems involved in in vivo coagulation 
(e.g. vitamin K cycle, intrinsic, extrinsic, and common coagulation pathways 
[according to classical definition], anticoagulant system, and fibrinolytic system) 
as well as common in vitro blood coagulation tests (e.g. prothrombin time (PT), 
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INR, and activated partial thromboplastin time tests). It also predicts the time 
course of drug concentrations and effects for warfarin, heparins, and vitamin K 
in humans. The model was previously applied to simulating PT and INR for 20 
patients identified  from the literature [31, 83] and was found to provide an 
adequate description of the observed data [31]. 
The model consists of 63 states, each corresponds to a specific coagulation 
component. The coagulation components can be broadly classified into 
inactivated components termed zymogens (e.g. factor II), the corresponding 
activated species, which acts as activating enzymes for clot formation (e.g. 
thrombin [factor IIa]), and cofactors (e.g. protein S). Briefly, in vivo coagulation is 
initiated when vascular injury exposes factor VII in the blood to tissue factor. 
Factor VII is activated to factor VIIa that leads to an accelerated pathway of 
activation of other zymogens as a result of the complex feedback and 
feedforward mechanisms within the coagulation network. This ultimately leads 
to rapid activation of factor II to thrombin, which in turn catalyses the conversion 
of fibrinogen to insoluble fibrin, which is cross-linked by factor XIIIa to form the 
stabilising component of a clot.   
In the QSP coagulation network model, the zymogen, cofactor, and 
activated species are assumed to follow a first-order degradation process 
(parameterised as 𝑘𝑜𝑢𝑡) but differ in the mechanism of formation. Each zymogen 
or cofactor is described by a turnover model (see Section 1.3.1.3.2) that assumes 
a zero-order natural production rate (𝑅𝑖𝑛). On the other hand, activated species 
is formed by activation of the zymogen and is assumed to be a time-varying 
reaction that depends nonlinearly on the concentration of specific activating 
enzyme via a Michaelis-Menten function.  
By default, the coagulation system is assumed to be in equilibrium 




(See Equation 1.13 in Section 1.3.1.3.2). On the other hand, the initial 
concentration of all activating enzymes (including complexes and products) are 
assumed to be zero so that the coagulation system is at a non-clotting condition 
at equilibrium.  
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QSP models tend to be complex. They are often difficult to work with, 
challenging to analyse, and generally not suitable for estimation purposes and 
for practical application in drug development or clinical settings [76, 82]. On the 
basis of parsimony and practicality, QSP models may be simplified based on a 
specific input-output relationship of interest. In general, model-order reduction 
can be achieved by either reducing the number of reactions (e.g. quasi steady-
state approximation) or the number of states (e.g. proper lumping). In particular, 
the technique of proper lumping has been successfully applied for model-order 
reduction for several systems models [84-86]. However, at the time this PhD 
work was undertaken, no exact solutions for lumping are available for nonlinear 
ODEs [85]. In this work, a heuristic model-order reduction technique in which 
an empirical approximation to predictions from the QSP coagulation network 
model is used and described in Chapter 4.       
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1.5. Warfarin and anticoagulant response 
Warfarin has been used to treat and prevent blood clots in humans for more 
than 60 years and despite the availability of newer oral anticoagulants, warfarin 
remains one of the most widely prescribed oral anticoagulants in the world. The 
effectiveness of warfarin is well-established for the treatment and prevention of 
venous thrombosis, pulmonary embolism, and systemic embolism associated 
with atrial fibrillation, myocardial infarction, and prosthetic heart valves [87-90].  
Warfarin has a narrow therapeutic range [1, 87, 91-93] and it is a difficult 
drug to dose safely and accurately. It requires a working knowledge of the 
relationship between warfarin dose and observed anticoagulant response, a 
relationship that is inherently nonlinear and therefore not necessarily intuitive. 
The overall aim of this thesis was to understand warfarin dose response by 
considering the underpinning coagulation kinetics. In the next following 
sections, the PK and PD of warfarin underpinning this relationship will be 
reviewed and the current status, knowledge gap, challenge, and need for 
improved warfarin dosing will be summarised and discussed.  
1.5.1. Physicochemical properties of warfarin 
Warfarin (4-hydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one) is a synthetic 
derivative of dicoumarol (4-hydroxy-3-[(4-hydroxy-2-oxochromen-3-
yl)methyl]chromen-2-one), which is a natural anticoagulant first discovered in 
spoiled sweet clover. Warfarin is a weak acid with a pKa of 5.08 and with a 
chemical formula of C19H16O4, warfarin has a molecular weight of 308 g/mol 
[94]. Commercially available warfarin tablets is a racemic mixture of two 
enantiomers, R- and S-warfarin [95]. The two enantiomers do not appear to 
undergo stereo-conversion in vivo and they differ in their PK and PD properties.   
  
Chapter 1: Introduction 
 46 
 
1.5.2. PK of warfarin 
Both R- and S-warfarin are essentially completely absorbed from the gut 
with an absolute bioavailability reported to be nearly 100% [96]. Warfarin is 
usually detectable in plasma within one hour of oral administration, and plasma 
concentrations peak between 0.3 to 4 hours [97, 98]. Following absorption, 
because warfarin is almost completely bound to plasma proteins (> 99%), 
principally albumin, warfarin distributes into a relatively small volume of about 
10 L/70kg [99]. Here, the volume of distribution does not appear to differ 
significantly between R- and S-warfarin [100-103].      
Warfarin is eliminated almost entirely by hepatic metabolism with only 
traces excreted unchanged in the urine. The metabolism of warfarin is capacity-
limited, which is characterised by a low plasma clearance (0.2 L/h/70kg) relative 
to the hepatic blood flow [99, 104]. S-warfarin is metabolised principally by 
cytochrome P450 (CYP) 2C9 whereas R-warfarin is metabolised by various 
enzymes including CYP2C19, CYP1A2, and CYP3A4 [97, 105, 106]. The inactive 
metabolites are excreted in faeces (80%) and urine (20%) [107]. For a patient with 
CYP2C9 wild-type genotype, the oral clearance of S-warfarin is approximately 2 
times higher (0.3 L/h/70kg) than that of R-warfarin (0.13 L/h/70kg) [100-103]. 
Since the volume of distribution of the enantiomers are largely similar, the 
plasma half-life of the S-warfarin (30 hours) is shorter than that of R-warfarin (45 
hours). With these half-lives, warfarin requires about a week to reach its steady-
state and that a relatively small fluctuation in the plasma drug concentrations is 
expected during each daily dosing interval.  
Polymorphism in the CYP2C9 gene affects the metabolism of warfarin. 
CYP2C9*2 and CYP2C9*3 are common variant alleles with single base 
substitutions at residue 144 (arginine to cysteine) and residue 359 (isoleucine to 
leucine), respectively, encoding an enzyme with reduced activity [108]. Carriers 
of these variant allele(s) typically have a 30 to 85% reduction in oral clearance 
and therefore are expected to have greater tendency to bleed as compared to 
homozygotes for the wild-type allele, CYP2C9*1 [100-103, 109]. For this reason, 
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carriers of variant alleles usually have warfarin dose requirement that are 20 to 
80% lower than those with the wild-type genotype [110].   
1.5.3. PD of warfarin 
Vitamin K-dependent clotting factors and anticoagulation proteins, factors 
II, VII, IX, X, protein C, and protein S, are biosynthesised in hepatocytes [111]. 
The required first step in the biosynthesis of functional clotting factors and 
anticoagulation proteins is the production of precursor proteins in the 
endoplasmic reticulum of the hepatocytes [112-114]. An important prerequisite 
for conversion of these precursor proteins to clotting factors and anticoagulation 
proteins involves oxidation of vitamin K hydroquinone to vitamin K epoxide 
[115, 116]. During the oxidation reaction, a short-lived oxygenated intermediate 
is produced to abstract the 𝛾 -proton from the glutamic acid residue on the 
precursor proteins [117]. This is sequentially coupled with a 𝛾-carboxylation 
reaction whereby CO2 is added to the 𝛾-carbon of the glutamic acid residue on 
the precursor proteins by the gamma-glutamyl carboxylase (GGCX) [111, 116, 
118]. The fully modified, mature clotting factors and anticoagulation proteins are 
then released from the hepatocytes for circulation as zymogens in the blood. The 
nomenclature regarding these factors and proteins remains somewhat 
confusing. Factors II, VII, IX, X and protein C are zymogens whereas protein S 
lacks the serine protease domain and is most likely a cofactor [119]. For 
simplicity, all these proteins are collectively denoted as vitamin K-dependent 
coagulation proteins in this thesis.  
Warfarin exerts its anticoagulant effect by inhibiting the enzyme VKOR 
[111, 120]. VKOR reduces vitamin K epoxide to vitamin K quinone and also 
converts vitamin K quinone to the active vitamin K hydroquinone [121]. By 
inhibiting the formation of vitamin K hydroquinone, warfarin prevents the 
production of vitamin K-dependent coagulation proteins leading to a prolonged 
clotting time. Warfarin PD effect is summarised in Figure 1.10. It is generally 
believed that S-warfarin, which is 1.6 to 3.4 times more potent than R-warfarin, 
Chapter 1: Introduction 
 48 
 
is responsible for the observed anticoagulant response [95, 102, 122]. However, 
recent findings suggest that contribution of R-warfarin may be important [123].    
The enzyme kinetics underpinning the interactions between warfarin and 
VKOR is a matter of contention. Reports from the 1980s have indicated the 
inhibition as irreversible [124, 125]. This was initially considered as inconsistent 
with the observation that warfarin effect can be rapidly reversed by using 
vitamin K but with emerging evidence of a salvage pathway for vitamin K 
reduction that is independent of VKOR, possibility of irreversible inhibition of 
VKOR by warfarin cannot be dismissed [126, 127]. The more prevailing belief is 
that the inhibition is reversible and non-competitive [128-130]. However, this 
was challenged by a recently published X-ray crystallography study that 
suggests that vitamin K epoxide, vitamin K quinone, and warfarin share the 
same binding site on VKOR that involves residue 55 (phenylalanine) [131].   
In the literature, warfarin is often referred to as vitamin K antagonist. This is 
a misnomer as warfarin exerts its effect by the inhibition of VKOR and does not 
antagonise the effect of vitamin K per se.  
Polymorphism in the gene VKORC1 has been shown to impact patient 
sensitivity to warfarin. Genetic variants in VKORC1 affects warfarin PD by 
causing a reduced expression of VKOR thereby leading to a reduction in the 
recycling of vitamin K [132]. Patients with the 1639A (rs992323) and 1173T 
(rs9934438) allele need a lower warfarin dose (24 to 26 mg/week) while patients 
with 9041A (rs7294) require a higher dose (40 mg/week) compared to the wild-
type carriers (35 mg/week) [133-135]. Genetic differences in VKORC1 therefore 
represents an important source of warfarin dose variability.      
        
 




Figure 1.10 Depletion of VKH2 as a result of the inhibitory action of warfarin on VKOR, 
which leads to reduced hepatic synthesis of functional coagulation proteins and, as a 
result, causes prolongation of the PT and an increase in the INR. GGCX gamma-
glutamyl carboxylase, II factor II, INR international normalised ratio, IX factor IX, PC 
protein C, PS protein S, PT prothrombin time test, VII factor VII, VK vitamin K 
quinone, VKH2 vitamin K hydroquinone, VKO vitamin K epoxide, VKOR vitamin K 
epoxide reductase, X factor X. The rectangular box indicates a compartment. The dashed 
arrow indicates a functional relationship and the solid arrow indicates a mass balance 
relationship. A cross indicates inhibition. 
 
1.5.4. Monitoring anticoagulant response 
Variability in the observed anticoagulant response is determined by both 
PK and PD factors. Warfarin drug concentrations do not reflect all of the 
observed variability in anticoagulant response and are therefore inadequate as a 
marker of anticoagulation. Since the physiological response to warfarin therapy 
is a prolonged clotting time, the anticoagulant response is monitored clinically 
using the PT test and is normally reported by the laboratory as the INR.   
1.5.4.1. PT 
PT is an in vitro test that measures the time required for a fibrin clot to form 
after the addition of thromboplastin (mixture of tissue factor and phospholipid) 
and calcium to decalcified, platelet poor plasma. Here, the tissue factor initiates 
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coagulation in the same way as it does in in vivo when vascular injury exposes 
factor VII in the blood to tissue factor (classically referred to as the extrinsic 
pathway). Hence, the PT test is sensitive to the coagulation proteins integral to 
the extrinsic pathway including fibrinogen, factors II, V, VII, and X [136, 137]. 
The PT for normal healthy individuals usually range from 12 to 14 seconds 
whereas for warfarin patients who have deficient level of factors II, VII, and X, 
the PT is usually prolonged.     
1.5.4.2. INR 
PT results are known to vary with the thromboplastin reagent used. For 








Equation 1.24 INR. 
 
Here, 𝑃𝑇 is the measured PT of a test sample, 𝑃𝑇𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 is the PT for standard 
normal plasma, and 𝐼𝑆𝐼 is the international sensitivity index. Inclusion of the 
exponent (ISI) standardises PT by correcting for the differences in sensitivity 
between the thromboplastin used and the international thromboplastin 
reference, which has a known sensitivity. Although the ISI corrects for major 
differences in PT results, disagreement between INR results are not uncommon, 
for instance, when different methods (e.g. the Quick method versus the Owren 
method) are used for the determination of PT [138].  
 




Figure 1.11 Incidence rates of thrombotic stroke (panel a), intracranial haemorrhage 
(panel b), and combined data (panel c) of warfarinised patients with non-valvular atrial 
fibrillation versus the INR. The plots are produced based on the data from Hylek and 
colleagues [1].   
 
The INR for normal healthy individuals usually range from 1 to 1.2 whereas 
for warfarin patients who have deficient level of factors II, VII, and X, the INR is 
elevated. The work of Hylek et al. provided support for the functional 
relationships between INR and the incidence rates of thrombotic stroke and 
intracranial haemorrhage in patients with non-valvular atrial fibrillation (see 
Figure 1.11) [1]. Panel c in Figure 1.11 identifies a safe range of INR from 
approximately 1.5 to 3.5 that is associated with low incidence rates of both 
thrombotic stroke and intracranial haemorrhage. Indeed, the INR therapeutic 
range for warfarin, in non-Asian patients, has been widely studied and a target 
INR of 2 to 3 was proposed for atrial fibrillation and for most other indications 
[87, 91-93]. The therapeutic range for warfarin is narrow with sub-therapeutic 
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INR associated with an increased risk of clotting while supra-therapeutic INR 
carries a significant risk of major bleeding events.  
1.5.4.3. Clotting factor activity 
Warfarin affects the production of vitamin K-dependent coagulation 
proteins. Coagulation proteins therefore provide the most direct measure of the 
anticoagulant response to warfarin. 
Use of prothrombin complex activity (PCA) had been proposed and 
explored. PCA is determined based on the calibration curve constructed by 
plotting the measured PT against dilutions of normal plasma [98]. Then, 
individuals with normal clotting activity will have a PCA of 100% whereas 
warfarin patients with therapeutic INR usually have a PCA ranging from 20 to 
40% [98, 139]. PCA is a composite measure of coagulation proteins activity and 
because the determination of PCA is based on PT, it is only sensitive to variation 
in fibrinogen, factors II, V, VII, and X [136, 137]. It is important to note that PCA 
is inversely proportional to INR [102, 140, 141]. Their relationship is defined by 






Equation 1.25 Mathematical relationship between INR and PCA. 
 
Here, 𝑎 = 80.65 and 𝑏 = 0.18 [141] although different values have been reported 
[102, 140].    
Concentration of the vitamin K-dependent coagulation proteins provide 
the most direct measure of the anticoagulant response to warfarin. Factors II, VII, 
IX, and X are quantified in the same manner as the PCA except that specific 
coagulation protein-deficient-plasma is used for the construction of the 
calibration curve [142]. The coagulation proteins concentration for patients on 
stable warfarin are compared and contrasted to the reference range for normal 
healthy individuals in Table 1.2.  
Chapter 1: Introduction  
53  
 
Table 1.2 Vitamin K-dependent coagulation proteins concentrations for normal healthy 
individuals and patients on stable warfarin. Proteins C and S are not shown as their 




𝑚𝑒𝑎𝑛 (95% 𝐶𝐼) 
Reference range for 
normal individuala 
Reported value for  
stable warfarin patientc 
Factor II 60 – 140b 24.9 (10.6 – 48.7) 
Factor VII 60 – 140b 38.7 (19.0 – 68.4) 
Factor IX 69 – 151b  49.7 (27.9 – 68.7) 
Factor X 60 – 140b  16.5 (6.49 – 28.9) 
a Sourced from Mann et al. 2004 (𝑛 = 150) [143] 
b Mean is not reported [143] 
c Based on data manually digitalised from Kumar et al. 1990 (𝑛 = 23), Lind et al. 1997 (𝑛 = 16), and Paul et 
al. 1987 (𝑛 = 36) [144-146]. Lind et al. 1997 did not report factor IX values. Note that the patients are on 
stable warfarin but their INR values are unknown. 
 
1.5.5. Warfarin dosing methods 
The goal of warfarin dose individualisation is to predict the warfarin 
maintenance dose that will keep the 𝐼𝑁𝑅𝑆𝑆  within this range. There is a large 
body of literature exploring ways to aid warfarin dose selection in clinical 
practice. A brief overview of published warfarin dosing methods is provided 
below. However, a comprehensive review of the vast literature on this subject is 
beyond the scope of this thesis.    
For the purposes of this thesis, warfarin dosing methods are broadly 
classified into two types, (1) covariate-based dosing methods and (2) response-
based dosing methods, although it is acknowledged that some methods consider 
both covariates and anticoagulant response for warfarin dose individualisation 
[12, 22, 102].      
1.5.5.1. Covariate-based dosing method 
Body size, age, ethnicity, concomitant drugs, CYP2C9 genotype, and 
VKORC1 genotype have been identified to affect the PK and PD of warfarin and 
to explain about 50% of the between-subject variability in warfarin maintenance 
dose requirement [8-16]. A large number of warfarin dosing algorithms that 
account for individual covariates have been developed based on the multiple 
linear regression analysis (see Equation 1.26 for an example) [10, 12, 22, 24, 25]. 
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In essence, warfarin maintenance dose requirements are modelled as a linear 
function of one or more covariates with the inclusion of covariates guided by 
statistical significance.  
 
𝐷 = 𝑒0.613+(0.425∙𝐵𝑆𝐴) − (0.0075 ∙ 𝑎𝑔𝑒) + (0.156 ∙ 𝐴𝑓𝑟𝑖𝑐𝑎𝑛𝐴𝑚𝑒𝑟𝑖𝑐𝑎𝑛)
+ (0.216 ∙ 𝐼𝑁𝑅𝑡𝑎𝑟𝑔𝑒𝑡) − (0.257 ∙ 𝑎𝑚𝑖𝑜𝑑𝑎𝑟𝑜𝑛𝑒) + (0.108 ∙ 𝑠𝑚𝑜𝑘𝑒𝑠)
+ (0.0784 ∙ 𝐷𝑉𝑇/𝑃𝐸) 
Equation 1.26 Linear model underpinning the algorithm proposed by Gage et al. for 
the prediction of warfarin maintenance dose [10]. 
 
Here, 𝐵𝑆𝐴 refers to body surface area, 𝐷 is the predicted warfarin daily dose, 
𝐷𝑉𝑇 is deep vein thrombosis, and 𝑃𝐸 is pulmonary embolism.   
The use of patient characteristics including genotype information to predict 
warfarin dosing requirements prior to the initiation of warfarin therapy is 
advocated by the FDA [147]. However, the method suffers from several 
drawbacks. First, it relies on prior knowledge of patient’s characteristics such as 
the CYP2C9 and VKORC1 genotypes, which may not be readily available in the 
clinical setting. In addition, using this approach, the intricacy and the complex 
interplay between warfarin, vitamin K cycle, coagulation proteins, and INR are 
simplified into an empirical linear regression equation. The assumption of 
linearity in warfarin dose-INR relationship may not necessarily hold true for the 
entire warfarin dose range that is clinically relevant and as a result, may have 
limited generalisability to other settings [5, 148]. Last but not least, while this 
method is useful to guide initial warfarin dosing, they provide no means of 
adjusting the dose of warfarin once INR responses become available.    
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1.5.5.2. Response-based dosing method 
Measures of anticoagulant response such as the INR reflect the between-
subject differences in warfarin PK and PD thereby representing a useful marker 
for warfarin dose individualisation.  
In clinical practice, warfarin dose adjustment is a largely heuristic process 
with the maintenance dose for a patient determined intuitively by the prescriber, 
often by trial and error, based on the magnitude of observed INR values. 
However, accurate prediction of the warfarin maintenance dose requirement is 
difficult owing to the non-steady-state conditions of warfarin, coagulation 
proteins, and INR during warfarin initiation or after a dose change in addition 
to the requirement of a working knowledge of the warfarin dose-response 
relationship. For these reasons, various dosing tools that are based on either 
single or multiple observed anticoagulant responses with or without accounting 
for a patient’s covariates simultaneously have been proposed to aid INR control 
in patients.  Non-adaptive methods to determine dose based on measurement of 
a response variable fall into the general category of nomogram approaches. 
Nomograms have a long history of use in clinical practice. They provide 
guidance for initial dose selection and recommendations for subsequent dose 
adjustment based on the observed INR responses. Nomograms for warfarin are 
most typically presented as dosing tables (see Figure 1.12 for an example) [17, 
149, 150] but may also take the form of computerised decision-support tools (see 
Poller et al. for an example [151]). Although they are easy to use, the pitfall of the 
nomograms lies in the often explicit assumption of a linear relationship between 
warfarin dose and response (though not always [Figure 1.12]) and the 
nomograms would therefore not be expected to produce credible predictions 
beyond the linear portion of the concentration-effect curve, i.e. at more than 20% 
of maximal inhibition. In addition, nomograms lack an in-built mechanism to 
adjust for factors such as the between-subject variability in the degradation half-
life of coagulation proteins [143] that may confound the observed INR. 
 




Figure 1.12 Nomogram for warfarin initiation proposed by Tait et al. [17]. It relies on 
measuring the INR at baseline, on day 5 and day 8 to individualise warfarin dosing. The 
nomogram is reproduced here with permission from the British Journal of Haematology. 
 
Only about 50% of the between-subject variability in warfarin maintenance 
dose requirement are accounted for by covariates [8-16]. In a small number of 
recent publications, the covariate-based linear regression method described in 
Section 1.5.5.1 is extended to include single INR response as a predictor for 
warfarin maintenance dose to account for dosing variability previously 
unexplained by covariates (see Lenzini et al. [12] for an example). These methods 
have been shown to have superior predictive performance compared to 
algorithms without anticoagulant response feedback [7].   
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Alternatively, warfarin dose individualisation can be achieved by the use 
of Bayesian forecasting methods with an underpinning PKPD or KPD model for 
warfarin. See Wright et al. [18] for an example and the underpinning warfarin 
KPD model [54, 152] is shown in Figure 1.13. Using this approach, key 
parameters (e.g. 𝐶𝐿) in the warfarin model can be individualised based on the 
dose-INR data obtained from individual patient then as more data become 
available, the parameter estimates become more refined thereby allowing 




Figure 1.13 A schematic of the warfarin KPD model developed by Hamberg et al. [54] 
and adopted by Wright et al. [18] for warfarin maintenance dose prediction using the 
Bayesian forecasting method. A is the amount of warfarin in the body, C1m and C2m are 
the mth compartment in the two transit chains, DR dosing rate, EDK50 dosing rate that 
corresponds to 50% maximal inhibition, EFF warfarin effect, Emax maximum inhibition 
of coagulation, KDE is the first-order elimination rate constant of warfarin, MTT mean 
transit time, γ empirical shape parameter. The figure was published by Hamberg et al. 
[54] and is reproduced here with permission from the Clinical Pharmacology & 
Therapeutics.   
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1.5.6. The need for improved warfarin dosing 
1.5.6.1. Biased prediction of dose requirement 
Existing warfarin dosing methods have been shown to predict warfarin 
dose requirements accurately on average [7, 153]. However, it was reported that 
current methods produce biased predictions in patients who require doses in the 
upper quartile (≥7 mg/day) of warfarin dose requirements [3-5, 7]. Interestingly, 
it was shown that even the flexibility of a Bayesian forecasting method was 
insufficient to accurately predict warfarin requirements in those who required 
higher doses [7]. In a recently published systematic review and meta-analysis 
that includes 47 evaluations of 22 warfarin dosing tools from 16 studies using 
data from 1492 patients who required warfarin doses of ≥7 mg/day, the bias in 
maintenance dose predictions was quantified as an average of -2.3 mg/day with 
a pooled estimate of under-predicted doses a staggering 92.3% (95% confidence 
interval 90.3% – 94.1%) [5]. The corresponding forest plot for the proportion of 
under-predicted doses of warfarin is reproduced here as Figure 1.14. In addition, 
warfarin dose requirements in patients who require doses in the lower quartile 








Figure 1.14 The proportion of doses that were over- or under-predicted in patients who 
required ≥7 mg/day of warfarin. The line of no bias corresponds to a value of 0.5 where 
the proportion of over-prediction is the same as that of under-prediction. The forest plot 
[5] is reproduced here with permission from the Clinical Pharmacology & Therapeutics. 
 
It appears that current methods do not accurately predict warfarin 
maintenance doses for patients in the lower or upper quartile of dose 
requirements. These patients will be those who are at the greatest risk of over- 
or under-anticoagulation, and who would therefore derive the most benefit from 
warfarin dose individualisation. 
1.5.6.2. A new perspective to warfarin dosing 
The reason for the poor performance of dosing algorithms in the upper and 
lower quartiles of dose requirements is not understood [5]. It is probable that the 
empirical models underpinning these dosing methods are too simple to 
accommodate the complexity of the coagulation system, with many models 
approximating the relationship between warfarin dose and INR by linear 
functions [12, 22-25] or an 𝐸𝑚𝑎𝑥  function [18, 54, 100, 154]. In these models, 
warfarin dose or concentration is linked directly and empirically to the INR. 
Using this approach, the vitamin K cycle and the coagulation proteins that lie 
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causally between warfarin dose and INR response are not considered [54, 100, 
102, 139, 140, 155, 156] and the intricacy and the complex interplay between 
different coagulation components are simplified into an empirical equation.  
In addition, to date, all response-based warfarin dosing methods (except 
Pitsiu et al. [157]) rely solely on the measurement of INR as feedback for warfarin 
dose individualisation [12, 17, 18, 22, 23, 25-30]. The INR is easily measured by 
commercial laboratories and has been directly linked to clinical outcomes of 
interest [92, 93]. This means that it is an attractive biomarker to assess the 
magnitude of anticoagulation and choice of warfarin dose. However, the INR is 
a blunt estimate of anticoagulant response that is a composite of fibrinogen, 
factors II, V, VII, and X [136, 137]. Its interpretation therefore relies heavily on 
understanding the (complex) mechanistic relationship of INR to warfarin dose. 
The coagulation kinetics governing the INR are poorly understood. Few studies 
were dedicated to improve the current state of knowledge but mostly were 
conducted or interpreted in cross-section, which greatly limits an in-depth 
understanding of the entire time course and natural variability in the coagulation 
proteins and INR [144-146, 158-162].  
In this thesis, it is hypothesised that the issues surrounding the poor 
predictive power of warfarin dosing methods relate to the use of INR as a sole 
marker of anticoagulation in warfarin dose individualisation. A new approach 
to predict the INR and warfarin dosing requirement is needed. In Figure 1.15, 
INR response represents a surrogate endpoint of interest in the causal path 
between warfarin dose and major clotting or bleeding event. However, due to its 
downstream location on the causal path, INR response is a conglomerate 
measure of the variability in all of the upstream components: warfarin PK, PD, 
and the coagulation network. In theory, inclusion of warfarin concentrations (PK 
marker) and / or coagulation protein concentrations (PD marker) will be helpful 
in elucidating the relationship from warfarin dose to INR response and in 
delineating the different sources of variability in anticoagulant response. In this 
thesis, the vitamin K-dependent coagulation proteins are of primary interest. The 
coagulation proteins not only provide a signal from the system that lies causally 
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between warfarin dose and INR response but also represent a measure of the 
anticoagulant effect that is directly relatable to the (unobserved) warfarin-VKOR 
interactions (Figure 1.15). In addition, due to the proximity of the coagulation 
proteins to the INR response in the chain of causal events, the coagulation 
proteins are also expectedly informative and predictive of the INR response. 
The overarching motivation for the work conducted in this thesis is the 
notion that a measure of coagulation protein response will be helpful in 
improving the prediction of the anticoagulant response and warfarin dose 
requirement. A choice of a coagulation protein that is particularly sensitive to 
warfarin and simultaneously, influential on the INR would be appropriate. This 
requires a working knowledge of the relationship between warfarin dose, 
warfarin concentrations, coagulation proteins, and INR response (Figure 1.15). 
In this thesis, a comprehensive description of the application of pharmacometric 
methods to understand the warfarin-coagulation proteins relationships 
(Chapter 2) and then to propose a coagulation protein-based method for the 
prediction of anticoagulant response to warfarin (Chapters 3 & 4) is provided. It 
is however important to note that the work conducted in this thesis were not set 
forth to propose a new framework for warfarin dosing that is instantly applicable 
for clinical use, but to introduce a new perspective on INR prediction.    
 




Figure 1.15 Causal path of warfarin dose response (panel b) mapped to a general causal 
path framework (Figure 1.8 reproduced here as panel a). INR response is routinely 
measured as a surrogate marker of major clotting or bleeding events in warfarin patients. 
Warfarin dose is causally linked to the INR response via warfarin concentration (PK 
marker) and coagulation protein concentration (PD marker). INR is the international 
















































Chapter 2:  A joint model for vitamin K-




















This chapter is based on the following peer-reviewed publication: 
Ooi QX, Wright DF, Tait RC, Isbister GK, Duffull SB. A joint model for vitamin K-
dependent clotting factors and anticoagulation proteins. Clin Pharmacokinet. 2017: 
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Warfarin exerts its anticoagulant effect by inhibiting the enzyme vitamin K 
epoxide reductase (VKOR). VKOR reduces vitamin K epoxide to vitamin K 
quinone and also then converts vitamin K quinone to the active vitamin K 
hydroquinone form. By inhibiting vitamin K hydroquinone formation, warfarin 
prevents the production of vitamin K-dependent coagulation proteins (factors II, 
VII, IX, X, and proteins C and S) that leads to a prolonged clotting time. The 
clotting time is usually monitored clinically using the international normalised 
ratio (INR), which is a known marker of clinical outcomes of interest such as 
major clotting and bleeding events [1].       
The time course of anticoagulant response to warfarin has been extensively 
studied [18, 54, 99, 100, 152, 154, 163, 164]. The majority of the published models 
link warfarin concentration directly to the INR or prothrombin complex activity, 
which is a composite measure of various coagulation proteins. In most cases, the 
published models for warfarin dose response do not account for the coagulation 
protein response although in theory, they provide a useful signal from the 
system that lies causally between warfarin concentration and INR response, 
thereby representing a direct measure of warfarin effect.  
Analyses of the time course of coagulation proteins in warfarin patients are 
limited. Most studies employ a naïve pooled approach to analysis or examine 
individual coagulation protein in isolation and its time course in cross-section, 
thereby reducing the time courses of anticoagulant responses to snapshot(s) of 
single coagulation protein response to warfarin [99, 157-159, 161, 165, 166]. Such 
a simplistic approach to analysis, while quick and convenient, results in a loss of 
information and individuality of patients in addition to failing to consider the 
natural variability and correlation between different coagulation proteins. This 
may have ramifications in understanding and predicting the time course of 
warfarin effects, for instance, in obtaining an accurate estimate of the 
degradation half-life of various vitamin K-dependent coagulation proteins and 
in estimating the time to steady-state of anticoagulant effects.  




The aim of this work was to develop a joint model for the vitamin K-
dependent coagulation proteins, factors II, VII, IX, and X and proteins C and S, 
following warfarin initiation. 
  





Clinical data were available from a published study conducted in Glasgow, 
Scotland [167]. The study was approved by the North Glasgow University 
Hospitals Ethics Committee and written informed consent from all patients were 
obtained prior to enrolment.  
The study included 18 adult patients (median age 70 years [range 53 - 84] 
and 11 were male) who were newly diagnosed with atrial fibrillation and 
initiated on oral daily warfarin according to the Tait and Sefcick warfarin 
induction regimen [17]. An initial dose of 5mg of warfarin was given for 4 days 
followed by adjustment of warfarin dose at days 5, 8, and 15 according to INR 
response [17]. 
A blood sample was collected at baseline, and at 1 - 5, 8, 15, and 29 days 
after warfarin initiation for each patient. Vitamin K-dependent coagulation 
proteins were measured using standard assays: (1) prothrombin time assay on 
ACL 3000 coagulation analyser for factors II, VII, and X; (2) activated partial 
thromboplastin time assay on ACL 3000 coagulation analyser for factor IX; (3) 
chromogenic assay on Amax 400 analyser for functional protein C; and (4) 
enzyme-linked immunosorbent assay for free protein S. These methods are 
described briefly in Appendix A1.1 and more details can be found elsewhere 
[142]. The samples were not assayed for S- or R-warfarin concentrations as this 
was not part of the original study design. 
 The nominal daily dose time was 6 p.m. and the blood sampling time was 
11 a.m., except for day 5 where sampling time was reported as 1.30 p.m. Missing 
dosing records were imputed using the last observation carried forward (LOCF) 
method.  
2.3.2. Statistical analysis 
Available data were fitted using a nonlinear mixed-effects model 
framework in NONMEM® Version 7.2 (ICON Development Solutions, Ellicott 
City, MD, United States) with the aid of a wrapper function around NONMEM® 
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(Wings for NONMEM® Version 720, Holford N, Auckland, New Zealand). The 
first-order conditional estimation method with interaction (FOCE-I) was used 
for model fitting. An AMD Opteron™ processor and a GNU Fortran compiler 
(GCC 4.6.0) were employed for the analysis. The convergence criterion was set 
to three to six significant digits (SIG=3 or SIG=6) and the precision of integration 
solution was set to nine significant digits (TOL=9). 
Initially, concentration-time profiles for the vitamin K-dependent 
coagulation proteins were modelled independently (termed individual model). 
Then the six models were combined into a single model (termed joint model).  
For each coagulation protein, the observations of the 𝑖th individual 𝒚𝒊(𝑛𝑖 ×
1)  at specific observation time points 𝒕𝒊(𝑛𝑖 × 1)  was given by the following 
equation: 
 
𝒚𝒊 = 𝒇(𝒕𝒊, 𝜷𝒊) ∙ (1 + 𝜺𝒑𝒓𝒐𝒑,𝒊) + 𝜺𝒂𝒅𝒅,𝒊. 
Equation 2.1 Model for the individual coagulation protein observations of the ith 
individual. 
 
Here, the regression function 𝒇(𝒕𝒊, 𝜷𝒊)(𝑛𝑖 × 1)  depends on the vector of 
regression parameters 𝜷𝒊(𝑝 × 1) in a nonlinear fashion. A combined error model 
was used. Vector of proportional errors, 𝜺𝒑𝒓𝒐𝒑,𝒊 (𝑛𝑖 × 1) , corresponds to the 
portion of residual unexplained variability (RUV) that varies linearly with the 
magnitude of prediction while additive errors, 𝜺𝒂𝒅𝒅,𝒊 (𝑛𝑖 × 1) , represent the 
remaining differences between observations and individual-level model 
predictions. Both error terms were assumed to be normally distributed with a 
mean of zero and variance of 𝜎𝑝𝑟𝑜𝑝
2  and 𝜎𝑎𝑑𝑑
2 , respectively. Between-subject 
variability (BSV) was accounted for by a general model for regression parameters 
𝜷𝒊 at individual level: 
 
𝜷𝒊 = 𝝍(𝜷, 𝜼𝒊), 
Equation 2.2 Model for the parameters of the ith individual. 
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where 𝜷 is a (𝑝 × 1) vector of population parameters and 𝜼𝒊 is a (𝑝 × 1) vector of 
corresponding between-subject random effects, which were assumed to be 
normally distributed with a mean of zero and variance of 𝜔2. 𝝍(𝜷, 𝜼𝒊) is a 𝑝-
dimensional vector-valued function with each element linked to the 
corresponding element in 𝜷𝒊 . A log-linear model (e.g. 𝐶𝐿𝑖 = 𝐶𝐿 ∙ 𝑒
𝜂𝑖 ) was 
specified for all elements of 𝜷𝒊 except for baseline concentration of individual 
coagulation protein for which a linear model (i.e. 𝑃𝑡=0,𝑖 = 𝑃𝑡=0 + 𝜂𝑖 ) was 
considered. 
For joint modelling, all the six coagulation proteins were modelled in 
parallel but shared a common kinetic model for warfarin. Equation 2.1 and 
Equation 2.2 described earlier form the statistical basis of joint modelling. Slight 
modifications were made to account for multiple responses (factors II, VII, IX, X, 
and proteins C and S). Of primary importance is the addition of coagulation 
proteins (e.g. factor VII) as a higher-order level preceding individuals and 
observations in the hierarchical structure of the model.  
In one version of the joint model, correlation between the individual 
parameter estimates (L1 correlation in NONMEM® parlance) was introduced by 
estimating the full covariance matrix of 𝜼𝒊 . The independence assumption of 
𝜺𝒑𝒓𝒐𝒑,𝒊  and 𝜺𝒂𝒅𝒅,𝒊  was also relaxed. Correlation in residual error space (L2 
correlation) was allowed by introducing a general covariance structure with non-
zero off-diagonal elements for 𝜺𝒑𝒓𝒐𝒑,𝒊 and 𝜺𝒂𝒅𝒅,𝒊. 
2.3.3. Model development 
Because parameter estimations for joint model are sometimes sensitive to 
initial estimates, individual model for each coagulation protein was developed 
prior to the construction of the joint model. The final estimates from these 
individual models were later used as initial estimates in the joint model.  
During model development, a kinetic-pharmacodynamic model was used 
because warfarin concentration-time data were not available. Disposition of 
warfarin from the body was assumed to be first-order, in accordance with 
previous studies [18, 31, 54, 98-100, 103, 152, 157, 164]. In our study, the amount 
Chapter 2: A joint model for vitamin K-dependent coagulation proteins  
71  
 
of warfarin in the body, 𝐴, was used to drive the inhibitory 𝐸𝑚𝑎𝑥 model such 
that: 
 




Equation 2.3 Inhibitory Emax model to describe warfarin effect. 
 
where 𝑃 is individual coagulation protein, 𝐼𝑚𝑎𝑥,𝑃 denotes maximum inhibitory 
effect and 𝐼𝐴50,𝑃 represents the amount of warfarin in the body that gives half 
the 𝐼𝑚𝑎𝑥,𝑃. Concentration-time data for each coagulation protein were described 
with a turnover model and were assumed to have zero-order input (𝑅𝑖𝑛,𝑃) and 
first-order output (rate constant 𝑘𝑜𝑢𝑡,𝑃). Consistent with our understanding of 
inhibitory action of warfarin on VKOR, the inhibitory 𝐸𝑚𝑎𝑥 function was used to 
scale 𝑅𝑖𝑛,𝑃 to give the residual synthesis rate of functional vitamin K-dependent 
coagulation proteins following warfarin exposure. The general system of 




= −𝑘𝑎 ∙ 𝑊;     𝑊𝑡=0 = 𝐷 
𝑑𝐴
𝑑𝑡
= 𝑘𝑎 ∙ 𝑊 −
𝐶𝐿
𝑉
∙ 𝐴;     𝐴𝑡=0 = 0 
𝑑𝑃
𝑑𝑡




Equation 2.4 ODEs for warfarin and coagulation proteins. 
 
Here 𝐶𝐿 is the clearance of warfarin, 𝐷 is the dose, 𝑡 is the time after dose, 𝑉 is 
the volume of distribution of warfarin, and 𝑊  is the amount of warfarin in 
absorption depot. 
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A formal structural identifiability analysis was conducted using popt_i® 
Version 1.0 (Duffull SB, Dunedin, New Zealand) prior to population analysis [64, 
168]. Structural identifiability relates to if a finite set of parameter values exist 
given perfect input-output conditions for the model. In popt_i®, two criteria 
define structural identifiability: (1) the logarithm of the determinant of the Fisher 
information matrix ( 𝑀𝐹 ) should have a continuous relationship with the 
logarithm of the variance of RUV; and (2) the determinant of 𝑀𝐹  should 
approach a non-infinite asymptote as the variance of RUV approaches zero [64]. 
In the case when the model was found structurally unidentifiable, parameters 
including both fixed-effects parameters (𝑘𝑎, 𝐶𝐿, 𝑉, 𝐼𝑚𝑎𝑥,𝑃, 𝐼𝐴50,𝑃, 𝑃𝑡=0, 𝑘𝑜𝑢𝑡,𝑃) and 
the corresponding variance were fixed systematically one- or two-at-a-time until 
a unique solution was obtained for all remaining parameters. Note that fixing 𝑉 
and its variance gave a structurally identifiable model. More details of the 
identifiability analysis can be found in Appendix A1.2.  
The final structural model was used for covariate analysis. Two covariates, 
age and sex, were available. However, age was excluded from the covariate 
analysis owing to the limited age range (53-84 year old) available in this dataset. 
Sex was tested as a covariate on liver function-related parameters (𝐶𝐿 and 𝑃𝑡=0) 
using a forward selection process and an additive shift model.     
 
𝐶𝐿𝑖 = (𝛽1 + 𝛽2 ∙ 𝑠𝑒𝑥𝑖) × 𝑒
𝜂𝑖 . 
Equation 2.5 Additive shift model for individual CL. 
 
2.3.4. Model evaluation 
Model selection was based on a reduction in the objective function value 
(OFV), a reduction in variance of BSV or RUV, and precision of the parameter 
estimates. For nested models, the likelihood-ratio test was used whereby a 
reduction in OFV of ≥ 3.84 represents a statistically significant difference for one 
degree of freedom (𝑑𝑓). 
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Precision of the final parameter estimates was also evaluated based on 
asymptotic estimates and either likelihood profiling (for the 95% confidence 
interval [CI]) or jackknife (for standard error [SE]). Likelihood profiling method 
is based on the likelihood ratio test where parameter estimate values associated 
with 3.84 units increase from the minimum OFV correspond to a (non-
asymptotic) 95% CI around a particular parameter estimate of interest (𝑑𝑓 = 1). 
In delete-one jackknife analysis, new datasets, which were constructed by 
deleting all observations of a unique patient one-at-a-time from the original 
dataset, were fitted using the final model structure. The mean and standard 
deviation of final parameter estimates from jackknife runs were used for 
calculation of relative SE (RSE). Only jackknife runs that minimised successfully 
or ended with rounding errors were used to derive the precision measures [169]. 
Graphical diagnostics were based on model fits for each individual’s data 
and prediction-corrected visual predictive checks (pcVPC) [170]. For pcVPC, a 
total of 1000 datasets were simulated from the model using NONMEM®. 
Simulation results were stratified based on dependent variables. The resulting 
50th percentile (median) of the observations and the simulated data, alongside 
the 10th and 90th percentiles that correspond to an 80% prediction interval, were 
plotted against time. The corresponding 95% CI for all simulated percentiles was 
also constructed and graphed. A small prediction interval was chosen because 
of the small sample size.  
  




Eight or nine samples for each of factors II, VII, IX, and X and proteins C 
and S were available for 18 patients. One patient (ID 7) was administered vitamin 
K on day nine and was excluded from the analysis. In addition, data related to 
the missing dosing records of ID 6 were censored. The missing dosing records 
were not imputed using the LOCF method because the imputed doses (0 mg) 
appeared to contradict the observation that the concentration-time profile of all 
coagulation proteins for ID 6 were continually suppressed. Concentration-time 
profiles of relevant coagulation proteins for the 17 patients included in the 
analysis are shown in Figure 2.1.  
  




Figure 2.1 Concentration-time profile of factors II (panel a), VII (panel b), IX (panel c), 
and X (panel d) and proteins C (panel e) and S (panel f) for all 17 patients after warfarin 
initiation at time zero. PC is protein C. PS is protein S. The marker indicates observation. 
The coloured solid line indicates the connector between observations by individual.   
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When 𝑘𝑎  was estimated during model development, the estimate was 
found to be much higher than literature values. Therefore, in the final model, 𝑘𝑎 
and its variance were fixed to values previously estimated [152]. 𝐼𝑚𝑎𝑥,𝑃 was fixed 
to one for the inhibitory 𝐸𝑚𝑎𝑥 model as 𝐼𝑚𝑎𝑥,𝑃 and 𝐼𝐴50,𝑃 were found to be highly 
correlated as shown in Appendix A1.3.  
Two final joint models were developed. The models differed in accounting 
for natural correlation structures that exist between parameters at the individual 
level and between residual errors of paired samples. In this work, the joint 
models were heuristically named the full joint model and the reduced joint model, 
respectively, to signify the presence or absence of the correlation structure. It is 
important to note that both the full and reduced joint models were stable to 
different initial parameter estimates, the final parameter estimates were similar, 
and the empirical SE values were of the same order of magnitude. It is important 
to note that individual model for each coagulation protein was built for the sole 
purpose of providing reliable initial estimates for joint modeling. Individual 
models were therefore modelling aids and do not in any way represent 
modelling endpoints. Model-building results for the individual models are 
therefore not elaborated in this thesis. The remainder of this chapter describes 
the development of the joint model. 
The construction of the joint models was built on several assumptions. The 
assumptions were evaluated in terms of the probability and impact of 
assumption violation. The list of assumptions and details of the evaluation are 
reported extensively in Chapter 5 and Appendix 4.    
2.4.1. Full joint model 
The BSV correlation matrix has a 13 × 13 dimension corresponding to the 
13 parameters (both 𝑃𝑡=0  and 𝑘𝑜𝑢𝑡,𝑃  across all six vitamin K-dependent 
coagulation proteins and a lag parameter, 𝐿𝐴𝐺 ). Because all the vitamin K-
dependent coagulation proteins were assayed in the same blood sample, part of 
the assay error and all of the process error (e.g. dosing time errors) will be 
correlated across different coagulation proteins for the same sample. Full L2 
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correlation was considered but the final model contained separate correlation 
matrices for proportional and additive error components. The correlation in the 
individual prediction error (a composite of proportional and additive errors) of 
the final full model for different coagulation proteins is shown in Figure 2.2.   
 
  
Figure 2.2 Correlation between individual prediction errors of the final full model for 
factors II, VII, IX, X, and proteins C and S.  The individual prediction error is calculated 
as the difference between observation and individual prediction (IPRED in NONMEM® 
parlance). The units are IU/dL. ρ denotes Pearson’s linear correlation coefficient. PC is 
protein C. PS is protein S. The red line indicates the corresponding linear function. 
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Since the full joint model contains 157 fixed- and random-effect parameters 
that were estimated from 17 patients who provided 894 data points, it was 
considered to be at risk of over-parameterisation. Details of the model-building 
process are summarised in a table in Appendix A1.4. The final parameter 
estimates and the corresponding RSEs of the full joint model are also not 
presented here but are given in Appendix A1.5 should need arise to simulate 
from the full joint model. In view of model complexity, the NONMEM® code 
with the final estimates inputted for the full joint model is also provided in 
Appendix A1.6. Individual fits and pcVPC can be found in Appendix A1.7 and 
Appendix A1.8, respectively. Precision of the parameter estimates for this model 
were evaluated using a jackknife procedure. The remainder of this work 
describes the development of the reduced joint model. 
2.4.2. Reduced joint model 
The reduced joint model does not include L1 (BSV) and L2 (RUV) 
correlation structures. It was built directly from the final joint model by the 
removal of the L1 and L2 correlation structures. No further model-building steps 
were taken because the reduced joint model performed comparably to the full 
model.   
The reduced joint model consists of a one-compartment model with first-
order absorption and elimination to describe the amount of warfarin in the body, 
which drives a series of six coagulation protein-specific inhibitory 𝐸𝑚𝑎𝑥 
functions, each linked to a turnover model. The system of ODEs for the final 
reduced joint model is shown in Equation 2.6 and is accompanied by a 
description of the final model structure in Figure 2.3 and presentation of the 
corresponding NONMEM® code with the final estimates inputted in Appendix 
A1.9. 
  





= −𝑘𝑎 ∙ 𝐷;     {
 𝑡 < 𝐿𝐴𝐺, 𝐷𝑡=0 = 0       




= 𝑘𝑎 ∙ 𝐷 −
𝐶𝐿
𝑉
∙ 𝐴;     𝐴𝑡=0 = 0 
𝑑𝐼𝐼
𝑑𝑡



































𝑃 = {𝐼𝐼, 𝑉𝐼𝐼, 𝐼𝑋, 𝑋, 𝑃𝐶, 𝑃𝑆} 




𝑅𝑖𝑛,𝑃 = 𝑃𝑡=0 ∙ 𝑘𝑜𝑢𝑡,𝑃 
Equation 2.6 ODEs for the reduced joint model. 
 
In Equation 2.6, all parameters were as previously defined with the addition of 
𝐿𝐴𝐺, which represents a delay in the dose reaching the depot compartment. The 
final parameter estimates of the reduced model are given in Table 2.1. A 
covariate analysis showed that sex had no significant effect on either 𝐶𝐿 or 𝑃𝑡=0. 
  




Figure 2.3 Structure of the final joint model. CL represents the clearance of warfarin, IP 
inhibitory Emax function, ka first-order absorption rate constant of warfarin, kout,P first-
order coagulation protein degradation rate constant, PC protein C, PS protein S, Pt=0 
coagulation protein concentration at baseline, Rin,P zero-order functional coagulation 
protein production rate (parameterised as kout,P∙Pt=0), V volume of distribution of 
warfarin. The rectangular box indicates a compartment and its mass balance is 
represented by one of the ODEs shown in Equation 2.6. The dashed arrow indicates 
inhibition and the solid arrow mass balance relationship.  
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Table 2.1 Parameter estimates for the final reduced joint model. LAG represents the lag 
parameter. ηi between-subject variability in parameter. CI confidence interval, CV 
coefficient of variation, CVpropP coefficient of variation for the proportional error 
associated with model prediction, CL clearance of warfarin, F bioavailability, IA50,P 
warfarin amount in the body that gives half the maximum inhibitory effect, Imax,P 
maximum inhibitory effect, ka first-order absorption rate constant of warfarin, kout,P first-
order coagulation protein degradation rate constant, PC protein C, PS protein S, Pt=0 
coagulation protein concentration at baseline, V volume of distribution of warfarin, ω 
standard deviation of between-subject variability in parameter, σadd,P standard deviation 
for the additive error associated with model prediction. Square bracket indicates inclusive 







𝐹 1.00 fixed – 
𝑘𝑎 (h-1) 1.19 fixedb – 
𝐶𝐿 (L/h) 0.211 [0.136, 0.323] 
𝑉 (L) 8.06 fixedb – 
𝐼𝑚𝑎𝑥,𝐼𝐼 1.00 fixed   – 
𝐼𝑚𝑎𝑥,𝑉𝐼𝐼 1.00 fixed – 
𝐼𝑚𝑎𝑥,𝐼𝑋 1.00 fixed – 
𝐼𝑚𝑎𝑥,𝑋 1.00 fixed – 
𝐼𝑚𝑎𝑥,𝑃𝐶 1.00 fixed – 
𝐼𝑚𝑎𝑥,𝑃𝑆 1.00 fixed – 
𝐼𝐴50,𝐼𝐼 (mg) 1.83 [1.34, 2.41] 
𝐼𝐴50,𝑉𝐼𝐼 (mg) 1.86 [1.38, 2.43] 
𝐼𝐴50,𝐼𝑋 (mg) 2.41 [1.79, 3.14] 
𝐼𝐴50,𝑋 (mg) 0.875 [0.631, 1.160] 
𝐼𝐴50,𝑃𝐶 (mg) 5.21 [3.93, 6.59] 
𝐼𝐴50,𝑃𝑆 (mg) 3.35 [2.46, 4.39] 
𝐼𝐼𝑡=0 (IU/dL) 115 [104, 125] 
𝑉𝐼𝐼𝑡=0 (IU/dL) 115 [98, 134] 
𝐼𝑋𝑡=0 (IU/dL) 141 [128, 155] 
𝑋𝑡=0 (IU/dL) 109 [99, 118] 
𝑃𝐶𝑡=0 (IU/dL) 101 [92, 111] 
𝑃𝑆𝑡=0 (IU/dL) 105 [92, 118] 
𝑘𝑜𝑢𝑡,𝐼𝐼 (h-1) 0.0135 [0.0108, 0.0171] 
𝑘𝑜𝑢𝑡,𝑉𝐼𝐼 (h-1) 0.0570 [0.0358, 0.0946] 
𝑘𝑜𝑢𝑡,𝐼𝑋 (h-1) 0.0323 [0.0208, 0.0523] 
𝑘𝑜𝑢𝑡,𝑋 (h-1) 0.0157 [0.0129, 0.0192] 
𝑘𝑜𝑢𝑡,𝑃𝐶 (h-1) 0.0376 [0.0234, 0.0663] 
𝑘𝑜𝑢𝑡,𝑃𝑆 (h-1) 0.0122 [0.0103, 0.0146] 
𝐿𝐴𝐺 (h) 12.5 [10.4, 14.2] 
CV 𝑘𝑎 (%) 73.0 fixedb (83.1%) – 







CV 𝐶𝐿 (%) 82.2 (0.6%) [55.9, 145.5] 
CV 𝐼𝐴50,𝑃𝐶 (%) 13.4 (45.9%)  (0, 29.2] 
𝜔 𝐼𝐼𝑡=0 (IU/dL)  17.8 (1.2%) [10.6, 25.2] 
𝜔 𝑉𝐼𝐼𝑡=0 (IU/dL)  26.9 (5.9%) [17.7, 42.3] 
𝜔 𝐼𝑋𝑡=0 (IU/dL)  25.0 (6.1%) [16.2, 39.1] 
𝜔 𝑋𝑡=0 (IU/dL)  17.5 (1.7%) [12.4, 26.0] 
𝜔 𝑃𝐶𝑡=0 (IU/dL)  17.4 (1.7%) [12.2, 25.8] 
𝜔 𝑃𝑆𝑡=0 (IU/dL)  24.4 (-0.6%) [17.8, 35.8] 
CV 𝑘𝑜𝑢𝑡,𝐼𝐼 (%) 41.4 (6.8%) [27.3, 66.7] 
CV 𝑘𝑜𝑢𝑡,𝑉𝐼𝐼 (%) 92.6 (14.7%) [54.4, 192.1] 
CV 𝑘𝑜𝑢𝑡,𝐼𝑋 (%) 89.6 (11.0 %) [53.6, 182.0] 
CV 𝑘𝑜𝑢𝑡,𝑋 (%) 36.3 (4.7%) [24.6, 56.8] 
CV 𝑘𝑜𝑢𝑡,𝑃𝐶 (%) 91.2 (12.1%) [53.9, 194.4] 
CV 𝑘𝑜𝑢𝑡,𝑃𝑆 (%) 19.0 (37.5%) (0, 38.7] 
𝜎𝑎𝑑𝑑𝐼𝐼 (IU/dL) 7.11 [5.62, 8.56] 
CVprop𝐼𝐼 (%)   3.69 (0, 7.56] 
𝜎𝑎𝑑𝑑𝑉𝐼𝐼 (IU/dL) 8.80 [5.34, 12.75] 
CVprop𝑉𝐼𝐼 (%)   15.3 (0, 24.5] 
𝜎𝑎𝑑𝑑𝐼𝑋 (IU/dL) 11.0 [7.1, 14.0] 
CVprop𝐼𝑋 (%)   10.9 [1.5, 17.3] 
𝜎𝑎𝑑𝑑𝑋 (IU/dL) 5.41 [4.35, 6.64] 
CVprop𝑋 (%)   5.96 [1.72, 8.93] 
𝜎𝑎𝑑𝑑𝑃𝐶 (IU/dL) 3.89 (0, 6.69] 
CVprop𝑃𝐶 (%)   8.58 [2.99, 12.27] 
𝜎𝑎𝑑𝑑𝑃𝑆 (IU/dL) 3.33 (0, 5.97] 
CVprop𝑃𝑆 (%)   10.6 [7.5, 13.5] 
a Given by likelihood profiling. Note that the lower bound of some 95% CIs has a value of zero, which is an 
asymptotic value. 
b Sourced from values estimated by Wright et al. [152]. 
 
A delay between warfarin exposure and coagulation protein reduction (e.g. 
factors VII and IX) was observed during model development. Two models for 
delay were proposed, a general lag model (note 𝐿𝐴𝐺  in Equation 2.6) and a 
coagulation protein storage model. 
The general lag model introduces a delay via inclusion of a parameter, 𝐿𝐴𝐺, 
that acts by delaying warfarin input into the absorption depot. In contrast, the 
storage model incorporates a reservoir of vitamin K-dependent coagulation 
proteins that needs to be depleted prior to a reduction in plasma coagulation 
proteins. The size of the coagulation protein storage at baseline ( 𝑃_𝑆𝑡=0) 
therefore functions as a lag parameter. Note that once the reservoir is depleted 
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no further delay will be seen on subsequent warfarin doses.  Using factor VII as 
an example, the proposed structure of the storage model is compared and 
contrasted with the general lag model in Figure 2.4.  
 
 
Figure 2.4 Alternative models to account for the delay between warfarin exposure and 
factor VII reduction. Panel a shows the general lag model and panel b represents the 
storage model. A represents the warfarin in the body, CL clearance of warfarin, IA50,VII 
warfarin amount in the body that gives half the maximum inhibitory effect, Imax,VII 
maximum inhibitory effect, ka first-order absorption rate constant of warfarin, KM 
Michaelis–Menten constant, kout,VII first-order degradation rate constant for factor VII, 
LAG general lag parameter, Rin,VII zero-order production rate of functional factor VII 
(parameterised as kout,VII∙VII_Bt=0), V volume of distribution of warfarin, VII_B factor 
VII in the blood compartment, VII_Bt=0 factor VII in the blood compartment at baseline, 
VII_S factor VII in the storage compartment. The rectangular box indicates the 
compartment. The dashed arrow indicates inhibition and the solid arrow indicates the 
mass balance relationship. 
 
Characteristics of the general lag model and the storage model for factor 
VII were explored via simulations using MATLAB® Version 2015a (The 
MathWorks, Inc., Natick, Massachusetts, United States). For the simulations of 
the general lag model, population parameter estimates from the best individual 
model for factor VII, which contains a 𝐿𝐴𝐺 parameter, was used. Simulations of 
the storage model, on the other hand, proceeded with the removal of the 𝐿𝐴𝐺 
parameter and imputation of the factor VII storage structure (Figure 2.4).  
For single warfarin dose simulation within the storage model framework, 
panel a in Figure 2.5 shows that time to factor VII nadir appeared to be fairly 
insensitive to a change in 𝐾𝑀. Panel b in Figure 2.5 reveals that time to factor VII 
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nadir increased with larger values of 𝑉𝐼𝐼_𝑆𝑡=0, which confirmed the ability of 
𝑉𝐼𝐼_𝑆𝑡=0  to function as a delay parameter. Of all the storage models, storage 
model with 𝑉𝐼𝐼_𝑆𝑡=0 = 110 IU/dL and 𝐾𝑀 = 1 IU/dL had simulated factor VII 
profile most similar to that of the best general lag model (𝐿𝐴𝐺 = 15.9 hours) for 
factor VII in terms of time to nadir.  
 
 
Figure 2.5 Factor VII profiles simulated using different magnitudes of KM (panel a) or 
VII_St=0 (panel b) after single 5 mg warfarin dose administration. The blood 
compartment was observed. LAG is the general lag parameter, KM represents the 
Michaelis–Menten constant and VII_St=0 denotes factor VII in the storage compartment 
at baseline. 
 
Available factor VII data were fitted using the general lag model and the 
storage model in NONMEM®. On the basis of the likelihood-ratio test, both the 
general lag model (Δ𝑂𝐹𝑉 = −36.6) and the best storage model (Δ𝑂𝐹𝑉 = −26.2) 
were found to be superior to the base model for factor VII. However, the general 
lag model was more parsimonious and provided a better statistical 
representation of the data in terms of OFV. In the joint model framework, 𝐿𝐴𝐺 
was estimated as 12.5 hours and was statistically preferred to be present on each 
dose.  
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2.4.3. Model evaluation 
The 95% CI of the parameter estimates was evaluated by likelihood 
profiling and is shown in Table 2.1. It is seen that all fixed- and random-effects 
parameters of the reduced joint model were estimated with reasonably good 
precision. The conditional-weighted residuals versus time plots show no 
discernible trend (see Appendix A1.10). Model misspecification was not evident. 
Individual fits of the concentration–time profile of vitamin K-dependent 
coagulation proteins for the reduced joint model organised according to patient 
identifier are shown in Appendix A1.11. Plots of five representative individuals 
are shown in Figure 2.6. Of note, the model appeared to overpredict the nadir 
for factors VII and IX for ID 2, ID 4, ID 5, ID 9, ID 10, ID 11, ID 13, ID 15, ID 16 
and ID 17. All data were otherwise well characterised but with a worse fit noted 
at later time points when sampling was sparse. 
The pcVPCs of the reduced model for each vitamin K-dependent 
coagulation protein are depicted in Figure 2.7. For the reduced model, the 
median of the data simulated from the final model were in close agreement with 
that of observed data. However, as with individual fit results, overprediction of 
the nadir was observed whereby the median model predictions appeared to 
overpredict median concentrations of factors VII and IX at 41, 65 and 91.5 hours 
after warfarin initiation (see Figure 2.7). 
  




Figure 2.6 Individual fits for the time course of factors II, VII, IX, X, and proteins C and 
S for five representative individuals following warfarin initiation. The black lines are 
predictions from the final reduced joint model. The grey markers are observations. PC 
denotes protein C and PS represents protein S.  
 




Figure 2.7 pcVPC for factors II, VII, IX and X, and proteins C and S based on the final 
reduced joint model. The blue circle indicates observation. The black solid line indicates 
the median of simulated data. The red solid line indicates the median of observed data. 
The black dashed line indicates the 10th and 90th percentiles of simulated data that 
correspond to the 80% prediction interval. The red dashed line indicates the 10th and 90th 
percentiles of observed data that correspond to the 80% prediction interval. The shaded 
area indicates the 95% confidence interval around the simulated percentiles. pcVPC 
stands for prediction-corrected visual predictive checks.  
 
The problem of overpredicting the nadir was further investigated using the 
factor VII framework as an exemplar. A mixture model for 𝐼𝐴50,𝑉𝐼𝐼  as well as 
inclusion of a variance component for BSV of 𝐼𝐴50,𝑉𝐼𝐼 did not improve the model 
fit. Two causes were postulated: (1) an unaccounted for process error (e.g. 
unrecorded dose change) or (2) an aspect of the underlying biology was not 
effectively captured. Simulation of factor VII concentration–time profiles 
showed that accounting for possible dose adjustment or incorporating a shape 
parameter for the inhibitory 𝐸𝑚𝑎𝑥  function, 𝛾, provided a better prediction of 
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observations compared with the original model (see Figure 2.8). Although 
estimation of 𝛾  as 1.96, to some extent, alleviated the problem in some 
individuals, improvement in the pcVPC was not apparent (not shown). Because 
these two approaches were exploratory and, in this setting, model 
misspecification based on mechanism or on process error provided similar 
benefits in the model prediction, neither was taken forward into the final model. 
 
 
Figure 2.8 Simulating overprediction of nadir as a result of unrecorded dose change 
(panel a) and biology (panel b) with duration of simulation of up to 120 hours. γ is the 
shape parameter for the inhibitory Emax function. 
  




Two final joint models were developed from this work and were able to 
accurately describe the time course of warfarin influence on all six vitamin K-
dependent coagulation proteins. In both models, the parameter values of all 
vitamin K-dependent coagulation proteins were estimated simultaneously but 
differed with respect to their correlation structures. The full joint model 
considered the full correlation structures that exist between parameters at the 
individual level and between residual errors within blood samples. However, 
because it is likely that the final full joint model is overparameterised owing to 
the sheer size of the correlation matrices that are required to be estimated, details 
of the full joint model are provided as additional material in the appendices and 
the reduced joint model is reported primarily in this chapter. The full joint model 
may be more useful for modellers who are interested in simulating from the 
model, whereas the reduced joint model is preferable for estimation purposes 
when computation time is a concern or when model parsimony is a priority. It is 
worth noting that both the full and reduced joint models are largely similar in 
terms of individual predictions in addition to having empirical SE values that 
are similar. Both models also have comparable final parameter estimates but 𝐶𝐿 
estimates are somewhat different (percentage difference 49.3%). 𝐼𝐴50,𝑃 estimates 
are also different, which most likely arise from a correlation between 𝐶𝐿 and 
𝐼𝐴50,𝑃. 
The KPD model used differs from those reported in the published 
literature. In this work, the amount of warfarin in the body was used to drive the 
inhibitory 𝐸𝑚𝑎𝑥 function (Equation 2.3) rather than the elimination rate [54, 59, 
60]. It is thought that the use of the elimination rate as a driver of 
pharmacodynamic effects is not pharmacologically intuitive and likely to be 
inconsistent with classical receptor theory underpinning drug effects. The results 
of the current analysis are broadly similar to those in the published literature. 
The 𝐶𝐿  estimate, 0.211 (95% CI 0.136–0.323) L/h, is in close agreement with 
reported values that range from 0.127 to 0.333 L/h (see Table 2.1) [99, 104]. The 
degradation half-life of factors II, VII, IX and X, and proteins C and S was 
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estimated as 51.3, 12.2, 21.5, 44.1, 18.4, and 56.8 hours, respectively, while 
reported values range from 72–115, 5–35, 18–40, 35–63, 8–32, and 43 hours, 
respectively [99, 159, 161, 165, 171-175]. Factor VII was found to have the shortest 
degradation half-life compared to other coagulation proteins. Then, upon 
warfarin initiation, factor VII is likely the first to decline and to reach a new 
steady-state level. This is supported by data shown in Figure 2.1.    
It is worth noting that the reported half-life should be interpreted with 
caution for coagulation proteins with a shorter plasma half-life than warfarin, 
i.e. when 𝑘𝑜𝑢𝑡,𝑃 ≫ 𝑘 (e.g. factors VII, IX, and protein C), as 𝑘𝑜𝑢𝑡,𝑃 was found to be 
less precisely estimated (see Table 2.1). This is not unexpected because the time 
course of observed coagulation protein concentrations will likely reflect the rate-
limiting step in the causal path from warfarin dose to response and therefore will 
appear relatively uninformative of other steps. However, within the joint 
modelling framework, the same cannot be said for the estimation of 𝑘  or 𝐶𝐿 
when the degradation of the coagulation proteins is the rate-limiting step (i.e. 
𝑘𝑜𝑢𝑡,𝑃 ≪ 𝑘 ). In the joint model, even though the coagulation proteins with 
𝑘𝑜𝑢𝑡,𝑃 ≪ 𝑘 (e.g. factors II, X, and protein S) is uninformative of 𝑘, estimation of 𝑘 
can be informed by other coagulation proteins with 𝑘𝑜𝑢𝑡,𝑃 ≫ 𝑘 (e.g. factors VII, 
IX, and protein C). This illustrate an important advantage of the joint model 
compared to modelling each coagulation protein individually.  
There have been few published analyses examining the time course of the 
coagulation proteins in response to warfarin therapy. To date, only two 
population analyses have been performed and both modelled the warfarin-
factor VII relationship [157, 165]. No models have been developed for the other 
coagulation proteins including factor II (prothrombin), which is an important 
determinant of in vivo prothrombin activation for clotting. In the majority of 
warfarin-coagulation protein studies, only the time to new steady state was 
quantified or, in some cases, nadir or depression of vitamin K-dependent 
coagulation proteins at selected time points after warfarin initiation was 
compared and contrasted to base concentrations [99, 157-159, 161, 165, 166]. In 
these studies, individual coagulation protein was studied in isolation and its 
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time course was typically examined in cross-section. This limits the supposed 
entire time course of anticoagulant responses to a snapshot of a single 
coagulation protein response to warfarin. In contrast, the model developed in 
this work, by jointly modelling factors II, VII, IX and X, and proteins C and S, 
during warfarin initiation, provides a means of quantifying the temporal 
influence of warfarin to all six vitamin K-dependent coagulation proteins 
simultaneously. 
A delay in the onset of coagulation protein reduction was observed, which 
was evident for factors VII and IX. A similar delay has been reported in previous 
studies [140, 157, 165] but the exact mechanism for the delay is unknown. The 
most prevalent hypothesis to explain the delay is the presence of a storage pool 
of vitamin K that becomes the rate-limiting step in the inhibition of the 
biosynthesis of vitamin K-dependent coagulation proteins [140, 157, 176, 177]. In 
this study, the delay was addressed using two models: a general lag model and 
the storage model. In the lag model, a 𝐿𝐴𝐺  parameter served as a heuristic 
solution to the observed delay and should not be interpreted as an absorption 
lag parameter per se but rather an all-purpose lag parameter that covers dose 
time deviation, delay in warfarin absorption, and delay in the influence of 
warfarin on factor production. Previously published 𝐿𝐴𝐺 estimates for factor VII 
data (6.90 and 10.9 hours, respectively) and for prothrombin complex activity 
data (8.00 hours) are comparable to that found in this study (12.5 hours), which 
was consistent across all doses [140, 157, 165]. In contrast, the storage model 
provides a potential mechanism and accounts for a coagulation protein-specific 
delay. However, the storage model only accounted for a single reservoir (and 
hence effective for first-dose delay only) and therefore it lacks the flexibility of 
the general lag model in terms of modelling repeated lag. In the absence of 
evidence regarding the mechanism of the lag, model selection can only be guided 
by statistical improvements in the model. It is important to note that the 
mechanisms of lag presented here are by no means exhaustive. Other 
mechanisms of lag, for instance, process error or existence of a storage pool of 
vitamin K hydroquinone, could be considered and explored in future studies. 
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In this work, overprediction of the nadir in factors VII and IX was 
identified. There are many potential sources for the overprediction and these 
could include a process error as simple as a dose change recording error to an 
unexpectedly more complicated biology of warfarin activity. Both were 
considered in model-building and both improved the fit. In the absence of 
confirmatory mechanistic data, parsimony supports discounting the more 
complicated mechanism. It is important to note that an estimated empirical 
shape parameter for the sigmoid 𝐸𝑚𝑎𝑥 model, 𝛾, is not uncommon in published 
warfarin models to describe the time course of INR, prothrombin complex 
activity, or factor VII, presumably because its inclusion is associated with 
improved goodness-of-fit [18, 54, 100, 103, 140, 157, 165]. In this study, 𝛾 was 
estimated as 1.96, which is incorporated within the previous published values 
(range 0.424–2.83) [18, 54, 100, 103, 140, 157, 165]. 
Our work has several drawbacks. Because warfarin concentration–time 
data were not available, then 𝑉  and its variance were not structurally 
identifiable. In addition, owing to the delayed time course of changes in 
coagulation proteins and sparse sampling relative to the time course of warfarin 
absorption, it was found that 𝑘𝑎  of warfarin and its variance were not 
deterministically identifiable. A sensitivity analysis did not reveal a dependence 
of the final model on the choice of 𝑘𝑎. It is worth noting that our sample size is 
small (𝑛 = 17), thus potentially limiting generalisability of the study’s results to 
all warfarin users. In addition, while likelihood profiling was used for precision 
assessment of the parameter estimates for the reduced joint model it was not 
used for the full joint model. Likelihood profiling requires a repeated estimation 
of model parameters for each instance when an individual parameter is fixed to 
different values. Challenges in ensuring positive definiteness in correlation 
matrix (over 157 correlation terms) during likelihood profiling together with 
significant computation time rendered likelihood profiling unsuitable for the full 
joint model. Instead, a delete-1 jackknife was used for the full joint model. Even 
though jackknife estimates of SE are asymptotically consistent and unbiased 
[178], it may have dubious properties for small samples [179]. Nevertheless, the 
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jackknife SE estimates obtained in this study appeared reliable considering their 
alignment with likelihood profiling for the reduced model. Furthermore, in 
accordance with previous studies, jackknife SE estimates even in small sample 
situations have been shown to be in close agreement with SE obtained by non-
parametric bootstrap, which is traditionally employed to evaluate the precision 
of model parameters [19, 180]. 
The model developed provides an initial framework for mechanistic 
insight into warfarin exposure and response, which is traditionally studied 
empirically using the pharmacokinetics and INR data of warfarin. A mechanistic 
and comprehensive depiction of warfarin exposure and response can be 
obtained by the incorporation of two additional components (vitamin K cycle 
and INR) to the warfarin-coagulation protein model developed. Integration of 
the vitamin K cycle as an intermediary step between warfarin exposure and 
coagulation protein response would allow the complex interactions between 
warfarin and vitamin K to be taken into consideration. This will be useful in 
understanding and predicting the time course of coagulation proteins after 
warfarin reversal with vitamin K in warfarin toxicity or for the prevention of 
perioperative bleeding. A comprehensive warfarin-vitamin K-coagulation 
protein-INR model also represents the first step towards understanding 
transient warfarin resistance, a phenomenon where the use of vitamin K for 
warfarin reversal frequently leads to curiously prolonged resistance to warfarin 
(>7 days) despite warfarin reintroduction. This has important clinical utility in 
the determination of the appropriate vitamin K dose, time, and frequency for 
warfarin reversal.  
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2.6. Conclusions  
A joint model for the vitamin K-dependent coagulation proteins following 
warfarin initiation is developed. The model adequately quantifies the time 
course of warfarin influence on factors II, VII, IX, and X, and proteins C and S 
simultaneously. Factor VII was found to have the shortest degradation half-life 
compared to other coagulation proteins thereby representing the coagulation 
protein that is the first to decline and to reach a new steady-state level following 
a perturbation introduced by warfarin. The influence of various vitamin K-
dependent coagulation proteins on the INR is discussed in Chapter 3 and 
Chapter 4.  
An important future step, although beyond the scope of the thesis, would 
be to incorporate the vitamin K cycle as an intermediary step between warfarin 
exposure and response, as well as to integrate INR into the model. This provides 
a focused framework describing the relationships between warfarin, vitamin K 
cycle, vitamin K-dependent coagulation proteins, and INR that would be useful 
for systematic exploration of complex clinical problems (e.g. warfarin reversal 
with vitamin K and transient warfarin resistance) involving multiple systems 
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The following two chapters outline the conception and development of a 
prediction method to quantify the anticoagulant response for warfarin dose 
individualisation. Despite a significant body of literature in this area, algorithms 
for predicting warfarin maintenance dose in patients remain inaccurate [2-7]. It 
is believed that much of these issues relate to the use of the international 
normalised ratio (INR) solely as a marker of coagulation. In routine clinical 
settings, the prediction of steady-state INR relies heavily on the interpretation of 
non-steady-state INR, which requires a working knowledge of the relationship 
between warfarin exposure, coagulation proteins and INR response, a 
relationship that is inherently nonlinear, and therefore, not necessarily intuitive. 
The motivation for this work is the overarching belief that a measure of 
coagulation protein response in addition to INR will better inform the steady-
state INR prediction. A choice of coagulation protein that is particularly sensitive 
to warfarin would therefore be appropriate to aid interpretation of the observed 
INR value for future INR prediction.  
Chapter 3 explores the coagulation kinetics underpinning the INR using a 
sensitivity analysis and an isobologram analysis. It seeks to identify an 
appropriate coagulation protein that provides a signal from the system that lies 
causally between warfarin exposure and INR that would be useful for INR 
prediction. This is followed by Chapter 4, which incorporates the information 
from the aforementioned coagulation protein of choice for the prediction of 
future INR in patients receiving warfarin. The methods used are based on 
approximations to a quantitative systems pharmacology (QSP) model and new 
insights are provided on the time to steady-state INR as an integral part of the 
process.  
  




The prothrombin time (PT) test, which is typically reported as the INR in 
routine clinical setting, is an in vitro blood test designed to measure the clotting 
time of blood as a proxy to the anticoagulant response. Both PT and INR provide 
a composite and blunt measure of coagulation activity related to fibrinogen, 
factors II, V, VII, and X but are generally unable to delineate contribution from 
individual coagulation proteins [136, 137].  
Exploration of the coagulation kinetics using standard experimental 
designs is difficult [31] due to (1) the complex positive-feedback, negative-
feedback, positive-feedforward, and negative-feedforward reactions that makes 
snapshot views of components of the coagulation network incomplete, 
potentially leading to descriptions that are incompatible with known 
mechanisms, (2) the different orders of magnitude in the rate of change of some 
components of the coagulation network, in addition to the diverse turnover rate 
of the different components ranging from seconds to days (i.e. multiscale on the 
time domain), and (3) the fact that the act of drawing a blood sample can itself 
activate the coagulation system.  
Using a QSP model, experiments that would otherwise be impossible or 
logistically impractical to undertake can be conducted. In this work, an in silico 
approach that was based on simulations from a (mechanistic) QSP model was 
used for exploring the influence of coagulation proteins and their complex 
interactions on the INR.   
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3.2. Aims and objectives 
The aim of this simulation study was to understand the coagulation kinetics 
underpinning the non-steady-state and steady-state INR to identify a 
coagulation protein of choice that is informative of the INR for future INR 
prediction. To this end, there were two specific objectives: (1) to evaluate the 
sensitivity of INR to a reduction in an individual coagulation protein in a single 
coagulation protein deficiency and multiple coagulation protein deficiency, and  
(2) to quantify the nature of interactions (sub-additivity, additivity, or supra-
additivity) between coagulation proteins with respect to the INR.  
  




The method section describes the definitions employed, model evaluation, 
simulation of PT and INR tests, sensitivity analysis, and isobologram analysis 
conducted in this work.  
3.3.1. Definitions 
For the purpose of this work, steady-state INR is defined as the INR that is 
no longer transitioning (i.e. changing over time). Mathematically, the steady-
state INR is represented by 
𝑑𝐼𝑁𝑅
𝑑𝑡
= 0  for 𝑡 > 0 . Single coagulation protein 
deficiency is defined as a deficiency in a single coagulation protein whereas 
multiple coagulation protein deficiency refers to a deficiency in more than one 
coagulation protein simultaneously.   
3.3.2. Model evaluation 
In this work, a QSP model of the coagulation network, which was 
developed by Wajima and colleagues [31] and later updated by Gulati and peers 
[38], was used for simulation of warfarin therapy and the corresponding effect 
on the coagulation proteins and the INR. The model consists of 63 compartments 
and includes components of in vivo coagulation as well as in vitro blood 
coagulation tests (e.g. PT and INR tests). The model was previously applied to 
simulating PT and INR and was found to provide an adequate description of the 
data from the literature [31, 83]. See Figure 3.1 for a schematic of the structure of 
the model.  
An important prerequisite to the use of the model for this simulation study 
is that the model provides an adequate description of the relationship between 
warfarin, coagulation proteins, and INR. Here, the model was evaluated using 
an external test dataset [167, 181]. In this dataset, dosing and anticoagulant 
response data from 17 patients with atrial fibrillation who had warfarin therapy 
initiated were available for analysis. Nine blood samples were collected from 
each patient at baseline, and at 1-5, 8, 15 and 29 days after warfarin initiation and 
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assayed for factors II, VII, IX, and X, and INR. Warfarin concentration-time data 
were not available.  
For model evaluation, missing dosing records in the external test dataset 
were imputed using last observation carried forward. Then, using available 
dosing information, factors II, VII, IX, and X, and INR response were simulated 
from the QSP coagulation network model in MATLAB® Version 2015a (The 
MathWorks Inc., Natick, Massachusetts, USA) using parameter values for a 
typical individual [31]. The predictive performance of the QSP coagulation 
network model was evaluated visually based on the level of agreement between 
plots of individual observed and simulated time course data.  
 
 
Figure 3.1 Schematics of the coagulation network model [31]. APC represents activated 
protein C, AT-III antithrombin-III, CA contact activator, DP degradation product, F 
fibrin, Fg fibrinogen, II factor II, IIa thrombin, K kallikrein, P plasmin, PC protein C, Pg 
plasminogen, Pk prekallikrein, PS protein S, TAT thrombin-antithrombin complex, TF 
tissue factor, TFPI tissue factor pathway inhibitor, Tmod thrombomodulin, VK vitamin 
K, VKH2 vitamin K hydroquinone, VKO vitamin K epoxide, XF cross-linked fibrin.       
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3.3.1. Simulation of PT and INR tests 
In laboratory settings, PT is quantified as the time required for a fibrin clot 
to form after the addition of tissue factor, phospholipid, and calcium to 
decalcified, platelet poor plasma.  
The PT test simulation implemented using the QSP coagulation network 
model [31] is summarised here. For PT test simulation, the initial condition of all 
states was reduced to one-third of the original values to mimic the plasma 
dilution process as a result of the addition of tissue factor, phospholipid, and 
calcium to the reaction mixture. Given that the majority of the coagulation 
components are biosynthesised in the hepatocytes, then the endogenous 
production rate of these components in isolated plasma sample for in vitro PT 
test is likely to be negligible if not non-existent. Furthermore, considering the 
observation time window for the PT test (i.e. in seconds) is much shorter than 
the endogenous turnover of coagulation components (i.e. in hours or days), the 
endogenous production rate of these components was set to zero.  
To initiate coagulation for PT test simulation, 300 𝑛𝑀 of tissue factor (TF) 
was given as input into the TF compartment of the model, which subsequently 
was available for complex formation with factor VII. The TF:VII complex 
eventually led to fibrin clot formation. In this model the PT was determined as 
the point at which the fibrin area under the curve (AUC) reached 1500 𝑛𝑀 ∙ 𝑠 
(equivalent to a 30% reduction in fibrinogen from baseline) [182, 183]. 









Equation 3.1 INR. 
 
Here, 𝑃𝑇  is the measured (simulated) PT, 𝑃𝑇𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑  is the PT for standard 
normal plasma and 𝐼𝑆𝐼 is the international sensitivity index that quantifies the 
sensitivity of the PT test to the thromboplastin (mixture of tissue factor and 
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phospholipid). For the purpose of this work, ISI was assumed to be one and 
𝑃𝑇𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑  was taken as 12 seconds. Finally, it is important to note that the 
simulations were deterministic and stochastic elements were not introduced.          
3.3.2. Sensitivity analysis 
A simulation-based local sensitivity analysis was conducted in MATLAB® 
Version 2015a using the QSP coagulation network model [31] to evaluate the 
sensitivity of the INR to a reduction in individual coagulation protein, first in 
single coagulation protein deficiency, and then in multiple coagulation protein 
deficiency.    
3.3.2.1. Single coagulation protein deficiency 
Deficiency in each of fibrinogen, factors II, V, VII, IX, and X was explored 
one-at-a-time. The single coagulation protein deficiency was introduced by 
adjusting the initial condition of a coagulation protein of interest in the QSP 
coagulation network model to 100% to 5% of normal basal concentrations with a 
step size of 5% (i.e. 100%, 95%, 90%, … , 5%). At each instance, the initial values 
of the other coagulation components remained unchanged (i.e. were initiated at 
the physiological concentrations for a typical patient). Subsequently, the INR 
values were simulated.   
In this work, sensitivity of INR to changes in coagulation protein 





| ;      𝑃 ∈ {𝐹𝑔, 𝐼𝐼, 𝑉, 𝑉𝐼𝐼, 𝐼𝑋, 𝑋}. 
Equation 3.2 Local sensitivity of INR to changes in coagulation protein concentration. 
 
Here, 𝑆𝐼𝑃  denotes the sensitivity index of INR to coagulation protein and 𝑃 
represents the concentration of a particular coagulation protein of interest. 
Assuming linearity in INR and coagulation protein concentration within the step 
size (5%), the above first partial derivative (Equation 3.2) was approximated by 
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using central differences where the difference in coagulation factor is far from 
the limit of zero. Values close to zero indicate that the INR is insensitive to the 
coagulation protein and larger values correspond to high sensitivity.   
3.3.2.2. Multiple coagulation protein deficiency 
Within the single coagulation protein deficiency framework, variation in 
multiple coagulation proteins simultaneously was not permitted. Consequently, 
the natural correlation that exists between coagulation proteins during warfarin 
therapy cannot be accounted for then it follows that the interactions between 
coagulation proteins with respect to the INR are unable to be characterised.  
In this work, the influence of multiple coagulation protein deficiency on the 
INR was investigated. A hypothetical clinical scenario where a typical patient 
who was newly commenced on 4mg of warfarin daily was considered. In the 
first stage, the time course of factors II, VII, and X (vitamin K-dependent 
coagulation proteins identified in Section 3.3.2.1 as influential on the INR) and 
INR following warfarin initiation were simulated. In the subsequent step, the 
local sensitivity of each of factors II (𝑆𝐼𝐼𝐼), VII (𝑆𝐼𝑉𝐼𝐼), and X (𝑆𝐼𝑋) were quantified 
at each simulated time point using Equation 3.2. The magnitude of 𝑆𝐼𝐼𝐼, 𝑆𝐼𝑉𝐼𝐼, 
and 𝑆𝐼𝑋  were compared during non-steady-state and steady-state INR. The 
dominating coagulation protein was identified. 
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3.3.3. Isobologram analysis 
The isobologram analysis, which is traditionally used as an empirical way 
to characterise drug interactions, was used to explore the interactions between 
coagulation proteins with respect to the INR. In this section, components and 
interpretation of an isobologram are introduced from the perspective of a drug-
drug interaction. This is followed by a detailed description of the isobologram 
analysis conducted in this work. The theory and philosophy underpinning an 
isobologram analysis can be found elsewhere [184-186].      
3.3.3.1. Components and interpretation of an isobologram 
A typical dose-normalised isobologram for two drugs is shown in Figure 
3.2. The isobologram axes represent the dose of a drug (e.g. drug A), denoted 
𝐷𝑥,𝐴, that gives a predetermined level of effect (e.g. 𝑥% inhibition) when given in 
combination with a dose of another drug (e.g. drug B), denoted 𝐷𝑥,𝐵. The axes 
may be normalised with the dose of the same drug that singly gives the 
predetermined level of effect i.e. the drug’s potency (e.g. 𝐸𝐷𝑥,𝑑𝑟𝑢𝑔 ). The 
normalisation process standardises the axes to range from zero to (typically) one 
and, importantly, yields a dimensionless dose matrix that is adjusted for the 
drug’s potency for effective comparison across different drugs. The diagonal 









Equation 3.3 Loewe’s additivity. 
 
All the points on the isobologram that correspond to the same level of 
effects, when connected together, form an isobole (isos means equal and bolus 
means effect in Greek). If the isobole coincides with the line of additivity, an 
additive effect is indicated. Isobole located below the additivity standard 
represents supra-additivity whereas isobole above the standard corresponds to 
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sub-additivity. In the drug interaction domain, sub-additivity and supra-
additivity are termed antagonism and synergism, respectively.    
 
 
Figure 3.2 A classic dose-normalised isobologram for two drugs, drug A and drug B. All 
the points on the isobologram represent combinations of drug A and drug B that give the 
same level of effect (e.g. 50% inhibition). When connected together, these points form an 
isobole. If the isobole falls on the black solid line, an additive effect is indicated. Isobole 
containing points b and c below the additive line is supra-additive in effect whereas the 
isobole containing point d and e above the additive line is sub-additive. D50,drug refers to 
the dose of a drug that gives half the maximal effect when given in combination with 
another drug. ED50,drug is the dose of a drug that singly gives half the maximal effect. The 
plot was adopted from a publication by Chou et al. [184].  
   
3.3.3.2. Constructing the isobologram 
In this work, the response of interest is the INR. Three levels of INR were 
considered: (1) physiological INR (𝐼𝑁𝑅 = 1.2 [the upper bound of normal]), (2) 
therapeutic INR (𝐼𝑁𝑅 = 2.5), and (3) supra-therapeutic INR (𝐼𝑁𝑅 = 4.5). At each 
level of INR considered, all pairwise combinations of factors II, VII, and X were 
explored: (1) factor II versus VII, (2) factor II versus X, and (3) factor VII versus 
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X. A total of nine normalised isobolograms were constructed. Note a full joint 
isobologram over the three factors was not considered (this is discussed later). 
Here, the quantity that is analogous to dose is the percentage reduction in 
the coagulation protein of interest. 𝑅𝑃,𝑐𝑜𝑚𝑏𝑖 refers to the percentage reduction in 
one coagulation protein to give a predetermined level of INR when another 
coagulation protein is simultaneously reduced and is analogous to 𝐷𝑥,𝑑𝑟𝑢𝑔. On the 
other hand, 𝑅𝑃 is the percentage reduction in a coagulation protein that singly 
results in the predetermined level of INR and from a drug interaction 
perspective, it is analogous to 𝐸𝐷𝑥,𝑑𝑟𝑢𝑔.  
The different regions on the resulting isobologram are shown in Figure 3.3. 
In this example, all the points on the isobologram correspond to the same level 
of effect (e.g. 𝐼𝑁𝑅 = 2.5) and the diagonal line represents the additivity standard. 
The 𝑦-axis relates to factor II and the 𝑥-axis to factor VII. At the 𝑦-intercept, since 




(i.e. y-intercept equals to one). Similarly, at the 𝑥-intercept, because 𝑅𝐼𝐼,𝑐𝑜𝑚𝑏𝑖 = 0, 
then 𝑅𝑉𝐼𝐼,𝑐𝑜𝑚𝑏𝑖 = 𝑅𝑉𝐼𝐼  and 
𝑅𝑉𝐼𝐼,𝑐𝑜𝑚𝑏𝑖
𝑅𝑉𝐼𝐼
= 1  (i.e. 𝑥 -intercept equals to one). On the 
other hand, the surface of the isobologram was constructed by using different 
combinations of factor II and factor VII (i.e. 𝑅𝐼𝐼,𝑐𝑜𝑚𝑏𝑖 ≠ 0 and 𝑅𝑉𝐼𝐼,𝑐𝑜𝑚𝑏𝑖 ≠ 0) that 
give the desired level of INR. The interpretation of the isobologram is similar to 
that of drug interactions discussed earlier except that terminologies usually 
coined to describe drug interactions such as antagonism and synergism are not 
used. 
Here, there are two prerequisite steps to constructing the isobologram: (1) 
to identify 𝑅𝑃 value for the two different coagulation proteins that singly gives 
the desired level of INR (e.g. 𝑅𝐼𝐼  or 𝑅𝑉𝐼𝐼  alone that gives 𝐼𝑁𝑅 = 2.5) and (2) to 
determine the 𝑅𝑃,𝑐𝑜𝑚𝑏𝑖  value for the aforementioned two coagulation proteins 
that jointly gives the predetermined level of INR (e.g. combinations of 𝑅𝐼𝐼,𝑐𝑜𝑚𝑏𝑖 
and 𝑅𝑉𝐼𝐼,𝑐𝑜𝑚𝑏𝑖  result in 𝐼𝑁𝑅 = 2.5). For a single level of INR, there is only one 
possible value of 𝑅𝑃 for each coagulation protein whereas multiple combinations 
of 𝑅𝑃,𝑐𝑜𝑚𝑏𝑖 of two different coagulation proteins are permissible.   




Figure 3.3 Example of an isobologram for factors II and VII that give a predetermined 
level of INR (e.g. INR=2.5). The diagonal solid line is the additivity line.    
    
Both 𝑅𝑃 and 𝑅𝑃,𝑐𝑜𝑚𝑏𝑖 that give a predetermined level of INR were obtained 
based on an adaptive grid search algorithm implemented in MATLAB® Version 
2015a. 𝑅𝑃 was searched while all other coagulation components were held at the 
physiological concentrations. 𝑅𝑃,𝑐𝑜𝑚𝑏𝑖 was searched in a similar manner but at 
fixed, reduced levels of another coagulation protein of interest. 
An adaptive grid search was used for identifying isobolic combinations of 
the coagulation proteins. Details and the corresponding MATLAB code are 
included in Appendix A2.1. The ratio of 𝑅𝑃,𝑐𝑜𝑚𝑏𝑖  to 𝑅𝑃  was calculated and 
plotted on the isobologram. Finally, the nature of interactions (sub-additivity, 
additivity, or supra-additivity) between coagulation proteins were qualified 
based on the isobologram.  
  




3.4.1. Model evaluation 
The data simulated from the QSP coagulation network model (based on 
each patient’s design [dose and timing of warfarin and blood samples]) provided 
a reasonable agreement, on average, to the external data for factors II, VII, IX, X, 
and INR at the individual level. Note that the coagulation model is built on 
parameters at the population level rather than individual level and hence 
predictions (simulations) are analogous to PRED rather than IPRED in 
NONMEM parlance. Discrepancies did not appear to be systematic when 
considered across patients suggesting that the QSP model, on the whole, 
provided an adequate description of the influence of warfarin on INR. Plots of 
five representative individuals are shown in Figure 3.4. Plots of all 17 patients 
are included in Appendix A2.2. 
3.4.2. Sensitivity analysis 
3.4.2.1. Single coagulation protein deficiency 
Plots of INR and the corresponding INR sensitivity, 𝑆𝐼𝑃, at different coagulation 
protein concentrations are shown in Figure 3.5. From Figure 3.5, INR was found 
to be sensitive to changes in fibrinogen, factors II, VII, and X but based on 
simulations from the QSP model appeared non-responsive to factors V and IX. 
Here, the INR sensitivity is inversely related to the concentration of influential 
coagulation proteins where high INR sensitivity is associated with low 
coagulation protein concentration and vice versa.     
 




Figure 3.4 Individual fits for the time course of factors II, VII, IX, X, and INR for five 
representative individuals following warfarin initiation. The black solid lines are 
prediction by the coagulation network model using parameters for a typical patient. The 
grey open circles are observations from the external dataset [167, 181]. INR refers to the 
international normalised ratio and nM stands for nanomolar.  
  
 




Figure 3.5 Sensitivity of INR to changes in coagulation protein concentration in single 
coagulation protein deficiency: fibrinogen (panel a), factor II (panel b), factor V (panel 
c), factor VII (panel d), factor IX (panel e), and factor X (panel f). Fg is fibrinogen, Pt=0 
is the baseline concentration of coagulation protein, INR is the international normalised 
ratio, SIP is the sensitivity index of INR to coagulation protein. 
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3.4.2.2. Multiple coagulation protein deficiency 
The simulated time course of INR, and factors II, VII, X, and the 
corresponding 𝑆𝐼𝐼𝐼 , 𝑆𝐼𝑉𝐼𝐼 , and 𝑆𝐼𝑋  following warfarin initiation is shown in 








40 ℎ𝑜𝑢𝑟𝑠) and finally, factor II (𝑡1
2
,𝐼𝐼
= 66 ℎ𝑜𝑢𝑟𝑠). 
At each time point, the magnitude of 𝑆𝐼𝐼𝐼, 𝑆𝐼𝑉𝐼𝐼, and 𝑆𝐼𝑋 were compared. It 
was observed that, at non-steady-state INR, 𝑆𝐼𝑉𝐼𝐼 is persistently higher compared 
to 𝑆𝐼𝐼𝐼  and 𝑆𝐼𝑋 , whereas at steady-state INR, 𝑆𝐼𝐼𝐼 , 𝑆𝐼𝑉𝐼𝐼 , and 𝑆𝐼𝑋  are similar in 
magnitude. These findings suggest that the INR is the most sensitive to changes 
in factor VII concentration at non-steady-state INR but equally sensitive to 
factors II, VII, and X at steady-state INR. Finally, an interesting and potentially 
important observation from Figure 3.6 is that, by visual comparison, the time 
course of change in 𝑆𝐼𝑉𝐼𝐼 seems similar to that of the INR. All these point to factor 
VII as the principal driving force for the INR.     
3.4.3. Isobologram analysis 
The isobologram of all pairwise combinations of factors II, VII, and X that 
correspond to different levels of INR are shown in Figure 3.7. In the 
isobolograms, the isoboles are located above the additivity line thereby 
indicating sub-additive interactions between two coagulation proteins with 
respect to the INR. This could be interpreted that the presence of more than one 
coagulation protein deficiency is redundant for INR effect. In addition, it was 
observed that the degree of sub-additivity increases with higher INR values. In 
fact, at therapeutic INR (𝐼𝑁𝑅 = 2.5) and supra-therapeutic INR (𝐼𝑁𝑅 = 4.5), 
extended horizontal and vertical segments were observed on the isobolograms. 
Here, INR is driven by a single coagulation protein that is the most deficient. In 
other words, given that a coagulation protein of interest is sufficiently deficient, 
then the same INR can be resulted regardless of the concentration of other 
coagulation proteins. This makes other coagulation protein concentrations of 
limited additional relevance to the changes in the INR.    




Figure 3.6 The simulated time course of INR (panel a), and factors II, VII, and X (panel 
b), and SIII, SIVII, and SIX (panel c) following initiation of 4mg warfarin daily. INR is 
the international normalised ratio, SIP is the sensitivity index of INR to a coagulation 
protein and t1/2,P is the degradation half-life of a particular coagulation protein.  




Figure 3.7 Isobolograms of pairwise combination of factors II, VII, and X for different 
INRs. The top, middle and bottom rows represent physiological, therapeutic, and supra-
therapeutic INR values. The columns represent different combinations of coagulation 
factors. The black circles correspond to pairwise combination of factors II, VII, or X that 
gives a predetermined INR. The diagonal solid line is the additivity line. INR is the 
international normalised ratio, RF,combi refers to the reduction in one coagulation protein 
when another coagulation protein is simultaneously reduced and RF is the reduction in 
a single coagulation protein. 
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3.4.4. Coagulation protein for INR prediction 
Based on the isobologram analysis, simultaneous reduction in factors II, 
VII, and X leads to less than additive increases in the INR. At therapeutic and 
supra-therapeutic INR, the most deficient coagulation protein drives the INR 
whereas other coagulation proteins appear irrelevant. Given the short 
degradation half-life of factor VII relative to that of factors II and X, factor VII is 
always more deficient or of equivalent deficiency compared to the deficiency of 
other factors and therefore will dominate the INR. The same inference was 
drawn independently from the sensitivity analysis, which showed that factor VII 
is the principal driving force for the INR and importantly, the time course of 
sensitivity of the INR to factor VII was shown to provide a good approximation 
to the time course of INR. Here, based on this work, factor VII, a warfarin-
sensitive coagulation protein appears to drive the INR, makes an attractive 
candidate for monitoring of anticoagulant response and future INR prediction.    
  




INR is sensitive to factors II, VII, and X. Of these coagulation proteins, 
factor VII appears to have the most dominant effect on the INR. This is 
attributable to the sub-additivity nature of interactions between the coagulation 
proteins on the INR, which implicates that INR can be driven solely by the 
coagulation protein that is the most deficient after warfarin initiation i.e. factor 
VII, which has the shortest degradation half-life amongst factors II, VII, and X. 
The same INR can then be resulted regardless of the concentration of other 
coagulation proteins. The above findings were further supported by the 
observation that the INR sensitivity to factor VII closely mimics the INR profile. 
This again highlights the potential informativeness of factor VII with respect to 
the INR and importantly, the ability and therefore the potential of the INR 
sensitivity to factor VII as an approximation to the anticoagulant response. On 
that basis, a measure of factor VII response accompanied by the quantification of 
the corresponding INR sensitivity may be useful in the prediction of future 
anticoagulant response for subsequent warfarin dose individualisation.   
The main outcome of this work was derived from the isobologram analysis, 
which is traditionally used for the analysis of drug interactions [187]. It is 
underpinned by Loewe’s additivity that implicitly assumes that dose 𝑎 of drug 
A and dose 𝑏  of drug B [termed 𝑏𝑎 ] that give the same level of effect are 
equivalent (principle of dose equivalence) and that 𝑏𝑎 can be added to any other 
dose 𝑏 of drug B to give the additive effect of the combination (principle of Sham 
combination) [185-187]. Here, with dose additivity for the construction of the 
isobologram, as long as the combination of doses give the predetermined level 
of effect, no particular assumption is made about the relationships between the 
two drugs or the doses of the two drugs, whether they are independent or 
correlated. The resulting isobologram is also not informative with respect to the 
mechanisms of drug interactions and instead serves as a black-box approach to 
give an empirical description of the nature of drug interactions (antagonism, 
additivity, or synergism) using Loewe’s criterion as a reference standard for no 
interactions [188].  
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In this work, the isobologram analysis was extended beyond the usual drug 
interactions framework to explore interactions of endogenous substrates within a 
biological system. Here, factors II, VII, and X, which work in concert within the 
coagulation network for clot formation, are inherently correlated due to the 
complex series of positive-feedforward, negative-feedforward, positive-
feedback, and negative-feedback reactions for maintaining haemostatic balance 
[31]. Based on the isobologram analysis, factors II, VII, and X were identified as 
sub-additive in their effects on the INR. In other words, the presence of more 
than one coagulation protein deficiency is redundant for INR effect. In this setting, 
terminologies usually coined to describe drug interactions are not used. For 
instance, antagonism, which relates to dampening of a biological response of 
interest due to receptor binding by a ligand, is underpinned by the classical 
receptor theory and is unsuitable to be used to describe the interactions between 
coagulation proteins. This is because coagulation proteins do not actually 
antagonise one another and in fact, they act on distinct targets. In the exploration 
of the effect of factors II, VII, and X on the INR, a three-dimensional (3D) 
isobologram can theoretically be constructed [189-192]. This is motivated by the 
criticism that when two-dimensional (2D) isobolograms are used to analyse three 
interacting coagulation proteins, one of factors II, VII, and X must be held 
constant, thereby rendering the analysis of interactions incomplete. However, 
the interpretation of a 3D isobologram is potentially difficult due to visualisation 
of a 3D structure on a 2D platform. For completeness, although a 3D isobologram 
was not constructed, the effect of varying factor X (𝑅𝑋,𝑐𝑜𝑚𝑏𝑖 = 0%, 30%, 60%) on 
the interactions between factors II and VII with respect to the INR were briefly 
explored. It was observed that almost identical combinations of factors II and VII 
are required to give an INR of 2.5 regardless of the magnitude of reduction in 
factor X (see Figure 3.8). This lends support to our finding that if one of factors 
II, VII, and X is sufficiently deficient, the presence of other coagulation proteins 
is redundant for INR effect.       
 




Figure 3.8 Isobolograms of factors II and VII at different level of factor X reduction that 
give a predetermined level of INR (INR=2.5). The diagonal solid line is the additivity 
line.    
 
The results of our analysis are broadly similar to those reported in the 
published literature with respect to the sensitivity of INR to fibrinogen, factors 
II, VII, and X and the concentration-dependent nature of the sensitivity [136, 
137]. It is well-documented in published case reports and case series that PT is 
prolonged (i.e. INR is elevated) in patients with isolated factor V deficiency [193-
195]. However, the influence of factor V on the INR was not identified by the 
QSP coagulation network model, indicating that this mechanism is not correctly 
specified in the QSP model. Similar results were previously reported by 
Yoneyama and colleagues [196] who evaluated the coagulation network model. 
However, for the purpose of this study and subsequent works within this thesis, 
factor V, which is not a vitamin K-dependent coagulation protein and therefore 
is unaffected by warfarin, is considered peripheral to the inferences. 
In this study, factor VII was identified as an important determinant of the 
INR. The influence of factor VII on the non-steady-state INR has been reported 
previously [161, 197]. In terms of steady-state INR, a conserved rank order 
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between steady-state factors II, VII, and X concentration was observed in 
warfarinised patients (see Figure 3.9) [144, 146, 167, 198]. Here, at steady-state 
INR, factor VII concentration is higher than the factor II concentration and factor 
II concentration is in turn is higher than the factor X concentration for all 
individuals (i.e. 𝑉𝐼𝐼𝑆𝑆 > 𝐼𝐼𝑆𝑆 > 𝑋𝑆𝑆). Using the same data, pairwise combinations 
of factors II, VII, and X were plotted (see Figure 3.10). A linear relationship was 
noted: factor II vs VII (Pearson’s linear correlation coefficient, 𝜌 = 0.830, 𝑝 <
0.05), factor X vs VII (𝜌 = 0.693, 𝑝 < 0.05), and factor II vs X (𝜌 = 0.847, 𝑝 <
0.05). This consistency in trend means that given the steady-state level of one of 
factors II, VII, and X, steady-state level of other coagulation proteins and the 
resulting INR can be predicted. Of these three coagulation proteins, factor VII 
with a short degradation half-life achieves its steady-state rapidly following 
warfarin initiation and therefore provides the earliest indication of the eventual 
steady-state concentrations of other coagulation proteins and INR. Taken 
together, these findings lend support to the proposal that factor VII is potentially 
informative and may be useful for the prediction of steady-state INR.    
  





Figure 3.9 Concentration of factors II, VII, and X at steady-state INR for 73 patients.  
The graph was reproduced based on the data from published literature: McCollum et al. 
2004 [167] (n = 9), Kumar et al. 1990 [144] (n = 23), Chan et al. 1987 [198] (n = 5), 
and Paul et al. 1987 [146] (n = 36). Factors II, VII, and X of the same patient are 
connected by lines. n represents number of patients. 
    
 
Figure 3.10 Pairwise plots of factors II, VII, and X. Panel a shows factor II versus VII, 
panel b factor X versus VII, and panel c factor II versus X. Steady-state factors II, VII, 
and X are highly correlated. The blue circles are observations from published literature 
[144, 146, 167, 198] and the red lines are the linear models fitted to the observations. ρ 
represents the Pearson’s linear correlation coefficient. 
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To date, only one published study, by Pitsiu and colleagues [157], 
considered coagulation protein activity for the prediction of warfarin 
maintenance dose regimens. It was shown that factor VII response 
measurements alone were adequate to determine warfarin dosing requirements 
but the generalisability of the study results to all warfarin users is limited due to 
a small sample size (𝑛 = 5) and the use of healthy volunteers.   
In this work, competing QSP coagulation models, which can mimic the PT 
or INR test [83, 182], were not considered and no formal evaluation was 
conducted to compare the predictive performance of these models to the QSP 
coagulation network model used. This is because these models, while able to 
simulate PT and INR, were not designed with the ability to simulate warfarin 
therapy and the corresponding coagulation protein response and therefore are 
not comparable and usable for this study.  
A local sensitivity analysis was conducted to quantify the sensitivity of the 
INR to factor VII for a simulated typical patient newly commenced on warfarin. 
One major criticism of the local sensitivity analysis is that the sensitivity to 
specific input (coagulation protein of interest) variation is only valid within the 
immediate vicinity of a given set of input (coagulation components) values. 
Here, although the entire coagulation protein space was not fully explored, the 
space considered is immediately relevant to warfarin use since factors II, VII, and 
X concentrations typically observed after warfarin initiation were used for the 
sensitivity analysis.    
In this work, factor VII was identified as sensitive to warfarin and 
influential to the INR thereby representing an attractive choice of anticoagulant 
response for future INR prediction and warfarin dose individualisation. The 
development and evaluation of a factor VII-based method for the prediction of 
anticoagulant response to warfarin is discussed in Chapter 4.    
 
  




This research has identified factor VII as influential and informative of the 
INR following warfarin initiation. This was based on the sensitivity analysis that 
showed that factor VII is the principal driving force for the INR and the 
isobologram analysis that demonstrated that the presence of more than one 
coagulation protein deficiency is redundant for INR effect due to the sub-
additivity nature of interactions between coagulation proteins. The use of factor 
VII as a marker of coagulation in addition to the INR may improve the prediction 
of the anticoagulant response and warfarin dosing requirements. The 
development and evaluation of a factor VII-based method for the prediction of 
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Despite a significant body of literature in this area, algorithms for 
predicting warfarin maintenance dose in patients remain inaccurate [2-7]. It is 
believed that this is related to the use of the international normalised ratio (INR) 
as a sole marker of anticoagulation for warfarin dose individualisation [12, 17, 
18, 22, 23, 25-30].  
Because the coagulation proteins are on the causal path from warfarin dose 
to INR response, warfarin dose response relationship can be informed by the 
inclusion of coagulation protein as an intermediary marker. In this setting, the 
coagulation proteins represent a direct measure of the anticoagulant response 
and because the coagulation protein response is located immediately 
downstream from warfarin concentration in the causal path for warfarin dose 
response, the response, in theory, will capture important between-subject 
differences in both warfarin pharmacokinetics and pharmacodynamics. Of all 
the vitamin K-dependent coagulation proteins, factor VII is the coagulation 
protein of interest due to its short degradation half-life, sensitivity to warfarin 
(Chapter 2), and profound influence on the INR (Chapter 3). A measure of factor 
VII response in addition to the INR is likely to improve the prediction of the 
anticoagulant response. 
4.2. Aims 
The aim of this work was to develop a factor VII-based method for the 
prediction of anticoagulant response to warfarin.  
4.3. Chapter structure 
The current chapter is divided into the following sections: underpinning 
theory; development of the prediction algorithm; application of the prediction 
algorithm; and finally, discussion of the proposed algorithm.  
  




The proposed approach for the prediction of anticoagulant response to 
warfarin includes a 2-step process; (1) determining the time to steady-state INR 
(𝑡𝑆𝑆,𝐼𝑁𝑅) and (2) from this predicting the steady-state INR (𝐼𝑁𝑅𝑆𝑆) at 𝑡𝑆𝑆,𝐼𝑁𝑅. The 
predicted 𝐼𝑁𝑅𝑆𝑆 could then provide a means of determining maintenance dose 
requirements. 
The steady-state INR is defined as the INR that is achieved at the 
maximum, which is when the system is essentially at equilibrium. It follows that 





= 0;      𝑡 > 0.  
Equation 4.1 Definition of the steady-state INR. 
 
It is important to note, however, that true steady-state is an asymptotic condition 





≤ 𝜀𝐼𝑁𝑅;      𝑡 > 0  
Equation 4.2 Relaxed definition of the steady-state INR. 
 
and 𝜀𝐼𝑁𝑅 is a pre-defined level of tolerance. Here, 𝑡𝑆𝑆,𝐼𝑁𝑅 is defined as the smallest 
value of 𝑡 that satisfies Equation 4.2. 
Once 𝑡𝑆𝑆.𝐼𝑁𝑅 has been determined it is then a matter of deriving 𝐼𝑁𝑅𝑆𝑆. If, 
for simplicity, and without loss of generality, warfarin dosing is assumed to be 






 𝑑𝑡 , the cumulative change in INR from baseline to 
𝑡𝑆𝑆,𝐼𝑁𝑅.  
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 𝑑𝑡;      𝑡 > 0  
Equation 4.3 Solution for the steady-state INR. 
 
Generalising this to variable dosing can be solved by a series of piecewise 
integrals with break points at times of dose change.   
Of the three coagulation proteins, factor VII has the shortest degradation 
half-life, of approximately 5-35 hours [159, 165, 171, 173, 181], and therefore 
declines at the greatest rate and is the first to attain a new steady-state 
concentration. Based on the assumptions that:  
 Assumption 1: simultaneous reduction in factors II, VII, and X leads to less 
than additive increases in the INR, 
 Assumption 2: the most deficient coagulation protein drives the INR,  
 Assumption 3: under non-steady-state INR conditions, factor VII is always 
the most deficient, and 
 Assumption 4: the non-steady-state INR is the most sensitive to factor VII,  
then, monitoring factor VII in addition to INR will be informative for the 
prediction of future INR responses. These assumptions are supported by the 
widely-accepted notion that factor VII is the principal driving force for the non-
steady-state INR [161, 197]. In addition, at steady-state INR, there exists a high 
correlation between the steady-state concentrations of the vitamin K-dependent 
factors II, VII and X and hence the steady-state concentration of factor VII would 
be informative of the eventual steady-state concentrations of the other factors 
and 𝐼𝑁𝑅𝑆𝑆  [144, 146, 167, 198]. Assumptions 1, 2, 3, and 4 were explored in 
Chapter 3 and formally evaluated in terms of the probability and impact of 
assumption violation in Chapter 5. Details of the evaluation can be found in 
Appendix 4. 
If non-steady-state INR is the most sensitive to changes in factor VII, then 
the sensitivity of the INR to factor VII should adequately approximate the non-
steady-state INR. In this study, the sensitivity of the INR to changes in the 
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concentration of factor VII, denoted here as 𝑆𝐼𝑉𝐼𝐼 , is quantified as the partial 





| ;      𝑡 > 0.  
Equation 4.4 Sensitivity of INR to factor VII. 
 
Here, 𝐼𝑁𝑅, 𝑉𝐼𝐼, and 𝑆𝐼𝑉𝐼𝐼 depend on time, 𝑡, and |∙| denotes the absolute value. 
𝑆𝐼𝑉𝐼𝐼 values close to zero indicate that INR is insensitive to factor VII whereas 
larger absolute values depict increased INR sensitivity to factor VII. 
Subsequently, the INR, which is approximated by 𝑆𝐼𝑉𝐼𝐼, can be expressed 
as a function of 𝑆𝐼𝑉𝐼𝐼. Similarly, the previously defined steady-state INR status 
and 𝑡𝑆𝑆,𝐼𝑁𝑅  (Equation 4.2) as well as 𝐼𝑁𝑅𝑆𝑆  (Equation 4.3) can be expressed in 
terms of 𝑆𝐼𝑉𝐼𝐼. The steady-state INR status is considered to be achieved when 




≤ 𝜀𝑆𝐼𝑉𝐼𝐼;      𝑡 > 0  
Equation 4.5 Definition of the steady-state INR based on SIVII. 
 
where 𝜀𝑆𝐼𝑉𝐼𝐼  is analogous to 𝜀𝐼𝑁𝑅  although scaled to 𝑆𝐼𝑉𝐼𝐼 . The corresponding 
expressions for 𝑡𝑆𝑆,𝐼𝑁𝑅 and 𝐼𝑁𝑅𝑆𝑆 in terms of 𝑆𝐼𝑉𝐼𝐼 are given below:   
  
𝑡𝑆𝑆,𝐼𝑁𝑅 ≈ min (𝑡 |
𝑑𝑆𝐼𝑉𝐼𝐼
𝑑𝑡
≤ 𝜀𝑆𝐼𝑉𝐼𝐼) ;      𝑡 > 0  
Equation 4.6 Solution for the tSS,INR based on SIVII. 
 






 𝑑𝑡;      𝑡 > 0.  
Equation 4.7 Solution for the INRSS based on SIVII. 
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). The steady-state INR, 𝑡𝑆𝑆,𝐼𝑁𝑅, and 𝐼𝑁𝑅𝑆𝑆, defined 
from the 𝑆𝐼𝑉𝐼𝐼 perspective, form the basis of this work.  
4.5. Development of the prediction algorithm 
In this section, the development of a four-step algorithm for the prediction 




Figure 4.1 The four-step workflow to predict tSS,INR and INRSS. Dref is the typical dose 
that would yield this value of INR (hence it is an indicator of the sensitivity of the patient 
to warfarin), INRSS the steady-state INR, SIVII the sensitivity index of INR to factor VII, 
and tSS,INR the time to reach steady-state INR.   
 
In this work, the relationships between warfarin dose, 𝑆𝐼𝑉𝐼𝐼, and INR, were 
derived empirically to match predictions from a quantitative systems 
pharmacology (QSP) model of the coagulation network [31]. This is a heuristic 
model-order reduction technique in which an empirical approximation to 
predictions from the QSP model was obtained. Using this approach, the 
mechanistic behaviour of the system over the range of simulations from the QSP 
were captured, albeit the mechanistic nature of the relationships was not 
retained. It is worth noting that, implicit to this approach, it is assumed that: 
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 Assumption 5: the QSP coagulation network model [31] is adequate in 
describing the warfarin-coagulation proteins-INR relationship and that  
 Assumption 6: the simulated coagulation proteins-INR time course is 
representative of that of typical patients initiated with warfarin.  
Of primary interest to the evaluation of these assumptions, is the predictive 
performance of the QSP coagulation network model. The model was previously 
evaluated and shown to perform well in characterising the INR based on the 
coagulation protein profiles of 20 patients [31, 83]. Additionally, in Chapter 3, 
predictions from the QSP coagulation network model were compared to 
available time course data of factors II, VII, X, and INR for 17 warfarin patients 
[167, 181]. The model predictions were in reasonable agreement with the 
observed data thereby suggesting that the QSP coagulation network model is 
likely to be adequate in characterising the warfarin-coagulation proteins-INR 
relationship. Assumptions 5 and 6 were formally evaluated in terms of the 
probability and impact of assumption violation in Chapter 5. Details of the 
evaluation can be found in Appendix 4.   
4.5.1. Calculation of SIVII and its derivative 
The time course of factors II, VII, and X, and INR for a typical patient 
commenced on warfarin doses of 1 mg, 4 mg, 7 mg, 10 mg, and, 13 mg daily were 
simulated from the QSP coagulation network model in MATLAB® Version 2015a 
(The MathWorks Inc., Natick, Massachusetts, USA) [31]. 𝑆𝐼𝑉𝐼𝐼  was quantified 
according to Equation 4.4 over a vector of 𝑡𝑖 (𝑛 × 1) . A representative time 
course of factors II, VII, X, INR, 𝑆𝐼𝑉𝐼𝐼 and their corresponding derivatives for a 
typical patient commenced on warfarin 4 mg daily is shown in Figure 4.2. It was 
observed that the time course of change in 𝑆𝐼𝑉𝐼𝐼 (panel f, Figure 4.2) is similar to 
that of the INR (panel b, Figure 4.2).    
 




Figure 4.2 The simulated time course of INR (panel a), factors II, VII, and X (panel c), 
and SIVII (panel e) following initiation of 4mg warfarin daily. The corresponding 
derivative plots with respect to time for INR (panel b), and factors II, VII and X (panel 
d), and SIVII (panel f) are shown in the right-hand column. SIVII refers to the sensitivity 
index of INR to factor VII.  
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For clinical application, blood samples of both factor VII and INR are 
needed for the calculation of 𝑆𝐼𝑉𝐼𝐼  and 
𝑑𝑆𝐼𝑉𝐼𝐼
𝑑𝑡
. To allow determination of the 
derivative from a single sample, a steady-state approximation was used (note 







;      𝑡𝑖 ≥ 𝑡𝑆𝑆,𝑉𝐼𝐼  
Equation 4.8 Approximation of SIVII. 
 
Here, 𝑞 is a proportionality constant and 𝑡𝑖 is the time after warfarin dose change 
(with index 𝑖 to denote a particular sampling time). A review of the relationship 
shown in Equation 4.8 is shown in Figure 4.3. The data were fitted in MATLAB® 
Version 2015a using the fitnlm algorithm. The proportionality constant, 𝑞, was 
estimated to be 0.233 with a relative standard error (RSE) of 0.300%. The INR-to-
factor VII ratio has intuitive appeal whereby a high INR-to-factor VII ratio 
indicates a high sensitivity of INR to factor VII, and vice versa, which is 
consistent with the original interpretation of 𝑆𝐼𝑉𝐼𝐼 . Finally, using the INR-to-
factor VII ratio as an approximation to 𝑆𝐼𝑉𝐼𝐼, the 
𝑑𝑆𝐼𝑉𝐼𝐼
𝑑𝑡
 can now be derived from 
paired, timed samples of factor VII and INR (Equation 4.9). Higher order models 
were not considered given the need for more blood samples and the acceptable 







;      𝑡2 > 𝑡1 ≥ 𝑡𝑆𝑆,𝑉𝐼𝐼  
Equation 4.9 Finite difference approximation of dSIVII /dt. 
 




Figure 4.3 Approximating SIVII using the ratio of INR-to-factor VII. The solid line is the 
model prediction from a one-parameter linear model (Equation 4.8) with slope, q = 0.233 
and the filled circles are the data vectors for SIVII and INR-to-factor VII ratio that were 
simulated from the coagulation network model. SIVII is the sensitivity index of INR to 
factor VII.  The units of factor VII here are % of change from baseline and INR is 
dimensionless.  
 




, an individualised measure of the typical dose, 𝐷𝑟𝑒𝑓 , can be 
obtained. 𝐷𝑟𝑒𝑓 quantifies the sensitivity of the patient to warfarin in terms of the 
dose that would be taken by a typical patient to achieve the same level of 
anticoagulant response. For instance, if a patient is particularly sensitive to 
warfarin therapy then a standard warfarin dose (e.g. 𝐷 = 4 𝑚𝑔/𝑑𝑎𝑦) will lead to 
an exaggerated anticoagulant response, which normally takes a much higher 
dose to achieve in a typical patient (e.g. 𝐷𝑟𝑒𝑓 = 8 𝑚𝑔/𝑑𝑎𝑦). In other words, if a 
patient is sensitive to warfarin then 𝐷𝑟𝑒𝑓 > 𝐷 , if the patient displays similar 
sensitivity to that of a typical patient then 𝐷𝑟𝑒𝑓 ≈ 𝐷, and if the patient is less 
sensitive then 𝐷𝑟𝑒𝑓 < 𝐷. The deviation of 𝐷𝑟𝑒𝑓  from 𝐷 therefore quantifies the 
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difference of the patient from the typical patient. The relationships between 
patient’s sensitivity to warfarin, 𝐷 , anticoagulant responses, and 𝐷𝑟𝑒𝑓  are 
summarised in Table 4.1.  
 
Table 4.1 Quantification of Dref based on the observed INR response and factor VII 
concentration for three patients who show different levels of sensitivity to warfarin. In 
this hypothetical example, all the patients are given the same dose of warfarin. D 
represents the warfarin dose administered, Dref warfarin dose that would be required by 
a typical patient to achieve the observed anticoagulant response, INR international 











4 ↑ ↓ 8 
Typical 4 ↔ ↔ 4 
Warfarin-
insensitive 
4 ↓ ↑ 2 
 
The value of 𝐷𝑟𝑒𝑓 relates to the dose-dependency of 𝑆𝐼𝑉𝐼𝐼 and 
𝑑𝑆𝐼𝑉𝐼𝐼
𝑑𝑡
 and no 
closed form function is available for this relationship from the QSP model. A 
function was, therefore, derived empirically. Individual model was fitted to the 
time course of 
𝑑𝑆𝐼𝑉𝐼𝐼
𝑑𝑡
 at a specific 𝐷𝑟𝑒𝑓 (1 mg, 4 mg, 7 mg, 10 mg, and, 13 mg daily 







;      𝑡 > 0.  
Equation 4.10 Individual model for the time course of dSIVII/dt at a specific Dref. 
 
Here, ℎ is the upper horizontal asymptote, 𝑝 is the shape parameter, and 𝑔 is the 
magnitude of horizontal shift. The individual models developed for the different 
levels of 𝐷𝑟𝑒𝑓 were combined into a single joint model. In the joint model, both ℎ 
and 𝑔  are functions of 𝐷𝑟𝑒𝑓  and 𝑝  is considered independent. The full model 
expression is given in Equation 4.11.  
 








;      𝑡 > 0  
ℎ(𝐷𝑟𝑒𝑓) = 𝑎0 + 𝑎1 × 𝐷𝑟𝑒𝑓 
𝑔(𝐷𝑟𝑒𝑓) = 𝑏0 + 𝑏1 × ln𝐷𝑟𝑒𝑓 
Equation 4.11 Joint model for the time course of dSIVII/dt at different Dref. 
 
Here, 𝑎𝑖  and 𝑏𝑖  are parameters that define the 𝐷𝑟𝑒𝑓 -dependency of ℎ  and 𝑔 , 
respectively. The final parameter estimates are given in Table 4.2 and the model 
fits are shown in Figure 4.4. Details of the individual models developed for the 




 (Section 4.5.1), 𝐷𝑟𝑒𝑓  can be quantified by solving Equation 4.11 
numerically.   
 
Table 4.2 Parameter estimates of the joint model for the time course of dSIVII/dt at 
different Dref. At different Dref, the p estimates obtained were largely similar (range 0.260 
- 0.301) and fixing of p to 0.300 resulted in an almost identical model fit. ai defines the 
Dref -dependency of h, bi defines the Dref -dependency of g, Dref is the warfarin daily dose 
for a typical patient, h the upper horizontal asymptote, g the magnitude of horizontal 
shift, p the shape parameter, SIVII the sensitivity index of INR to factor VII, r2 the 
adjusted coefficient of determination, and RSE the relative standard error.   








𝑎0 (/%/day) 𝑎1 (/%/mg) 0.988 
0.000392 (123) 0.00108 (5.46) 
𝑔(𝐷𝑟𝑒𝑓) 
𝑏0 (days) 𝑏1 (days) 0.995 
-1.48 (17.9) 4.13 (3.42) 
 




Figure 4.4 Model fits of the joint model for the time course of dSIVII/dt at different Dref. 
The solid lines are the model predictions (Equation 4.11) and the filled circles are the data 
vectors for dSIVII/dt that were derived based on simulations from the QSP coagulation 
network model. SIVII is the sensitivity index of INR to factor VII.  
 
4.5.3. Calculation of tSS,INR  
An expression for 𝑡𝑆𝑆,𝐼𝑁𝑅  that is now dependent on 𝐷𝑟𝑒𝑓  is obtained by 
combining Equation 4.6 and Equation 4.11:  
 
𝑡𝑆𝑆,𝐼𝑁𝑅 ≈ min(𝑡 |
ℎ(𝐷𝑟𝑒𝑓)
1 + 𝑒𝑝×(𝑡−𝑔(𝐷𝑟𝑒𝑓))
≤ 𝜀𝑆𝐼𝑉𝐼𝐼) ;      𝑡 > 0  
ℎ(𝐷𝑟𝑒𝑓) = 𝑎0 + 𝑎1 × 𝐷𝑟𝑒𝑓 
𝑔(𝐷𝑟𝑒𝑓) = 𝑏0 + 𝑏1 × ln𝐷𝑟𝑒𝑓 . 
Equation 4.12 Solution for the tSS,INR based on Dref. 
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From Equation 4.5, a pre-requisite to the calculation of 𝑡𝑆𝑆,𝐼𝑁𝑅 is the choice of a 
suitable value of 𝜀𝑆𝐼𝑉𝐼𝐼. The choice of 𝜀𝑆𝐼𝑉𝐼𝐼 should correctly classify a given INR 
as non-steady-state (or steady-state) when the INR is truly non-steady-state (or 
steady-state). The choice of 𝜀𝑆𝐼𝑉𝐼𝐼 was based on optimising the receiver operating 
characteristic (ROC). Details of the method are provided in Appendix 3.2. It is 
seen that a choice of 𝜀𝑆𝐼𝑉𝐼𝐼 = 0.000150  provides the optimal operating 
characteristics of the error tolerance. Based on the 𝐷𝑟𝑒𝑓 obtained from Section 
4.5.2, 𝑡𝑆𝑆,𝐼𝑁𝑅 can be quantified using Equation 4.12. 
4.5.4. Calculation of INRSS  




) in Equation 4.7 has an explicit expression. However, no mechanistic 
function is available and a function was derived empirically.  
Factor VII and INR data were simulated from the QSP coagulation network 






 were computed. At each level of 𝐷𝑟𝑒𝑓 , individual quadratic model was 






 data. Because the 𝑦-intercept was approximately 













;      𝑡 > 0.  
Equation 4.13 Individual model for the dINR/dt versus dSIVII/dt data at a specific Dref. 
 
Here, 𝑘 is the second-order coefficient and 𝑚 is the first-order coefficient of the 
quadratic function. Final parameter estimates and model fits for the alternative 
models considered are shown in Appendix 3.3. Subsequently, the five individual 
quadratic functions, each corresponds to a specific 𝐷𝑟𝑒𝑓, were combined into a 
single joint function. In this expression, 𝑘 and 𝑚 were empirically expressed as 
a function of 𝐷𝑟𝑒𝑓, 
 



















Equation 4.14 Joint model for the dINR/dt versus dSIVII/dt data at different Dref. 
 
where, 𝑐𝑖  and 𝑠𝑖  are parameters defining the 𝐷𝑟𝑒𝑓-dependency of 𝑘 and 𝑚. The 






 data was evaluated visually by superimposing the model 
predictions on the simulated data (Figure 4.5). The quadratic model provided an 
adequate fit to the data. 
 
Table 4.3 Parameter estimates of the joint model for the dINR/dt versus dSIVII/dt data 
at different Dref. Dref is the warfarin daily dose for a typical patient, k and m are 
coefficients of the quadratic function, ci defines the Dref-dependency of k, and si the Dref-
dependency of m, r2 is the adjusted coefficient of determination, RSE the relative standard 
error, and SIVII the sensitivity index of INR to factor VII.   
Function Final estimate (%RSE) 𝒓𝟐 
ℎ(𝐷𝑟𝑒𝑓) 𝑐0 𝑐1 0.997 
 11.9 (1.03) -2.05 (3.18)  
𝑚(𝐷𝑟𝑒𝑓) 𝑠0 𝑠1 0.987 
 5.26 (1.62) -0.672 (6.75)  
 




Figure 4.5 Model fits of the joint quadratic function for the dINR/dt versus dSIVII/dt data 
at different Dref. The solid lines are the prediction from the empirical quadratic model 
(Equation 4.14) and the filled circles are the data that were derived based on simulations 
from the QSP coagulation network model. SIVII is the sensitivity index of INR to factor 
VII.  
 
Equation 4.7 and Equation 4.14 were combined to give an expression for 
𝐼𝑁𝑅𝑆𝑆: 
 

















Equation 4.15 Solution for the INRSS based on Dref and tSS,INR. 
 
Here, the definite integrals can be solved analytically. An algebraic solution to 
the definite integrals and the 𝐼𝑁𝑅𝑆𝑆 is given in Appendix 3.4. This relationship 
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however does not hold for the first two days of warfarin initiation since factor 
VII level is not at equilibrium at this time. 
4.5.5. Prediction algorithm 
The mathematical features and parameter values of the four-step algorithm 
to predict 𝑡𝑆𝑆,𝐼𝑁𝑅  and 𝐼𝑁𝑅𝑆𝑆  are shown in Figure 4.6. The corresponding 
MATLAB® code for the implementation of the algorithm is available in 
Appendix 3.5.  
 




Figure 4.6 Prediction algorithm of tSS,INR and INRSS. ai defines the Dref-dependency of h, 
bi the Dref-dependency of g, ci the Dref-dependency of k, Dref the typical dose that gives a 
specific value of INR, g the horizontal shift, h the upper horizontal asymptote, INRSS the 
steady-state INR, INR0 the INR at baseline, si defines the Dref-dependency of m, k and m 
are the coefficients of the quadratic function, p the shape parameter, q the proportionality 
constant, SIVII the sensitivity index of INR to factor VII, t the time after warfarin dose 
change (with index i to denote a particular sampling time), and εSIVII the tolerance below 
which the dSIVII/dt corresponds to the steady-state INR. 
Chapter 4: A factor VII-based method for the prediction of anticoagulant response to warfarin 
143  
 
4.6. Application of the prediction algorithm 
The proposed method was applied to a typical simulated patient and two 
real patients to illustrate proof-of-principle. 
4.6.1. Predicting INRSS for a virtual patient 
Data relating to a typical patient were simulated from a QSP coagulation 
model [31] under different dosing scenarios. Factor VII concentrations and INR 
data at days 3 and 4 were simulated for typical patients who were commenced 
on warfarin (𝐷 =1 mg, 4 mg, 7 mg, 10 mg, or 13 mg daily). These data were 
analysed according to the four-step algorithm (Figure 4.6) and the predictions of 
𝑡𝑆𝑆,𝐼𝑁𝑅 and 𝐼𝑁𝑅𝑆𝑆 were compared to the simulated values and reported in terms 
of prediction bias (predicted value minus the simulated value). The simulation 
and prediction results are shown in Table 4.4. As expected, the predicted 𝐷𝑟𝑒𝑓 is 
approximately equal to 𝐷  since the simulated patient is a typical patient. At 
different simulated warfarin dosing rates, the bias was within a clinically 
reasonable range for both the 𝑡𝑆𝑆,𝐼𝑁𝑅  ( ±2.0  days) and 𝐼𝑁𝑅𝑆𝑆  ( ±0.20 ). One 
exception was that at a dose of warfarin of 1 mg/day, 𝑡𝑆𝑆,𝐼𝑁𝑅  was under-
predicted ( −3.7  days). However, this is unlikely to be important clinically 
considering such a dosing rate is uncommon in clinical practice and furthermore 
the corresponding prediction of 𝐼𝑁𝑅𝑆𝑆 was not evidently biased (−0.02).  
 
Table 4.4 Performance of the proposed algorithm to predict the tSS,INR and INRSS for a 
simulated typical patient commenced on warfarin at different dosing rates. D denotes the 
warfarin daily dose given, Dref the warfarin daily dose for a typical patient, INRSS the 






𝒕𝑺𝑺,𝑰𝑵𝑹 (days) 𝑰𝑵𝑹𝑺𝑺 
Obs. Pred. Bias Obs. Pred. Bias 
1 1.35 11.5 7.8 -3.7 1.41 1.39 -0.02 
4 3.97 17.5 15.6 -1.9 2.40 2.28 -0.12 
7 6.78 20.5 19.5 -1.0 3.23 3.09 -0.14 
10 9.90 22.5 22.3 -0.2 3.98 3.88 -0.10 
13 13.3 24.5 24.5 0.0 4.70 4.66 -0.04 
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4.6.2. Predicting INRSS for patients 
The method was retrospectively assessed in two patients newly 
commenced on warfarin 𝐷 =5 mg daily based on a previously published dataset 
[167, 181]. These two patients represent all of the patients who have available 
data that fulfil the requirements to apply the INR prediction method. 𝑡𝑆𝑆,𝐼𝑁𝑅 and 
𝐼𝑁𝑅𝑆𝑆 were predicted using factor VII and INR available at day 3 and day 4. The 
factor VII and INR profiles of these two patients are shown in Appendix 3.6. The 
predicted 𝐼𝑁𝑅𝑆𝑆 was later compared to the observed INR at day 28 for ID A and 
day 14 for ID B. Observed INR at later time points were not used as the 
observations were confounded by non-steady-state conditions introduced by 
warfarin dosage adjustment. Observed 𝑡𝑆𝑆,𝐼𝑁𝑅 was also unavailable due to sparse 
sampling of INR. Results of the assessment using real patient data are 
summarised in Table 4.5. Both patients showed reasonable agreement in the 
predicted and observed INRs.  
 
Table 4.5 Performance of the proposed algorithm in predicting the INRSS for two real 
patients commenced on warfarin 5 mg daily. D is the warfarin daily dose given, Dref the 






Pred. 𝑰𝑵𝑹𝑺𝑺 Obs. INR 
Difference 
in INR 
A 5 6.12 2.9 3.3 (day 28) -0.4 
B 5 7.32 3.2 3.2 (day 14) 0.0 
 
  




A factor VII-based approach to predict 𝑡𝑆𝑆,𝐼𝑁𝑅  and 𝐼𝑁𝑅𝑆𝑆  in patients 
receiving warfarin was proposed. By considering factor VII as the main driver 
for the INR, this allows the 𝑡𝑆𝑆,𝐼𝑁𝑅 to be determined and from this the 𝐼𝑁𝑅𝑆𝑆 can 
be calculated. The proposed method represents a unique approach to predicting 
the anticoagulant response to warfarin. It incorporates information from factor 
VII for the prediction of INR and evaluates the INR from the perspective of 
determining 𝑡𝑆𝑆,𝐼𝑁𝑅. From a practical viewpoint, the proposed method requires 
timed, paired blood samples of INR and factor VII. The use of the method was 
demonstrated in a typical simulated patient and two real patients. The prediction 
errors were found to be within clinically acceptable limits.  
The proposed method differs from those reported in the published 
literature. Several warfarin dosing algorithms quantify the likely anticoagulant 
response for warfarin maintenance dose prediction using patient characteristics 
known to influence warfarin dose-response such as body size, age, ethnicity, 
concomitant drugs, cytochrome P-450 2C9 (CYP2C9) genotype, vitamin K 
epoxide reductase complex subunit 1 (VKORC1) genotype (see Klein et al. [11] 
for example). These methods provide no guidance for warfarin dose adjustment 
once anticoagulant response data (e.g. INR) become available. Other warfarin 
dosing methods, including traditional initiation nomograms, rely solely on the 
INR, a composite and blunt measure of anticoagulant response, to guide the 
prediction of future INR and subsequently, warfarin dose adjustment (see Gedge 
et al. [28] for example). Bayesian forecasting methods use both prior INR and 
covariates for INR and warfarin dose prediction (see Wright et al. [18] for 
example). In this study, it was proposed that measuring the coagulation protein 
data in addition to the INR will be more informative and superior to measuring 
the INR alone because factors II, VII, and X bridge the gap between warfarin dose 
and INR response. The coagulation protein data therefore provide a direct 
measure of the anticoagulant response as well as sensitivity of the patient to 
warfarin therapy. Here, it is worth noting that measures of anticoagulant 
response, such as INR and factor VII concentration, will capture between-subject 
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differences in both warfarin pharmacokinetics and pharmacodynamics, 
including those related to CYP2C9 and VKORC1 genotypes. Therefore, in 
theory, once the time course of anticoagulant responses for a given warfarin dose 
is accounted for, it may not be necessary to consider these and other covariates 
separately. This would, however, require prospective evaluation. To date, only 
one published study (Pitsiu and colleagues [157]) considered coagulation protein 
activity for the prediction of warfarin maintenance dose regimens. It was shown 
that factor VII response measurements alone were adequate to determine dosing 
requirements although it is important to point out that the sample size is small 
(𝑛 = 5) and the use of healthy volunteers potentially limits generalisability of the 
study’s results to all warfarin users.  
The proposed approach also differs from those previously reported as it 
attempts to predict 𝑡𝑆𝑆,𝐼𝑁𝑅  and from this, the 𝐼𝑁𝑅𝑆𝑆  is derived. Based on 
simulations from the QSP coagulation network model [31], 𝑡𝑆𝑆,𝐼𝑁𝑅 is observed to 
be dose-dependent (see Figure 4.7). It is thought that the dose-dependency of 
𝑡𝑆𝑆,𝐼𝑁𝑅  is due to the inverse relationships between INR sensitivity and 
coagulation protein concentrations (i.e. increasing INR sensitivity to coagulation 
proteins at low coagulation protein concentrations). Since greater warfarin 
exposure is typically associated with lower coagulation protein concentrations, 
then a disproportionate increase in the INR and delayed achievement of steady-
state INR (i.e. longer 𝑡𝑆𝑆,𝐼𝑁𝑅) are expected with high warfarin exposure. In this 
work, sensitivity of the INR to factor VII was considered and was used to provide 
an alternative definition for the steady-state INR, which allows the dose-
dependency in 𝑡𝑆𝑆,𝐼𝑁𝑅 to be captured and quantified. Predicting 𝑡𝑆𝑆,𝐼𝑁𝑅 allows for 
a more meaningful interpretation of observed INR response data, which are 
frequently confounded by non-equilibrium conditions. Then, dosing decisions 
based on INR measured will be better informed and unnecessary dose 
adjustments as well as frequent INR monitoring can be avoided. 
 




Figure 4.7 tSS,INR is dose-dependent based on simulations from the QSP coagulation 
network model [31]. tSS,INR is the time to reach steady-state INR. The vertical lines 
represent the minimum value of time where the change in INR over time is within a 
predefined tolerance. 
 
The current work has several drawbacks. Due to the absence of explicit 
functions to describe the relationships between warfarin dose, 𝑆𝐼𝑉𝐼𝐼, and INR, the 
relevant functions were derived empirically to match predictions from a QSP 
coagulation network model [31]. Despite the empiricism attached to this work, 
the underpinning theory outlined in Section 4.4 should remain intact and 
unaffected. Hence if a scale-reduced version of the QSP model is developed at a 
later stage then the theory could be applied to a fully mechanistic model. It is 
also worth noting that despite the effort to verify the QSP coagulation network 
model, it is acknowledged that there remain uncertainties in the applicability of 
the QSP coagulation network model. It is possible for a potential inconsistency 
in the QSP coagulation network model to propagate to the proposed INR 
prediction method thereby affecting the predictive performance of the method. 
As a result, it is essential to evaluate and if required, to recalibrate the INR 
prediction model using prospectively collected warfarin-factor VII-INR data in 
a large cohort of warfarin patients.  
Chapter 4: A factor VII-based method for the prediction of anticoagulant response to warfarin 
 148 
 
In this study, the observed anticoagulant response was used for 
individualisation of 𝐷𝑟𝑒𝑓, which in turn was used for the prediction of 𝑡𝑆𝑆,𝐼𝑁𝑅 and 
𝐼𝑁𝑅𝑆𝑆. 𝑔(𝐷𝑟𝑒𝑓) is not defined when 𝐷𝑟𝑒𝑓 ≤ 0. This defines the boundary beyond 
which the proposed method no longer works and thereby represents a limitation 
of the method. The limitation, however, is unlikely to be clinically important as 
the conditions where this would occur, for example if factor VII concentration 
increases after warfarin initiation, is unlikely in clinical practice. In addition, the 
individualisation of 𝐷𝑟𝑒𝑓 relies on factor VII being at steady state and therefore 
is confounded by factors that affect the rate of change of factor VII. For instance, 
an abnormally long degradation half-life of factor VII will lead to a deflated 𝑆𝐼𝑉𝐼𝐼 
estimate and a similarly depressed 𝐷𝑟𝑒𝑓  estimate, which in turn results in 
predicted 𝑡𝑆𝑆,𝐼𝑁𝑅  and 𝐼𝑁𝑅𝑆𝑆  that are biased downward. The proposed method 
should be adjusted to account for the between patient variability in the 
degradation half-life of factor VII or alternatively, to sample factor VII at later 
time points when its steady state has been established. It is important to 
recognise that the above limitations can also be circumvented by accounting for 
non-steady state values of factor VII – although this will require additional blood 
samples to enable quantification of 𝑆𝐼𝑉𝐼𝐼. Another limitation of the study is that 
the practical feasibility of the proposed method in routine clinical settings was 
not considered. For instance, it is assumed that an assay that is appropriately 
precise and accurate is available to measure blood factor VII concentrations. The 
proposed method was applied to a typical simulated patient and two real 
patients to illustrate proof-of-principle. Evaluation of the method in a larger 
cohort of warfarin patients is not currently possible using retrospectively 
available data because factor VII is not routinely measured. These results are 
therefore not generalisable to clinical use. Further work to evaluate the clinical 
utility of the method using prospectively collected warfarin, factor VII, and INR 
data would be required. This work would evaluate the predictive performance 
of the method with respect to both 𝑡𝑆𝑆,𝐼𝑁𝑅 and 𝐼𝑁𝑅𝑆𝑆. Briefly, patients who will 
be initiated on warfarin (any indication) will be prospectively recruited. In these 
patients, factor VII concentrations and INRs in close temporal proximity (e.g. day 
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3 and day 4) will be used as input into the proposed algorithm for the prediction 
of 𝑡𝑆𝑆,𝐼𝑁𝑅  and 𝐼𝑁𝑅𝑆𝑆 . The observed and predicted 𝑡𝑆𝑆,𝐼𝑁𝑅  and 𝐼𝑁𝑅𝑆𝑆  will be 
compared using mean prediction error (MPE) and root mean square error 
(RMSE) to quantify the prediction bias and imprecision, respectively [199].  
Finally, a note on sampling times. The sampling times after the 
achievement of factor VII’s steady-state (e.g. 𝑡1 = 𝑑𝑎𝑦 3  and 𝑡2 = 𝑑𝑎𝑦 4 ) are 
likely to be preferable considering that steady-state factor VII is informative of 
𝐼𝑁𝑅𝑆𝑆 [144, 146, 167, 198] and that by avoiding sampling on day 1 and day 2, the 
lag in the onset of factor VII reduction observed in some patients can be bypassed 
[140, 157, 165, 181]. In addition, 𝑡1 and 𝑡2 should be in temporal proximity to 
allow accurate approximation of the derivative required for the quantification of 
𝑆𝐼𝑉𝐼𝐼. At this stage, the sampling times are proposed based on heuristic reasons 
and an optimal design analysis may be able to offer better alternative sampling 
times – one that minimise the bias in the prediction of 𝐼𝑁𝑅𝑆𝑆.   
It is important to note that the work conducted in this chapter was not set 
forth to propose a new framework that is instantly applicable for clinical use, but 
to introduce a new perspective on INR prediction and subsequently, for warfarin 
dosing. A natural succession to this work would be to extend the current method 
beyond the prediction of 𝐼𝑁𝑅𝑆𝑆 to prediction of warfarin maintenance dose. This 
will be discussed in Chapter 6.    
  




A conceptually different approach for the prediction of future INR has been 
proposed. The method was associated with minimal bias and its use was 
illustrated using patient data supporting a proof-of-principle. The proposed 
method represents a unique approach to predict the INR. It considers factor VII 
as the main driver for INR and furthermore, it represents the first work to 
evaluate the INR from the 𝑡𝑆𝑆,𝐼𝑁𝑅  perspective. Future research to extend the 
method for warfarin maintenance dose prediction and to assess the predictive 
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The construction of a joint model for warfarin, vitamin K-dependent 
clotting factors, and anticoagulation proteins (Chapter 2) as well as the 
development of a factor VII-based method for the prediction of anticoagulant 
response to warfarin (Chapter 4) were built on several assumptions. Models or 
methods that are predicated on erroneous assumptions are likely to be flawed 
and hence evaluation of assumptions that are likely to have impact on model 
performance is crucial. This chapter describes the development of a framework 
for systematic evaluation of model assumptions. The framework was applied to 
the assumptions underpinning the aforementioned models. Selected 
assumptions from these models are shown in this chapter as examples to 
illustrate the utility of the framework. The current chapter is divided into the 
following sections: introduction, aims and objectives, workflow, definition and 
classification of assumptions, a flowchart for assumption evaluations, table of 
assumptions, application, discussion, and conclusion.     
  




All models are underpinned by assumptions. The validity of any inference 
drawn from a model depends on the appropriateness and likely impact of the 
underlying assumptions [34]. This makes assumption evaluation an integral part 
of model building and model use.  
The importance of assumption evaluation is well-recognised. Current 
guidelines by the Food and Drug Administration (FDA) [200], the European 
Medicines Agency (EMA) [201, 202], and the European Federation of 
Pharmaceutical Industries and Associations (EFPIA) [34] stipulate that all 
assumptions inherent to model development and model application should be 
explicitly expressed in the data analysis plan and study report. A transparent 
description of how these assumptions were assessed and what impact they 
would have on model inferences should also be included. Here, the 
recommendations pertaining to acknowledgement, evaluation, and 
documentation of assumptions are applicable regardless of the type of 
pharmacometric analyses including: pharmacokinetic (PK) analysis [200, 201, 
203-206], pharmacokinetic and pharmacodynamic (PKPD) analysis [207, 208], 
quantitative systems pharmacology (QSP) modelling [209], and physiologically 
based pharmacokinetic (PBPK) modelling [210-213].   
However, assumptions inherent to model development and use are not 
routinely acknowledged, evaluated, or documented in journal articles reporting 
pharmacometric analyses. This is also apparent in the analyses submitted for 
regulatory review, where the EMA outlined the lack of transparent description 
of influential assumptions and an ineffective evaluation or reporting of the 
impact of assumptions on model inference to be a major limitation [214]. All 
these form an unequivocal barrier for effective model use and regulatory review.      
Two articles were identified which provided specific frameworks for 
evaluating model assumptions. The first article by Karlsson and colleagues used 
the development of a population PK model as an exemplar to demonstrate how 
assumptions intrinsic to model building may be evaluated [205]. In this work, 
Karlsson and colleagues exhaustively stated all the assumptions associated with 
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the PK model, gave examples on how violations of assumptions can be detected, 
and introduced new models that allow some standard assumptions to be relaxed 
[205]. The second article was a white paper published by the EFPIA Model-
Informed Drug Discovery and Development (MID3) Workgroup [34]. In this 
work, the importance of assumption evaluation and documentation is 
highlighted. Here, assumptions were broadly classified into five principal 
categories: (1) pharmacological assumptions, (2) physiological assumptions, (3) 
disease assumptions, (4) data assumptions, and (5) mathematical or statistical 
assumptions. Importantly, a table of assumptions was proposed for adoption by 
modellers to document assumptions, uncertainties, and impact of assumption 
violations [34].  
While the importance of assumption evaluation is well-recognised, how 
these assumptions should be systematically approached and be effectively 
assessed has received limited attention. The overarching goal of this work was 
therefore to enrich and expand on the aforementioned frameworks for 
assumption evaluation in order to encourage greater transparency in the 
description, evaluation, and documentation of influential assumptions for model 
building and model use. The two common approaches to model development in 
pharmacometrics are: (1) top-down approach (developing model empirically i.e. 
based on data and usually with parsimony prioritised) and (2) bottom-up 
approach (building a model based on prior knowledge about a system and is not 
necessarily bound to the principle of parsimony). These two modelling 
approaches will be used to assess the assumption framework presented here.      
5.2. Aims and objectives 
In this work, existing frameworks [34, 205] were expanded for evaluating 
model assumptions systematically. The objectives of this work were: (1) to define 
the concept of an assumption within the context of this work, (2) to develop a 
flowchart for systematic evaluation of assumptions, (3) to propose a standard 
table for documentation of assumptions and evaluation results, and finally (4) to 
apply the flowchart to top-down and bottom-up modelling approaches. 




Existing frameworks were used as a starting point for this work. The 
frameworks were expanded based on an evaluation of the risk management 
literature, expert opinion, and logical reasoning.  
A simple four-step workflow was proposed for the evaluation of model-
related assumptions (Figure 5.1). Here, specific tools were developed to facilitate 
this process and will be detailed in the next following sections: (1) definition and 
categorisation of assumptions, (2) flowchart for systematic evaluation of 
assumptions, and (3) assumptions table.     
 
 
Figure 5.1 The four-step workflow and proposed tools for assumption evaluation. 
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5.4. What is an assumption? 
This section is dedicated to defining assumptions. Here, the definition of 
an assumption and related terms are compared and contrasted. Subsequently, 
systems for classification of different assumptions are introduced and 
recommendation for systematic identification of assumptions is detailed. 
5.4.1. Definition of an assumption and related terms 
For the purpose of this work, an assumption is defined as an 
unsubstantiated claim (belief) about a system that is required (need) to be made 
in order for the system to be manipulated in a manner that is advantageous to 
the modeller (model building or model use). An assumption therefore is a belief that 
is needed to build or use a model. 
A subset of these assumptions are hypotheses, which by definition, are 
testable. An assumption is distinguished from an axiom (a self-evident truth), a 
theorem (a proven belief [a truth]) and a limitation (a boundary beyond which 
the assumption no longer holds). The relationships between a belief, an 
assumption, an hypothesis, an axiom, and a theorem are summarised in Figure 
5.2.        
More elaborate definition of these terms, each accompanied by a list of 
examples, are provided in Table 5.1. Here, it is acknowledged that there may be 
some nuanced differences in the adopted definitions compared to that defined 
in other fields of study (e.g. mathematics, philosophy, psychology).     
 




Figure 5.2 The Venn diagram depicting the relationships between a belief, an 
assumption, an hypothesis, an axiom, and a theorem.  
Chapter 5: Evaluation of assumptions underpinning pharmacometric models 
 160 
 
Table 5.1 Definition and examples of an assumption and related terms.  
Term Definition Examples (not exhaustive) 
Belief 
A belief connotes a proposition 
that is considered to be true but 
for which substantive evidence 
is not available. 
Example 1: Constant receptor system 
The turnover of receptors are negligible if the observation time window is 
relatively short in in-vitro experiments. 
Example 2: Metabolic pathways 
All metabolic pathways of a drug are known. 
Example 3: Paediatric versus adult population 
The variability in clearance of a drug is similar between paediatric and adult 
patients.  
Assumption 
An assumption is a belief 
where needs define its 
existence and necessitate its 
use. 
Example 1: Accurate recorded sampling time 
The recorded sampling time is free of error.  
Example 2: 𝜀 ~ 𝑖𝑖𝑑 𝑁(0, 𝜎2) 
All error terms 𝜀 are independent and identically distributed (iid) from a normal 
distribution with a mean of zero and a variance of 𝜎2. 
Example 3: 𝐺𝐹𝑅 ≈ 𝑒𝐺𝐹𝑅 
The estimated glomerular filtration rate (eGFR) obtained from the Cockcroft-Gault 
equation provides an unbiased measure of the actual glomerular filtration rate 
(GFR) of a patient.   
Hypothesis 
An hypothesis is a testable 
assumption.  
Example 1: Bioequivalence 
A given generic drug is bioequivalent to the original brand-name drug. 
Example 2: Hepatic clearance 
The fraction of a drug administered that is metabolised is 0.4.  
Example 3: Active compound 
Only the parent drug is pharmacologically active. 
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Term Definition Examples (not exhaustive) 
Axiom 
An axiom is a belief that is 
regarded as self-evidently true.  
Example 1: 𝐶𝐿 ∈ ℝ+  
Clearance of a drug (CL) is a positive quantity.  
Example 2: Volume of distribution 
Plasma volume represents the lower limit of the volume of distribution of any 
intravenously administered drugs.  
Theorem 
A theorem is a belief that is 
proven to be true based on 
logical or mathematical 
reasoning.  
Example 1: Bayes’ theorem 





Example 2: Central limit theorem 
Let 𝑋1, 𝑋2, ⋯ , 𝑋𝑛 be a random sample from a distribution (any distribution) with 
mean 𝜇 and finite variance 𝜎2. If the sample size 𝑛 is sufficiently large, then the 
sampling distribution of the sample mean (?̅?) approaches a normal distribution 





A limitation represents the 
boundary beyond which the 
use of an assumption is 
unsound or invalid.  
Example 1: Linear exposure-response model 
The assumed linear relationship between a drug’s exposure and response may not 
hold beyond the dose range modelled.  
Example 2: Small sample size 
The sample size for the study is small thus potentially limiting generalisability of 
the study’s results to the intended population.  
Example 3: Making inferences by extrapolation 
Inferences drawn from extrapolation about the clinical effects of dosing beyond 
the scope of the model may not be valid.    
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5.4.2. Classification of assumptions 
Here, assumptions are classified into two groups, implicit or explicit, based 
on the origin of the assumptions (i.e. how does the assumption arise). Implicit 
and explicit assumptions are briefly introduced here. A detailed explanation and 
examples of implicit and explicit assumptions are provided in Table 5.2.   
5.4.2.1. Implicit assumptions 
Implicit assumptions arise from an inherent component or aspect of a 
method or model. They are not defined by the users of the method or model but 
based on science. For instance, the Cockcroft-Gault equation carries the implicit 
assumption of steady-state creatinine and the analysis of variance (ANOVA) 
requires the errors to be normally distributed. Here, a method or model may 
become invalid if the conditions required for the founding assumptions to be 
valid have not been met. Since the assumption attached to the method or model 
is not necessarily obvious, this type of assumption is termed implicit.  
5.4.2.2. Explicit assumptions 
Explicit assumptions arise from heuristic principles or the application of a 
method or model. Assumptions may represent a heuristic solution to a problem. 
They may arise due to need, lack of alternative methods or models, and 
parsimony. For instance, the recorded blood sampling time and dosing time are 
assumed to be accurate.  
Explicit assumptions may also include assumptions that are originally 
implicit. This occurs when the knowledge of the (implicit) assumptions itself are 
matched to the structure of the problem to inform the choice of a method or a 
model. For example, since the binding equilibrium is quicker than changes in 
concentration, application of an 𝐸𝑚𝑎𝑥 model is appropriate. Implicit and explicit 
assumptions are therefore not mutually exclusive.   
In all cases, additional assumptions of appropriateness may be necessary. 
Since these assumptions are made by the user, they are termed explicit.   
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Table 5.2 Definition and examples of implicit and explicit assumptions.  
 Implicit assumption Explicit assumption 
Origin Arise from an inherent component or aspect of a 
method or model. 
Arise from heuristic principles or the application of a 
method or model. 
Definition 1. There are assumptions inherent in a method or 
model that underpin its derivation and use.  
2. They are not defined by users of the method or 
model but derived from science.   
 
1. Assumptions may represent a heuristic solution to 
a problem. They may arise due to need, lack of 
alternative methods or models, and parsimony.  
2. Additionally, knowledge of implicit assumptions 
can be matched to the structure of the problem to 
inform decisions on the application of a method or 
a model. Here, assumptions that are originally 
implicit become explicit.   
3. Additional assumptions of appropriateness are 
often necessary.  
4. Explicit assumptions are usually user-defined. 
Observations 1. Since assumptions are inherent they may not always 
be apparent and hence are termed implicit.   
1. In most cases, the need for assumptions is based on 
a gap in knowledge, which requires an imputation. 
2. In all cases, these assumptions are made by the user 
and hence are termed explicit (even if the user does 
not directly acknowledge the assumption).  
Note All structural models (e.g. in pharmacokinetic-
pharmacodynamic (PKPD) modelling) have some 
implicit assumptions (see examples). These are typically 
related to the structure itself and also the alternative 
structures that are not permitted within the current 
framework.  
Implicit and explicit assumptions are not mutually 
exclusive. 
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 Implicit assumption Explicit assumption 
Assumption 
Examples 
Assumptions related to the derivation of an equation: 
1. Cockcroft-Gault equation carries the implicit 
assumption of steady-state serum creatinine. 
2. The 𝐸𝑚𝑎𝑥 model implicitly assumes that the total 
ligand concentration is in excess of the concentration 
of the receptors. Receptor binding therefore has a 
negligible effect on the free ligand concentration.  
 
Assumptions require for a method to work:   
1. The analysis of variance (ANOVA) requires the 
errors to be normally distributed. 
2. The maximum likelihood (ML) estimation method 
typically requires the observations, 𝑦1, 𝑦2, ⋯ , 𝑦𝑛, to 
be independent and identically distributed (iid).   
  
Assumptions of common PKPD models: 
1. The turnover model typically assumes that the 
precursor pool for the physiological intermediate is 
abundant.  
2. The relationship that specifies 𝐶𝐿 =
𝐷×𝐹
𝐴𝑈𝐶
 is predicated 
on elimination occurring from the central 
compartment (as per below). Note that 𝐴𝑈𝐶 is the 
area under the concentration time curve, 𝐶𝐿 drug 
clearance, 𝐷 dose, and 𝐹 bioavailability. 
 
 
Assumptions that arise due to need, lack of 
alternative method or model, and parsimony: 
1. Need / lack of alternative method or model: The 
recorded blood sampling time and dosing time are 
accurate.  
2. Parsimony: For a particular PKPD dataset, a linear 
model provides an appropriate description of the 
relationship between drug concentration and effect. 
 
 Explicit assumptions that are originally implicit: 
1. That binding equilibrium is quicker than changes in 
concentration, hence application of an 𝐸𝑚𝑎𝑥 model 
is appropriate. 
2. Since the sampling of the drug concentrations is 
sparse, the error terms are unlikely to be 
autocorrelated, hence the use of the ML estimation 
method is appropriate.  
  
Assumptions of appropriateness: 
1. Cockcroft and Gault equation provides a good 
approximation to the measured glomerular 
filtration rate (mGFR) for up to 70 ml/min. 
2. Application of an immediate effect model is 
acceptable for steady-state data even if the drug is 
known to have a delayed effect. 
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Use of Janmahasatian’s equation to derive the fat free 
mass (FFM) for patient groups other than those of 
European descent. 
Application of FFM equation to a patient who has 
recently lost weight via bariatric surgery. 
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5.4.3. Identification of assumptions 
Identification of a potentially exhaustive list of model-related assumptions 
is challenging. Due to the inherent nature of some assumptions and model 
complexity, the very existence of some assumptions may not be immediately 
obvious to modellers. This represents a major barrier to assumption evaluation 
and subsequent mitigation of risks and uncertainties.  
To spot these unknown unknowns, it is useful for modellers to adopt a 
systematic approach that is to list assumptions methodically according to the 
nature of assumptions. To this end, six categories of assumptions have 
previously been proposed [34]: (1) biological or physiological assumptions, (2) 
pathophysiological assumptions, (3) pharmacological or pharmaceutical 
assumptions, (4) experimental assumptions, (5) study conduct assumptions, and 
(6) statistical or mathematical assumptions. In this work, the definition and 
examples of these assumptions are provided and summarised in Table 5.3.    
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Table 5.3 Nature of assumptions and the corresponding definition and examples.  
Nature of 
assumption 
Definition Examples (not exhaustive) 
Biological / 
physiological 
Relating to normal structures and 
functions of living organisms 
(including that of humans). 
1. Alternative pathways for the formation of an endogenous entity 
X are unimportant and negligible 
2. Constant receptor system 
3. Bone mineral density is predictive of the risk of fractures 
4. The fat free mass derived from the Janmahasatian’s equation is 
unbiased 
5. The glomerular filtration rate estimated based on the Cockcroft-
Gault equation is unbiased 
Pathophysiological 
Relating to abnormal structures or 
functions of living organisms 
(including that of humans) associated 
with a disease or an injury.   
1. Linear disease progression 




Relating to formulations, preparations, 
mechanisms, uses, and effects of drugs.   
1. Linear pharmacokinetics 
2. Constant drug’s clearance (i.e. not time-varying) 
3. The drug concentration obtained is at steady-state 
4. The plasma drug concentration is representative of the target 
site concentration 
5. The drug binding to the target receptor is irreversible 
6. Only the parent drug is pharmacologically active 
7. The effect of two drugs are non-additive 
Experimental 
Relating to wet lab experiments and is 
distinguished from in silico experiments 
or other theoretical work.  
1. The drug concentration quantified based on a bioassay is 
accurate 
2. The point of care testing device is sensitive and specific 





Definition Examples (not exhaustive) 
Study conduct 
Relating to the data collection process 
that is beyond the confines of a 
laboratory setting.    
1. There is no study protocol violation 
2. Perfect adherence 
3. The recorded blood sampling time is accurate 
Statistical / 
mathematical 
Relating to statistics or mathematics.  
1. The data are missing completely at random 
2. The last observation carried forward method is appropriate for 
imputation of missing dosing history 
3. Handling data that are below the limit of quantitation using the 
M3 method is appropriate 
4. Outlying observations are not influential 
5. The residual error terms are not autocorrelated 
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5.5. Flowchart for assumption evaluation 
The typical workflow for assumption evaluation was generalised into a 
qualitative flowchart. A flowchart was developed in a stepwise manner. In the 
first step, a decision tree that mapped all possible outcomes from a sequential 
evaluation of the impact and the probability of assumption violation was built. 
In the next step, the multilevel decision tree was streamlined to a simple 
flowchart for systematic evaluation of assumptions. The flowchart developed is 
shown in Figure 5.3.  
For each assumption, the impact, 𝐼, and the probability, 𝑃, of assumption 
violation are assessed. Here, both 𝐼 and 𝑃 were evaluated for their influence on: 
(1) an internal component of model building (termed internal evaluation and 
represented by subscript [𝑖]), or (2) an external use of the model (termed external 
evaluation and represented by subscript [𝑒] ). The outcomes of the flowchart 
include the potential go / no-go decision for internal model-building or external 
use of the model, the acknolwedgement of a limitation of the model or simply 
the acknowledgement of the assumption and continued model use. 
Evaluation of 𝐼  and 𝑃  as well as internal versus external evaluation are 
further discussed in section 5.5.1 and section 5.5.2, respectively. The utility of 
the flowchart for decision making is illustrated in section 5.7 for both: (1) a top-
down model building process and (2) a bottom-up work based on a QSP model.  
5.5.1. Evaluation of I and P  
For each assumption, evaluation of the impact (𝐼)  as significant, non-
significant, or unknown precedes the evaluation of the probability of assumption 
violation (𝑃) as likely, unlikely, or unknown. If 𝐼 is significant or unknown then 𝑃 
is evaluated. In this hierarchical approach, 𝑃 is otherwise not tested. Here, the 
ratings for 𝐼  and 𝑃  are rated based on either prior knowledge (e.g. existing 
literature, logical reasoning) or, in the absence of prior information, posterior 
knowledge which results from a bespoke study (e.g. experimental work, 
simulation study, sensitivity analysis). 
 




Figure 5.3 Flowchart for systematic evaluation of model assumptions. I is the impact and 
P is the probability of assumption violation. The subscript [i] relates to internal 
evaluation (an evaluation relating to model development) and [e] external evaluation (an 
evaluation relating to use of the model after development). 
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5.5.1. Internal versus external evaluation 
For internal evaluation, both 𝐼  and 𝑃  are evaluated with respect to the 
performance of the model. Here, the goal of the assessment of 𝐼 is to quantify the 
influence of a violation in the assumption on the resulting model fit and 
evaluation of 𝑃 is to assess the corresponding chance of assumption violation. 
External evaluation is carried out in a similar manner except that it is with 
reference to an external aim of interest, which typically involves simulation from 
the final model and extrapolation beyond the original scope of the model. The 
evaluation of either component concludes with a go / no-go decision.         
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5.6. Table of assumptions 
A tabular approach to documentation is proposed (with particular 
emphasis on recording information of interest) to enhance the effectiveness of 
communicating assumptions. The table is divided up into three components, 
Impact, Probability, and Decision. The impact and probability components are 
further divided into Methods, Results, and Rating. The structure of the table of 
assumptions, its components, and generic description of each component are 
shown in Table 5.4.    
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Table 5.4 Table for documentation of assumption and their evaluation. I is the impact of assumption violation, L means likely, P is the probability 
of assumption violation, S means significant, NS means not significant, U means unlikely, UK means unknown, and NA not applicable.  
Assumption 
Impact (𝑰) Probability (𝑷) 
Decision 

































for the rating 
assigned.  











unknown.   


















for the rating 
assigned. 





ratings are 𝐿 
for likely, 𝑈𝐿 
unlikely, and 
𝑈𝐾 unknown.  
State if it is a 















The utility of the flowchart and table of assumptions was illustrated for 
both a: (1) top-down model building process and (2) bottom-up approach based 
on application of a QSP model. The top-down approach was based on the joint 
model for warfarin and vitamin K-dependent coagulation proteins described in 
Chapter 2. For the bottom-up approach, the development of a factor VII-based 
method for the prediction of international normalised ratio (INR) based on 
simulations from a QSP coagulation network model [31] was considered (see 
Chapter 4). Selected assumptions from the top-down work are shown here as 
examples to illustrate the assumption evaluation process using the flowchart.  
Here, four application examples are included: (1) internal evaluation of 
implicit assumption, (2) internal evaluation of explicit assumption, (3) external 
evaluation of implicit assumption, and (4) external evaluation of explicit 
assumption. The evaluation results of these assumptions are described in the 
next sections. A summary of the evaluation is also provided in Table 5.5.   
Other assumptions underpinning the joint model (11 assumptions) and the 
factor VII-based method (6 assumptions) were also evaluated internally. For 
brevity, these are not presented here but are summarised in Appendix A4.1 and 
Appendix A4.2, respectively.   
5.7.1. Internal evaluation 
5.7.1.1. Implicit assumption example 
Implicit to the development of the joint model in NONMEM® Version 7.2 
(ICON Development Solutions, Ellicott City, MD, USA), the residual error terms, 
𝜀, were assumed to be normally distributed with a mean of zero and have a 
variance of 𝜎2. NONMEM® is reported to be sensitive to a misspecification in the 
residual error model. Parameter estimates, in particular, random-effect 
parameters, may be biased [215]. For these reasons, 𝐼 was conservatively rated 
as significant.  
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𝑃 was subsequently evaluated. Since no prior information were available, 
𝑃  was assessed by comparing the distribution of the conditional weighted 
residuals (𝐶𝑊𝑅𝐸𝑆) to a standard normal distribution using quantile-quantile (Q-
Q) plots and the one-sample Kolmogorov-Smirnov goodness-of-fit tests. Here, 
𝐶𝑊𝑅𝐸𝑆 represent a composite measure of the additive and proportional error 
terms. In Figure 5.4, the majority of the 𝐶𝑊𝑅𝐸𝑆 quantiles fall on the reference 
line that corresponds to a standard normal distribution. In addition, based on 
the Kolmogorov-Smirnov tests, 𝐶𝑊𝑅𝐸𝑆 for factors II (𝑇 = 0.0315, 𝑝 = 0.998), IX 
(𝑇 = 0.0895, 𝑝 = 0.173), X (𝑇 = 0.0767, 𝑝 = 0.328), proteins C (𝑇 = 0.0588, 𝑝 =
0.660 ), and S ( 𝑇 = 0.0432 , 𝑝 = 0.933 ) do not have a distribution that is 
significantly different from a standard normal distribution. An exception was 
the 𝐶𝑊𝑅𝐸𝑆 for factor VII (𝑇 = 0.111, 𝑝 = 0.0458), although visually the Q-Q plot 
does not look significantly worse than the other plots. Taken together, these 
results suggest that 𝐶𝑊𝑅𝐸𝑆 are likely to have a standard normal distribution. In 
other words, 𝑃 was unlikely.  
According to the flowchart (Figure 5.3), significant 𝐼 and low 𝑃 give a go 
decision for model building.     
 
 
Figure 5.4 The Q-Q plot for the CWRES of the joint model. CWRES is the conditional 
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5.7.1.2. Explicit assumption example 
Actual daily dose time of warfarin were not recorded. For the joint model 
development, a daily dose time of 6 p.m. was assumed for all patients based on 
the study protocol. In the absence of prior knowledge regarding 𝐼 , 𝐼  was 
evaluated a posteriori. A sensitivity analysis was conducted whereby different 
daily dose time of 8 a.m., 10 a.m., 12 p.m., 2 p.m., 4 p.m., 8 p.m., and 10 p.m. were 
used as alternative imputation values for dose time. The resulting model fits and 
parameter estimates were compared to the original model. Identical objective 
function values (OFV) and final parameter estimates were obtained thereby 
indicating insensitivity of model fits and parameter estimations to the different 
imputed daily dose time. 𝐼  was considered insignificant and therefore 
unimportant and as a result, 𝑃 was not evaluated. According to the flowchart 
(Figure 5.3), this leads to an expedited go decision for model building.  
5.7.2. External evaluation  
For the purpose of this thesis, development of the joint model for warfarin 
and vitamin K-dependent coagulation proteins is of primary interest. At this 
stage, the model has not been used externally. However, in this section, the 
model was applied to explore two hypothetical external aims of interest to 
illustrate the external evaluation process.    
5.7.2.1. Implicit assumption example 
A possible external aim is to use the joint model for the prediction of the 
time course of coagulation protein concentrations in an external population and 
in this example, warfarin patients with vitamin K supplementation. Implicit to 
the inhibitory 𝐸𝑚𝑎𝑥 model used as part of the joint model, warfarin binding to 
the vitamin K epoxide reductase (VKOR) enzyme is assumed to be reversible 
and that the binding affinity is a constant (hence time-invariant).   
Based on logical reasoning, a deviation from the assumptions, for instance, 
if warfarin has a different binding affinity to VKOR and hence has a different 
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potency ( 𝐼𝐴50,𝑃 ), predictions from the model with the new 𝐼𝐴50,𝑃  would be 
different from that produced by the original model. 𝐼 was rated as significant.     
Next, 𝑃 was evaluated. 𝐼𝐴50,𝑃 is an apparent potency parameter for warfarin 
that depends positively on the amount of vitamin K in the body. In essence, the 
higher the amount of vitamin K in the body, the higher is the 𝐼𝐴50,𝑃 (i.e. warfarin 
becomes apparently less potent) and vice versa. Whereas in the model-building 
population where vitamin K intake is normal and rather constant, in this specific 
example, the new population receives vitamin K supplements. Then, 𝐼𝐴50,𝑃 will 
vary according to the extent (e.g. upward shift of 𝐼𝐴50,𝑃) and consistency (e.g. 
time-varying 𝐼𝐴50,𝑃)  in the vitamin K supplementation. Due to the discrepancy 
in the 𝐼𝐴50,𝑃, simulations from the joint model are likely to be biased as compared 
to the actual time course of coagulation protein concentrations in the new 
population. For these reasons, 𝑃 was rated as likely. According to the flowchart 
(Figure 5.3), significant 𝐼 and high 𝑃 result in a no-go decision for model use 
with respect to the external aim of interest.       
5.7.2.2. Explicit assumption example 
Another possible external aim of interest is to use the joint model to predict 
the time course of coagulation protein concentrations beyond the original dose 
range used for model building. In the absence of warfarin PK data, volume of 
distribution of warfarin (𝑉) was found to be not structurally identifiable. 𝑉 was 
assumed as 8 L in the joint model. In the first step of assumption evaluation, the 
impact of a wrongly specified 𝑉 was considered with respect to the external aim 
of interest. Because 𝑉 was structurally not identifiable given the input-output 
data, value of 𝑉, even if incorrectly specified, does not affect the resulting model 
fits (although arrives at a biased 𝐶𝐿  estimate) and as such it has no specific 
bearings on subsequent simulations from the model for external application 
(regardless of whether it is within or beyond the original dose range used for 
model building). 𝐼 was rated as insignificant. According to the flowchart (Figure 
5.3), evaluation of 𝑃 was not required and an expedited go decision for model 
use was resulted.     
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Table 5.5 Four assumption examples and their evaluation. I is the impact of assumption violation, L means likely, P is the probability of assumption 




Impact (𝑰) Probability (𝑷) 
Decision 




Example: For each 
coagulation protein, 
the errors, 𝜀 (𝑛 × 1), 
are assumed 
normally distributed 
with a mean of zero 
and a variance of 𝜎2 
Previous evaluation 
of impact of non-
normality available in 




is sensitive to 
specification of the 
residual error. 
Misspecification may 
result in biased 
parameter estimates 
and predictions. 
S The distribution of 
𝐶𝑊𝑅𝐸𝑆 was 
compared to a 
standard normal 
distribution by using 
a Q-Q plot and a one-
sample Kolmogorov-
Smirnov test.   
𝐶𝑊𝑅𝐸𝑆 of all 
coagulation proteins 
do not have a 
distribution that is 
significantly different 
from a standard 
normal distribution. 







imputed daily dose 
time of 6 p.m. is 
appropriate and as a 
whole unbiased 
A sensitivity analysis 
was conducted. Daily 
dose time of 8 a.m., 
10 a.m., 12 p.m., 2 
p.m., 4 p.m., 8 p.m., 
and 10 p.m. were 
considered.   




of the daily dose time 
used for imputation. 
NS NA NA NA Go for 
model 
building. 






Impact (𝑰) Probability (𝑷) 
Decision 













and logical reasoning.  
Two models that are 
exactly the same but 
differ in the value of 
potency parameter 
(𝐼𝐴50,𝑃) will give 
different predictions.  
S Prior knowledge 𝐼𝐴50,𝑃 is an apparent 
potency parameter 
that depends 
positively on the 
amount of vitamin K 
in the body. With 
vitamin K 
supplementation, 
𝐼𝐴50,𝑃 is almost 
definitely altered. 





Example: Volume of 
distribution of 
warfarin (𝑉) is equal 
to 8 L 
*Extrapolation 
beyond the original 
dose range used for 
model building 
   Prior knowledge  Structural non-
identifiability of 𝑉 
means that value of 𝑉 
even if incorrectly 
specified does not 
affect the model fits 
and subsequent 
simulations from the 
model.   
NS NA NA NA Go for 
model use 




A framework for systematic evaluation of assumptions is proposed. The 
framework consists of a general workflow for assumption evaluation, definition 
of an assumption (and related terms), classification of assumptions, 
identification of assumptions, a flowchart for evaluating assumptions, and also 
a standardised table for documenting assumptions and evaluation results. In this 
work, the utility of the framework is demonstrated using both top-down and 
bottom-up examples. Selected assumptions are included as exemplars of implicit 
and explicit assumptions.  Finally this work illustrates how to determine go- / 
no-go decisions as well as providing criteria for determining when an 
assumption is deemed to be a limitation of the model.   
There have been few published works that address how model-related 
assumptions should be systematically approached and be effectively assessed. 
To date, only two published works are available that provide specific 
frameworks for evaluating model assumptions. The first work by Karlsson and 
colleagues used the development of a population PK model for moxonidine as 
an exemplar to demonstrate how assumptions intrinsic to model building may 
be evaluated [205]. The second article by the EFPIA MID3 Workgroup [34] 
provides recommendations on how assumptions may be evaluated and 
documented. Noteworthy, an assumptions table was proposed for modellers to 
document assumptions, uncertainties, and impact of assumption violations. Our 
work is viewed as an extension of these existing frameworks. Interested readers 
are referred to these works for more examples and guidance on assumption 
evaluation. In this work, a one-stop framework that covers the typical workflow 
for assumption evaluation, i.e. from identifying assumptions, evaluating 
assumptions, to documenting assumptions, is proposed. With this, modellers are 
encouraged to describe, evaluate, and document influential assumptions for 
effective model building and model use.       
This work is not free from drawbacks. The term assumption, and related 
terms, are defined within the context of model development and use. These are 
rather heuristic definitions employed to empower modellers to differentiate 
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these closely-related but potentially confusing terms. It is acknowledged that 
there may be nuanced differences in the adopted definitions compared to that 
defined in other fields of study (e.g. mathematics, philosophy, psychology). 
Although this work aims to assist modellers to evaluate assumptions objectively, 
the use and application of the framework for assumption evaluation is somewhat 
subjective. For instance, the choice of evaluation methods, the rigor in which 
assumptions should be interrogated, and the rating assignments for 𝐼 and 𝑃 are 
all subjective and dependent on the modellers’ expertise, past experience, 
preference, available resources, and time constraints. In addition, the required 
first step for assumption evaluation is successful identification of pertinent 
assumptions. In this work, it is suggested for the modellers to list the 
assumptions methodically according to the nature of assumptions. However, 
despite the systematic approach suggested, identification of an exhaustive list of 
model-related assumptions is challenging. Due to the implicit nature of some 
assumptions and model complexity, it is possible for some assumptions to have 
gone unnoticed i.e. unknown unknowns. Here, it remains unanswered as to how 
to mitigate the risk associated with these unknown unknowns.      
This framework has been applied to both top-down and bottom-up 
approaches. Although these examples are sufficient to illustrate how the 
proposed framework may be used for assumption evaluation, it is in no way a 
form of validation. The robustness of the framework to the different modelling 
processes and model use settings as well as the utility and practicality of the 
framework have not been explored fully. An important next step of this work is 
therefore to apply the framework to other settings. Finally, in view that the 
bottom-up work (factor VII-based method for INR prediction) considered in this 
thesis is somewhat atypical to the conventional model building process for a QSP 
model, it is important to apply the framework to the development of a QSP 
model. 
  




A framework for systematic evaluation of assumptions is proposed and its 
utility is demonstrated using both top-down and bottom-up examples. The next 
step of this work is to apply the framework to a series of other settings to fully 
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The current chapter provides a synopsis of key findings from the thesis and 
a discussion of these findings in the context of other work. These are followed 
by a summary of limitations and future work that arise from this thesis. 
Discussions in this chapter are targeted at the main outcome of the thesis – 
application of pharmacometric methods that leads to the identification of factor 
VII as a prominent driver of the international normalised ratio (INR) and the 
development of a factor VII-based method for the prediction of anticoagulant 
response to warfarin. Discussions specific to individual chapters of the thesis will 
not be reiterated here.  
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6.1. Synopsis and theoretical basis of the thesis 
In this thesis, pharmacometric methods were applied to understand the 
coagulation kinetics underpinning warfarin dose response and to introduce a 
new perspective to the prediction of anticoagulant response to warfarin. It was 
argued that the issues surrounding the poor predictive performance of existing 
warfarin dosing methods relate to the use of the INR, a blunt measure of 
anticoagulant response that is a composite of the influence of several coagulation 
proteins, co-factors, and other causes, as a sole marker of anticoagulant response 
due to warfarin.  
The overarching premise of this thesis was that a measure of coagulation 
protein response in addition to the INR response will be helpful in the prediction 
of the anticoagulant response and warfarin dose requirement. This was argued 
and rationalised based on the full causal path of warfarin dose and system 
response. The full causal path, which is previously presented in Figure 1.15 in 
Chapter 1, is summarised in Figure 6.1 in terms of the possible points of 
biomarker sampling to inform the prediction of anticoagulant response and 
warfarin dose requirement. In Figure 6.1, INR response represents a surrogate 
endpoint of interest due to its association with major clotting and bleeding 
events. However, due to the aforementioned conglomerate nature of INR with 
respect to warfarin pharmacokinetic (PK), pharmacodynamic (PD), and system 
variabilities, its interpretation relies heavily on understanding the mechanistic 
relationship between warfarin dose and INR response. To this end, the inclusion 
of PK marker (e.g. warfarin concentration) and / or PD marker (e.g. coagulation 
protein concentration) may be helpful in elucidating warfarin dose response. 




Figure 6.1 Causal path of warfarin dose response presented in terms of the points of 
biomarker sampling. INR response is routinely measured as a surrogate marker of major 
clotting or bleeding events in warfarin patients. Warfarin dose is causally linked to the 
INR response via warfarin concentration (PK marker) and coagulation protein 
concentration (PD marker). Panel a represents an ideal case when PK, PD, and system 
markers are available simultaneously. Panel b (PD and system markers), panel c (PK and 
system markers), and panel d (system marker only) are practical approximation to Panel 
a. INR is the international normalised ratio, PD pharmacodynamic, and PK 
pharmacokinetic.    
 
Panel a in Figure 6.1 represents an ideal case where PK, PD, and system 
markers are all observed, which can be fitted into a single coherent, multivariate 
prediction framework to inform the relationship from dose to response. In 
Figure 6.1, panels b, c, and d are practical approximations to panel a. Although the 
least informative, panel d, which reduces the full causal path to a simple (and 
often empirical) link between warfarin dose and INR response, is the most 
widely described method for warfarin dose individualisation literature. This 
includes warfarin dosing methods that adjust warfarin doses based on the 
observed INR responses such as the nomograms (see Tait et al. [17] for an 
example), algorithms based on the linear regression analysis (see Lenzini et al. 
[12] for an example), and prediction methods with an underpinning kinetic-
pharmacodynamic (KPD) model (see Wright et al. [18] for an example). Panel c 
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shows the streamlined causal link between warfarin, PK marker, and INR 
response, which underpins the majority of warfarin pharmacokinetic-
pharmacodynamic (PKPD) models (see Xue et al. [164] for an example).  
In this thesis, the causal link of warfarin dose, PD marker, and INR 
response as outlined in panel b of Figure 6.1 is of primary interest. This 
corresponds to a type of “KPD-system” framework where INR response is a 
system response that is downstream of the PD target effects. This approach was 
initially explored piecewise in Chapter 2 of this thesis with the development of 
a KPD model for warfarin and coagulation proteins and in Chapter 3 that 
investigated the coagulation kinetics governing the INR response based on a 
model of the coagulation system [31]. It was shown that, of all the vitamin K-
dependent coagulation proteins, factor VII is the coagulation protein of interest 
due to its short degradation half-life, sensitivity to warfarin, and profound 
influence on the INR. On that basis, Chapter 4 of this thesis explored the 
incorporation of a bivariate response variable of factor VII and INR for the 
prediction of future anticoagulant response to warfarin. In this setting, factor VII 
is a PD marker that provides a signal from the system that lies causally between 
warfarin dose and INR response. Here, a PD marker is arguably superior to a PK 
marker. This is due to its proximity to the clinical endpoints of interest in the 
chain of causal events (Figure 6.1) and its informativeness with respect to both 
PK and PD variabilities as compared to the PK markers, which are informative 
of the variability in PK only. Finally, the use of factor VII in addition to the INR 
response provides an opportunity to isolate the PKPD variability from system 
variability. This is helpful in elucidating the different sources of variability 
underpinning warfarin dose response.   
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6.2. Synopsis of individual chapters 
Chapter 2 of this thesis described the development of a joint model for the 
vitamin K-dependent coagulation proteins (factors II, VII, IX, X, and proteins C 
and S) during warfarin initiation. Initially, the coagulation proteins were 
modelled independently, then the six models were combined into a single joint 
model where the full correlation structures that exist between parameters at the 
individual level and between residual errors of different coagulation proteins 
were considered. The joint model developed was able to describe accurately the 
time course of warfarin influence on all six coagulation proteins simultaneously. 
Factor VII was found to have the shortest degradation half-life compared to 
factors II, IX, X, and proteins C and S thereby representing the coagulation 
protein that is the first to decline and to reach a new steady-state level following 
a perturbation introduced by warfarin.      
Chapter 3 of this thesis outlined the exploration of the influence of 
coagulation proteins and their interactions on the INR based on simulations from 
a previously developed quantitative systems pharmacology (QSP) coagulation 
network model [31]. In this chapter, of factors II, VII, and X, factor VII was found 
to be the most influential on the INR. This was based on the sensitivity analysis 
that showed that the INR is the most sensitive to factor VII and the isobologram 
analysis that demonstrated that the presence of more than one coagulation 
proteins deficiency is redundant for INR effect due to the sub-additivity nature 
of interactions between coagulation proteins. This led to the hypothesis that the 
use of factor VII as a marker of coagulation (in addition to the INR) may improve 
the prediction of the anticoagulant response.        
Chapter 4 of this thesis builds on the findings from Chapter 2 and Chapter 
3 to develop a factor VII-based method for the prediction of anticoagulant 
response to warfarin. The method was developed based on a heuristic model-
order reduction technique where predictions from the QSP coagulation network 
[31] were empirically approximated over an appropriate span of the input-
output response. The prediction method was shown to be associated with 
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minimal bias and its use was illustrated using data from one typical simulated 
patient and two real patients supporting a proof-of-principle.     
The pharmacometric analyses presented in Chapter 2 and Chapter 4 of this 
thesis were founded on several assumptions. Chapter 5 of this thesis describes 
the development of a framework for systematic evaluation of model 
assumptions. In this work, definition of an assumption and a system to classify 
assumptions to aid the identification of assumptions were provided. A flowchart 
was introduced for systematic evaluation of assumptions and a corresponding 
assumption table was proposed for documentation of assumptions and 
evaluation results. The assumptions underpinning Chapter 2 and Chapter 4 of 
this thesis were evaluated and used to illustrate the utility of the proposed 
framework.    
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6.3. The thesis findings in the context of other work 
6.3.1. Application and development of pharmacometric methods 
The clinical outcome of this thesis was derived from pharmacometric 
analyses. Pharmacometric methodologies that are unique to this work are 
summarised and briefly discussed in this section.  
Isobologram analysis is traditionally used for the analysis of drug 
interactions [187]. No particular assumption is made about the relationships 
between the two drugs or the doses of the two drugs, whether they are 
independent or correlated. In Chapter 3, the isobologram analysis was extended 
beyond the usual drug interactions framework to explore interactions between 
factors II, VII, and X, which are known to be inherently correlated due to the 
complex series of interactions within the coagulation network for haemostatic 
control. In this setting, terminologies usually coined to describe drug interactions 
such as antagonism (which implies receptor binding and receptor-level 
interactions) were not used because coagulation proteins do not actually 
antagonise one another and they act on distinct targets. Here, terminologies that 
are neutral in the underpinning interaction mechanisms and descriptive of the 
observed interaction, for instance, sub-additivity in effect, were preferred. In this 
thesis, the isobologram analysis highlighted redundancies in the system where 
factors II, VII, and X were found to be sub-additive in effect. The term 
redundancies is used here since not all coagulation proteins are required to be 
depleted in order to observe a full anticoagulant effect with respect to the effect 
of warfarin on INR.   
In the development of a method for the prediction of warfarin 
anticoagulant response (Chapter 4), a heuristic model-order reduction method 
was employed. In this work, a statistical model was used to approximate 
empirically the fully-mechanistic coagulation network model such that all 
anticoagulant responses of interest were captured over an appropriate span of 
the input-output relationships. The resulting statistical model is considerably 
simpler than the full mechanistic model and is amenable to manipulation for 
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clinical application, particularly the potential for Bayesian forecasting. A similar 
approach to approximate complex systems model has been described, albeit to 
serve a different purpose of incorporating expected variability and correlation to 
the output of QSP model [196, 216]. Model-order reduction can generally be 
achieved by either reducing the number of reactions (e.g. quasi steady-state 
approximation) or the number of states (e.g. proper lumping). The technique of 
proper lumping has been used for model-order reduction for several systems 
models [84-86]. In proper lumping, the original states of the model are lumped 
into a reduced number of pseudo-states thereby giving rise to a model of lower 
dimensionality but preserving similar input-output relationships of interest. 
However, at the time this thesis work was undertaken, no exact solutions for 
lumping are available for nonlinear ordinary differential equations (ODEs) such 
as that underpinning the coagulation network model. In particular, the process 
of proper lumping is unable to provide the parameter values for the reduced 
states when a system is nonlinear [85]. Recent methods suggest linearising the 
original nonlinear model (e.g. by inductive linearisation [217, 218]) to produce a 
linear system which is then ready for proper lumping. An important additional 
advantage of a linear system is the availability of analytical solutions (e.g. matrix 
exponential solutions) that are known to be accurate and associated with short 
solution time. Alternative methods have been described that operate within the 
nonlinear domain and employ lumping and empirical balanced truncation 
under the Petrov-Galerkin projection to achieve a reduction [219, 220].   
The work conducted in this thesis is also unique in that variability in 
anticoagulant response between patients is accounted for and quantified within 
a QSP setting. Chapter 4 describes characterisation of the sensitivity of the 
patient to warfarin in terms of the dose (𝐷𝑟𝑒𝑓) that would be taken by a typical 
patient to achieve the same level of observed anticoagulant response. The 
deviation of 𝐷𝑟𝑒𝑓 from the actual dose taken provides a quantitative assessment 
of the difference of the patient from a typical patient. Armed with an 
individualised measure of patient’s sensitivity, the anticoagulant response at 
steady-state can be predicted. Derivation of the expected anticoagulant response 
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using this approach is untested but should function in theory and seems to work 
based on the evaluation conducted in Chapter 4. However, generalisation of the 
method to other settings requires prospective testing.    
In Chapter 5, a framework for systematic evaluation of assumptions is 
proposed. The framework was developed based on expansion of existing works 
by Karlsson et al. [205], who illustrated how model-related assumptions may be 
evaluated using the development of a population PK model for moxonidine as 
an example, and the European Federation of Pharmaceutical Industries and 
Associations (EFPIA) Model-Informed Drug Discovery and Development 
(MID3) Workgroup, who provided recommendations on the evaluation and 
documentation of assumptions [34]. Whereas previous studies address specific 
aspects of assumption evaluation, the current work proposes a comprehensive, 
one-stop framework that encompasses the full workflow for assumption 
evaluation, i.e. from identifying assumptions, evaluating assumptions, to 
documenting assumptions and acknowledging limitations. This is critical to 
formally and systematically address the model-based components that form the 
basis of inference drawn from pharmacometric analyses such as that 
underpinning the proposed prediction method of warfarin anticoagulant 
response described in this thesis.  
6.3.2. Factor VII as a driver of the INR 
In this thesis, factor VII was postulated as the coagulation protein of choice 
for the prediction of the anticoagulant response to warfarin. Factor VII’s 
sensitivity to warfarin and influence on the INR can be ascribed to the short 
degradation half-life of factor VII relative to other vitamin K-dependent 
coagulation proteins. Based on the joint model developed in Chapter 2, the 
degradation half-life of factors II, VII, IX, and X, and proteins C and S was 51.3, 
12.2, 21.5, 44.1, 18.4, and 56.8 hours, respectively, which was in good agreement 
with previously reported values range from 72-115, 5-35, 18-40, 35-63, 8-32, and 
43 hours, respectively [99, 159, 161, 165, 171-175]. Despite arriving at similar 
values, it is important to note the differences in the approaches used elsewhere 
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with that used here. Previous studies investigated the coagulation proteins 
relationship in cross-section, limiting the time course to a snapshot of the 
anticoagulant response to warfarin. In this work, the factors were analysed 
longitudinally in a joint model framework across all vitamin K-dependent 
coagulation proteins (factors II, VII, IX, and X, and proteins C and S) 
simultaneously. This provides a framework to account for the natural correlation 
that exists between parameters at the individual level and between residual 
errors of different coagulation proteins.  
There have been few published studies examining the concentration of 
factors II, VII, and X at steady-state INR. At steady-state INR, factor VII 
concentration is consistently higher than that of factor II, which in turn is higher 
than the factor X concentration for patients on stable warfarin (i.e. 𝑉𝐼𝐼𝑆𝑆 > 𝐼𝐼𝑆𝑆 >
𝑋𝑆𝑆) [144, 146, 167, 198]. This consistency in trend means that given the steady-
state concentration of one of factors II, VII, and X, the steady-state concentration 
of other coagulation proteins and the resulting INR can be predicted. Since factor 
VII has a short degradation half-life relative to that of factors II and X, it achieves 
the new steady-state rapidly following a perturbation in production (e.g. 
warfarin initiation) and thereby provides the earliest indication of the eventual 
steady-state concentrations of other coagulation proteins and INR.  
With respect to the non-steady-state INR, the dominance of factor VII has 
been described previously [161, 197]. However, because the antithrombotic effect 
of a deficiency in factor VII was shown to be less important as compared to that 
of factors II and X [159, 221-225], factor VII, which governs the non-steady-state 
INR, is often overlooked or viewed as a nuisance factor in the monitoring of 
anticoagulant response using the INR. Indeed, attempts were made to factor out 
the influence of factor VII in the monitoring of anticoagulant response. Furie et 
al. proposed the use of factor II [221, 226] and Onundarson et al. designed a factor 
VII-insensitive prothrombin time test [224] for the monitoring of anticoagulant 
response to warfarin. Importantly, the goal of the work conducted as part of this 
thesis was not to contest the lack of antithrombotic role of a reduction in factor 
VII but to exploit the short degradation half-life of factor VII and its inherent 
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correlation with factors II and X and the INR for early and accurate prediction of 
anticoagulant response at steady-state. 
6.3.3. Factor VII-based method to predict anticoagulant response 
The proposed method differs from those reported in the published 
literature. A significant number of existing warfarin dosing methods quantify 
the likely anticoagulant response using patient covariates such as body size, age, 
ethnicity, concomitant drugs, cytochrome P450 2C9 (CYP2C9) genotype, and 
vitamin K epoxide reductase complex subunit 1 (VKORC1) genotype [8-16]. 
However, these methods provide no guidance for warfarin dose adjustment 
once measures of anticoagulant response (e.g. INR or clotting factor activity) 
become available. Importantly, anticoagulant response data will capture 
between-subject differences in warfarin dose response, including those related 
to patient covariates such as the CYP2C9 and VKORC1 genotypes. Therefore, in 
theory, once the time course of anticoagulant response for a given warfarin dose 
is accounted for, it may no longer be necessary to consider these covariates.  
Whereas the proposed method is based on factor VII (and INR), all existing 
response-based methods rely solely on the measurement of INR for warfarin 
dose individualisation [12, 17, 18, 22, 23, 25-30]. This is attributable to the ease of 
measuring the INR and the wide availability of INR tests in the clinical setting 
as well as the well-established association of INR to clinical outcomes of interest 
(e.g. thrombotic stroke and intracranial haemorrhage) [92, 93] although INR is 
arguably difficult to interpret owing to its nonlinear dependence on fibrinogen, 
factors II, V, VII, and X [136, 137]. An exception was a published work by Pitsiu 
et al. that considered factor VII for the prediction of warfarin maintenance dose 
[157]. It was shown that factor VII response measurements alone were adequate 
to determine dosing requirements although it is important to point out that the 
sample size is small ( 𝑛 = 5 ) and the use of healthy volunteers limits 
generalisability of the study’s results to all warfarin users.  
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6.4. Limitations and future work 
The work conducted in this thesis was not set forth to propose a new 
framework for warfarin dosing that is instantly applicable for clinical use, but to 
introduce a new perspective on INR prediction and subsequently, for warfarin 
dosing. A natural succession to this work would be to extend the current method 
to predict warfarin maintenance dose. This would require (1) mathematical 
rearrangement and adaptation of the current method and (2) setting up a dose 
individualisation algorithm (perhaps Bayesian) as a dose prediction method that 
incorporates a bivariate response variable. Using a Bayesian forecasting 
approach, key parameters in the dose prediction algorithm can be individualised 
by minimising the maximum a posteriori (MAP) objective function based on 
information about the patient and the dose-factor VII-INR data obtained from 
individual patient. Then, as more data become available, the individual 
parameter estimates become more refined to allow accurate prediction of 
warfarin dose that is required to achieve the therapeutic INR.  
In Chapter 4, the proposed INR prediction method was applied to a typical 
simulated patient and two patients. The evaluation was conducted not to 
illustrate clinical applicability but to show that the method may potentially work 
(i.e. akin to a proof of principle). Application of the proposed method, be it 
prediction of 𝐼𝑁𝑅𝑆𝑆 or warfarin maintenance dose, relies on the availability of 
paired blood samples of factor VII and INR. However, factor VII is not routinely 
measured due to the need for factor VII-deficient plasma [142], which has not 
been readily available in the clinical setting and therefore it is not possible to 
fully evaluate the proposed method using data available retrospectively. Limited 
by a small sample size, the evaluation results of the proposed INR prediction 
method are not generalisable to clinical use.  
A prospective study specially designed to systematically evaluate the 
method would be essential. The required first step is to prospectively assess the 
predictive performance of the proposed dosing algorithm by comparing the 
predicted 𝐼𝑁𝑅𝑆𝑆 and / or warfarin maintenance dose to that observed in a cohort 
of patients initiating warfarin therapy. This allows quantification of systematic 
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bias in prediction and the corresponding imprecision by calculating the mean 
prediction error (MPE) and the root mean square error (RMSE), respectively. In 
addition, the time-in-therapeutic range (TTR), which is an accepted surrogate for 
warfarin safety and effectiveness [227], could be determined in silico. 
Subsequently, conditioned on an acceptable predictive performance, a 
prospective randomised controlled trial (RCT) is needed to fully evaluate the 
clinical utility of the proposed warfarin dosing method. Here, patients initiating 
warfarin therapy would be randomised so that warfarin dosing is guided either 
by the proposed method or by a standard care model or an alternative dosing 
algorithm. The outcomes of the RCT could include incidence of major bleeding 
or thromboembolic events, cost effectiveness, and / or a biomarker of effect such 
as TTR. Importantly, because existing dosing methods produce biased 
predictions in patients who require doses in the upper quartile (≥7 mg/day) [3-
5, 7] and lower quartile (≤2 mg/day) [2, 6] of warfarin dose requirements, these 
patients would be of particular interest. A stratified analysis based on dose that 
is sufficiently powered and with an acceptable overall type I error could be 
considered.   
At present, the sampling times for factor VII and INR are proposed based 
on heuristic reasons (Chapter 4). An optimal design analysis may be able to offer 
better alternative sampling times – one that improves the precision of key 
parameter estimates and minimises the bias in the prediction of 𝐼𝑁𝑅𝑆𝑆  and 
warfarin maintenance dose. In addition, because the proposed method was 
based on empirically modelling the predictions from the QSP coagulation 
network model [31], it is important not to extrapolate beyond the original 
conditions used for method development. In addition, despite the effort to verify 
the QSP model (Chapter 3), it is acknowledged that there remain uncertainties 
in the accuracy of the model in describing the warfarin dose-coagulation 
proteins-INR relationships. It is possible for a potential inconsistency in the QSP 
model to propagate to the proposed prediction method, which may impact the 
performance of the proposed method in predicting 𝐼𝑁𝑅𝑆𝑆  and warfarin 
Chapter 6: Discussion and future work  
199  
 
maintenance dose requirement. Recalibration of the proposed method using 
prospectively collected warfarin-factor VII-INR data may be required.   
In Chapter 5, a framework for systematic evaluation of model-related 
assumptions was proposed and its utility was demonstrated using both top-
down and bottom-up examples. These examples are included to demonstrate 
how the proposed framework may be used for assumption evaluation. However, 
it is important to note that the framework was applied to evaluate assumptions 
underpinning an application of the bottom up model (i.e. coagulation network 
model), which differs from a typical model-building process for a bottom up 
model. The robustness of the framework to the different model-building 
processes and model use settings as well as the practicality of the framework 
have not been explored fully. The next step of this work is to apply the 
framework to a series of other settings, including both top-down and bottom-up 
works of different levels of complexity, to fully assess its practicality and its 
value in identifying and making inference from assumptions.     




In this thesis, both the top-down and bottom-up approaches to 
pharmacometric analyses were applied to explore the coagulation kinetics 
underpinning the warfarin dose response and to introduce a new perspective to 
the prediction of anticoagulant response to warfarin.   
Factor VII was identified as having a short degradation half-life and 
influential on the INR thereby representing an attractive marker of anticoagulant 
response to inform INR prediction for warfarin dose individualisation. A factor 
VII-based method for the prediction of anticoagulant response was developed 
and evaluated to illustrate proof of principle. An important next step of this work 
would be to extend the current method to predicting warfarin maintenance dose 
using the Bayesian forecasting method.      
A framework for systematic evaluation of model-related assumptions was 
proposed and evaluated. The next step of this work is to apply the framework to 
a series of other settings to fully explore the utility and robustness of the 
framework to different model-building processes and model use settings. The 
framework is crucial in formally addressing and mitigating the risks attached to 
assumptions underpinning pharmacometric models.        
The work conducted in this thesis illustrates a model-based approach to 
elucidate dose response of a drug. This provides a scientific basis for safe and 
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A1.1. Assay methods 
A brief description of assay methods for quantification of factors II, VII, IX, 
and X, and proteins C and S is provided. More details of these assays can be 
found elsewhere [142]. 
A1.1.1. Assay for factors II, VII, IX, and X 
Factors II, VII, and X were quantified using an assay based on the 
prothrombin time on ACL 3000 coagulation analyser. Factor IX were measured 
in a similar manner except that an assay based on the activated partial 
thromboplastin time was used. The first step of coagulometric (bioactivity) assay 
for factors II, VII, IX, and X involved mixing the test plasma with relevant 
coagulation protein deficient plasma and measurement of the time required for 
clot formation. This was followed by comparing the clotting time obtained 
against a reference curve for determination of coagulation protein concentration 
(IU/dL). 
A1.1.2. Assay for protein C 
Protein C activity was measured using a chromogenic assay on Amax 400 
analyser. Quantification of protein C involved the addition of an activator for 
activation of protein C to activated protein C, which was later measured using 
an amidolytic substrate.   
A1.1.3. Assay for protein S 
Free protein S antigen levels were quantified using an enzyme-linked 
immunosorbent assay. Measurement of protein S involved precipitation of C4b-
bound protein S with polyethylene glycol and the free protein S was 
subsequently quantified using suitably labelled antibodies during the detection 
stage of the assay. 
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A1.2. Structural identifiability analysis 
A1.2.1. Rationale and aim 
In the absence of warfarin concentration data, some model parameters may 
not be structurally identifiable. The aim of this analysis was therefore to evaluate 
structural identifiability of the individual model to be used in population 
analysis. 
A1.2.2. Methods 
A formal structural identifiability analysis was conducted using popt_i® 
Version 1.0 (Duffull SB, Dunedin, New Zealand) [64, 168]. In the case when the 
individual model was found structurally unidentifiable, parameters including 
both fixed-effect parameters (𝑘𝑎 , 𝐶𝐿 , 𝑉 , 𝐼𝑚𝑎𝑥,𝑃 , 𝐼𝐴50,𝑃 , 𝑃𝑡=0 , 𝑘𝑜𝑢𝑡,𝑃 ) and the 
corresponding between-subject variance (𝜔2) were fixed systematically one- or 
two-at-a-time until a unique solution was obtained for all remaining parameters.   
A1.2.3. Results 
The model was found to be structurally not identifiable when none or just 
one of the parameters was fixed. Either one of the four pairwise combinations of 
parameters when fixed resulted in a structurally identifiable model: (1) 𝑉 and 
𝜔2(𝑉); (2) 𝐶𝐿 and 𝜔2(𝐶𝐿); (3) 𝑉 and 𝜔2(𝐶𝐿); and (4) 𝐶𝐿 and 𝜔2(𝑉). 
A1.2.4. Implication for population analysis 
𝑉 was fixed to typical values previously estimated [152] and 𝜔2(𝑉) was 
fixed to a value of zero to obtain a structurally identifiable model and to ensure 
structural identifiability during the empirical Bayesian estimation step to derive 
individual parameters. 
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A1.3. Co-dependency of IA50,P and Imax,P  
 
Figure A 1.1 Co-dependency between IA50,P and Imax,P. This was explored by using 
individual model for proteins C and S. IA50,P was estimated at multiple instances while 
having Imax,P fixed at different values. IA50,P was found to be highly co-dependent with 
Imax,P. Imax,P for proteins C and S was fixed to one in the final models. IA50,P is the warfarin 
amount in the body that gives half the maximum inhibitory effect. Imax,P is the maximum 
inhibitory effect. PC stands for protein C and PS is protein S.  
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A1.4. Model-building steps for the full joint model 
Due to the sheer size of the full joint model that contains 157 parameters, 
the parameters are separated into different tables: (1) Table A 1.1 (fixed-effects 
parameters); (2) Table A 1.2 (parameters for between-subject variability); (3) 
Table A 1.3 (parameters for the residual unexplained variability); (4) Table A 1.4 
(parameters in the L1 correlation matrix), and (5) Table A 1.5 (parameters in the 
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Table A 1.1 Fixed-effects parameter estimates for the full joint model during important 
model-building steps. LAG represents the lag parameter, CL clearance of warfarin, F 
bioavailability of warfarin, IA50,P warfarin amount in the body that gives half the 
maximum inhibitory effect, Imax,P maximum inhibitory effect, ka first-order absorption 
rate constant of warfarin, kout,P first-order coagulation protein degradation rate constant, 
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Table A 1.2 Estimates of the BSV parameters for the full joint model during important 
model-building steps. BSV is the between-subject variability. CV coefficient of variation, 
LAG lag parameter, CL clearance of warfarin, kout,P first-order coagulation protein 
degradation rate constant, ω variance of BSV, PC protein C, PS protein S, Pt=0 
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Table A 1.3 Estimates of the RUV parameters for the full joint model during important 
model-building steps. CV coefficient of variation, LAG lag parameter, CL clearance of 
warfarin, kout,P first-order coagulation protein degradation rate constant, ω variance of 
BSV, PC protein C, PS protein S, Pt=0 coagulation protein concentration at baseline, 








Appendix 1: Appendices to Chapter 2 
215  
 
Table A 1.4 Parameter estimates for the L1 matrix in the full joint model during 
important model-building steps. Note that for brevity, only selected models directly 
related to the inclusion of the L1 matrix are shown. η is the between-subject variability 
in parameter, LAG lag parameter, kout,P first-order coagulation protein degradation rate 
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Table A 1.5 Parameter estimates for the L2 matrix in the full joint model during 
important model-building steps. Note that for brevity, only selected models are shown. 
εprop,P is the proportional error, εadd,P additive error, PC protein C, and PS protein S.   
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A1.5. Parameter estimates for the final full joint model 
Table A 1.6 Parameter estimates for the final full joint model. LAG represents the lag 
parameter. ηi between-subject variability in parameter. CV coefficient of variation, 
CVpropP coefficient of variation for the proportional error associated with model 
prediction, CL clearance of warfarin, F bioavailability of warfarin, IA50,P warfarin 
amount in the body that gives half the maximum inhibitory effect, Imax,P maximum 
inhibitory effect, ka first-order absorption rate constant of warfarin, kout,P first-order 
coagulation protein degradation rate constant, PC protein C, PS protein S, Pt=0 
coagulation protein concentration at baseline, RSE relative standard error, SE standard 
error, V volume of distribution of warfarin, ω standard deviation of between-subject 







Meana SEa %RSEb 
𝐹 1.00 fixedc - - - 
𝑘𝑎 (h-1) 1.19 fixedc - - - 
𝐶𝐿 (L/h) 0400 0.416 0.259 62.3 
𝑉(L) 8.06 fixedc – – – 
𝐼𝑚𝑎𝑥,𝐼𝐼 1.00 fixedc   – – – 
𝐼𝑚𝑎𝑥,𝑉𝐼𝐼 1.00 fixedc – – – 
𝐼𝑚𝑎𝑥,𝐼𝑋 1.00 fixedc – – – 
𝐼𝑚𝑎𝑥,𝑋 1.00 fixedc – – – 
𝐼𝑚𝑎𝑥,𝑃𝐶 1.00 fixedc – – – 
𝐼𝑚𝑎𝑥,𝑃𝑆 1.00 fixedc – – – 
𝐼𝐴50,𝐼𝐼 (mg) 0.720 0.702 0.529 75.3 
𝐼𝐴50,𝑉𝐼𝐼 (mg) 0.950 0.924 0.675 73.1 
𝐼𝐴50,𝐼𝑋 (mg) 1.15 1.12 0.823 73.3 
𝐼𝐴50,𝑋 (mg) 0.324 0.316 0.258 81.5 
𝐼𝐴50,𝑃𝐶 (mg) 2.58 2.52 1.82 72.4 
𝐼𝐴50,𝑃𝑆 (mg) 1.51 1.47 1.13 76.9 
𝐼𝐼𝑡=0 (IU/dL) 112 112 4.71 4.2 
𝑉𝐼𝐼𝑡=0 (IU/dL) 109 109 6.00 5.5 
𝐼𝑋𝑡=0 (IU/dL) 136 136 6.79 5.0 
𝑋𝑡=0 (IU/dL) 106 107 4.13 3.9 
𝑃𝐶𝑡=0 (IU/dL) 98.1 98.2 3.62 3.7 
𝑃𝑆𝑡=0 (IU/dL) 104 105 6.13 5.9 
𝑘𝑜𝑢𝑡,𝐼𝐼 (h-1) 0.00987 0.00984 0.000797 8.1 
𝑘𝑜𝑢𝑡,𝑉𝐼𝐼 (h-1) 0.0379 0.0377 0.00424 11.3 
𝑘𝑜𝑢𝑡,𝐼𝑋 (h-1) 0.0198 0.0197 0.00210 10.6 
𝑘𝑜𝑢𝑡,𝑋 (h-1) 0.0127 0.0127 0.000794 6.3 
𝑘𝑜𝑢𝑡,𝑃𝐶 (h-1) 0.0204 0.0203 0.00342 16.9 
𝑘𝑜𝑢𝑡,𝑃𝑆 (h-1) 0.0101 0.0100 0.00131 13.0 
𝐿𝐴𝐺 (h) 13.5 12.9 2.39 18.6 







Meana SEa %RSEb 
CV 𝑘𝑎 (%) 73.0 fixedc (94.2%) – – – 
CV 𝐶𝐿 (%) 68.2 (1.6%) 67.4 23.7 35.2 
CV 𝐼𝐴50,𝑉𝐼𝐼 (%) 18.0 (22.7%) 17.1 13.4 78.6 
CV 𝐼𝐴50,𝑋 (%) 23.1 (19.4%) 22.9 14.0 61.2 
CV 𝐼𝐴50,𝑃𝐶 (%) 14.4 (27.4%)  13.8 11.5 83.0 
𝜔 𝐼𝐼𝑡=0 
(IU/dL) 
17.3 (-0.4%) 17.4 4.07 23.3 
𝜔 𝑉𝐼𝐼𝑡=0 
(IU/dL) 
22.7 (2.7%) 23.0 3.36 14.6 
𝜔 𝐼𝑋𝑡=0 
(IU/dL) 
28.7 (0.2%) 28.8 7.94 27.6 
𝜔 𝑋𝑡=0 (IU/dL) 16.9 (-0.7%) 16.9 3.49 20.6 
𝜔 𝑃𝐶𝑡=0 
(IU/dL) 
16.9 (-0.4%) 16.9 3.65 21.6 
𝜔 𝑃𝑆𝑡=0 
(IU/dL) 
21.9 (-1.3%) 21.8 4.68 21.5 
CV 𝑘𝑜𝑢𝑡,𝐼𝐼 (%) 24.3 (0.9%) 23.9 8.14 34.0 
CV 𝑘𝑜𝑢𝑡,𝑉𝐼𝐼 (%) 42.6 (2.8%) 42.4 12.7 29.9 
CV 𝑘𝑜𝑢𝑡,𝐼𝑋 (%) 35.5 (2.4%) 34.9 11.1 31.8 
CV 𝑘𝑜𝑢𝑡,𝑋 (%) 19.5 (-0.7%) 19.3 2.67 13.8 
CV 𝑘𝑜𝑢𝑡,𝑃𝐶 (%) 37.4 (3.9%) 37.3 11.2 30.0 
CV 𝑘𝑜𝑢𝑡,𝑃𝑆 (%) 17.4 (3.1%) 17.4 8.07 46.4 
CV 𝐿𝐴𝐺 (%) 57.9 (0.4%) 61.0 14.9 24.5 
𝜎𝑎𝑑𝑑,𝐼𝐼 (IU/dL) 8.75 8.64 1.48 17.1 
CVprop,II (%)   3.21 3.62 2.62 72.2 
𝜎𝑎𝑑𝑑,𝑉𝐼𝐼 
(IU/dL) 
10.7 10.6 1.45 13.6 
CVprop,VII (%)   10.6 11.0 3.73 34.0 
𝜎𝑎𝑑𝑑,𝐼𝑋 (IU/dL) 13.7 13.6 2.23 16.4 
CVprop,IX (%)   10.1 10.6 2.32 22.0 
𝜎𝑎𝑑𝑑,𝑋 (IU/dL) 6.41 6.36 1.78 27.9 
CVprop,X (%)   3.19 3.52 2.58 73.1 
𝜎𝑎𝑑𝑑,𝑃𝐶 
(IU/dL) 
6.07 6.01 1.24 20.7 
CVprop,PC (%)   5.96 5.98 1.80 30.2 
𝜎𝑎𝑑𝑑,𝑃𝑆 
(IU/dL) 
4.79 4.82 1.21 25.0 
CVprop,PS (%)   8.78 8.75 1.48 16.9 
a Jackknife statistics were computed based on all 17 runs, of which 5 (29.4%) runs minimised successfully 
and another 12 (70.6%) runs ended with rounding errors 
b Jackknife estimate of parameter (mean) and standard error (SE) were used for calculation of relative 
standard error (RSE) 
c Sourced from estimated values by Wright et al. [152] 
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Table A 1.7 Parameter estimates of the L1 correlation matrix for the final full joint model. RSE (%) is given in the bracket that follows the final 
estimate. LAG denotes the lag parameter. ηi between-subject variability in parameter. Pt=0 coagulation protein concentration at baseline. kout,P 
first-order coagulation protein degradation rate constant. PC protein C. PS protein S. RSE relative standard error. SE standard error. 
𝒃𝒊 𝑰𝑰𝒕=𝟎 𝑽𝑰𝑰𝒕=𝟎 𝑰𝑿𝒕=𝟎 𝑿𝒕=𝟎 𝑷𝑪𝒕=𝟎 𝑷𝑺𝒕=𝟎 𝒌𝒐𝒖𝒕,𝑰𝑰 𝒌𝒐𝒖𝒕,𝑽𝑰𝑰 𝒌𝒐𝒖𝒕,𝑰𝑿 𝒌𝒐𝒖𝒕,𝑿 𝒌𝒐𝒖𝒕,𝑷𝑪 𝒌𝒐𝒖𝒕,𝑷𝑺 𝑳𝑨𝑮 





















































































































































































a Jackknife estimate of parameter (mean) and SE were used for calculation of RSE. Jackknife statistics were computed based on all 17 runs, of which 5 (29.4%) runs minimised 
successfully and another 12 (70.6%) runs ended with rounding errors  
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Table A 1.8 Parameter estimates of the L2 correlation matrix for the final full joint model. RSE (%) is given in the bracket that follows the final 
estimate. εprop,P is the proportional error. εadd,P additive error. PC protein C. PS protein S. RSE relative standard error. SE standard error. 
𝜺𝒑𝒓𝒐𝒑,𝑷 𝑰𝑰 𝑽𝑰𝑰 𝑰𝑿 𝑿 𝑷𝑪 𝑷𝑺  𝜺𝒂𝒅𝒅,𝑷 𝑰𝑰 𝑽𝑰𝑰 𝑰𝑿 𝑿 𝑷𝑪 𝑷𝑺 
𝑰𝑰 1.00      
 























































































a Jackknife estimate of parameter (mean) and SE were used for calculation of RSE. Jackknife statistics were computed based on all 17 runs, of which 5 (29.4%) runs minimised 
successfully and another 12 (70.6%) runs ended with rounding errors 
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A1.6. NONMEM® code for the final full joint model 
 













Appendix 1: Appendices to Chapter 2 
 226 
 
A1.7. Individual fits for the final full joint model 
 
Figure A 1.2 Individual fits for the time course of factors II, VII, IX, X, and proteins C 
and S following warfarin initiation. The black lines are predictions from the final full 
joint model. The grey markers are observations. PC denotes protein C and PS represents 
protein S. 
  




Figure A 1.2 Continued. 
  




Figure A 1.2 Continued.  
  




Figure A 1.2 Continued.  
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A1.8. pcVPC for the final full joint model 
 
Figure A 1.3 pcVPC for factors II, VII, IX and X, and proteins C and S based on the 
final full joint model. The blue circle indicates observation. The black solid line indicates 
the median of simulated data. The red solid line indicates the median of observed data. 
The black dashed line indicates the 10th and 90th percentiles of simulated data that 
correspond to the 80% prediction interval. The red dashed line indicates the 10th and 
90th percentiles of observed data that correspond to the 80% prediction interval. The 
shaded area indicates the 95% confidence interval around the simulated percentiles. 
pcVPC stands for prediction-corrected visual predictive checks. 
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A1.9. NONMEM® code for the final reduced joint model 
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A1.10. CWRES versus time plots for the final joint models 
 
Figure A 1.4 CWRES versus time plots for the final joint models. PC is protein C and PS is protein S. 
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A1.11. Individual fits for the final reduced joint model 
 
Figure A 1.5 Individual fits for the time course of factors II, VII, IX, X, and proteins C 
and S following warfarin initiation. The black lines are predictions from the final reduced 
joint model. The grey markers are observations. PC denotes protein C and PS represents 
protein S. 




Figure A 1.5 Continued. 




Figure A 1.5 Continued. 
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A2.1. Adaptive search algorithm for RP and RP,combi  
An adaptive grid search algorithm was implemented in MATLAB® Version 
2015a (The MathWorks Inc., Natick, Massachusetts, USA) to determine the 
percentage reduction in a coagulation protein that singly (𝑅𝑃) or jointly with 
reduction in another coagulation protein (𝑅𝑃,𝑐𝑜𝑚𝑏𝑖) gives a predetermined level 
of INR. The simulation-based search for a reduction in factor VII, 𝑅𝑉𝐼𝐼,𝑐𝑜𝑚𝑏𝑖, when 
factor II is simultaneously reduced, 𝑅𝐼𝐼,𝑐𝑜𝑚𝑏𝑖, is illustrated here as an example.  
The search algorithm can be summarised in the following 7 steps. The 
corresponding MATLAB code is also included.     
1. Fix 𝑅𝐼𝐼,𝑐𝑜𝑚𝑏𝑖 to 0%. 
2. The initial search space for 𝑅𝑉𝐼𝐼,𝑐𝑜𝑚𝑏𝑖 was set to range from 0% to 100%.  
3. The 0th, 25th, 50th, 75th, and 100th percentile of the search space for 𝑅𝑉𝐼𝐼,𝑐𝑜𝑚𝑏𝑖 
were obtained.  
4. The 𝑅𝑉𝐼𝐼,𝑐𝑜𝑚𝑏𝑖  was set to each of the percentile values one-at-a-time. The 
corresponding INR was simulated from the QSP coagulation network model 
[31]. 
5. The two percentiles that give the INR values enveloping the INR target were 
used to define a more refined search space for 𝑅𝑉𝐼𝐼,𝑐𝑜𝑚𝑏𝑖 . If none of the 
percentile pairs contain the INR target, go to step 7.   
6. Step 3 to step 5 were repeated until the smallest distance between the 
simulated and target INRs is less than 0.01. The corresponding percentile 
value was then taken as the final 𝑅𝑉𝐼𝐼,𝑐𝑜𝑚𝑏𝑖 estimate.  
7. Step 1 to step 6 were repeated for 𝑅𝐼𝐼,𝑐𝑜𝑚𝑏𝑖 = 5%,⋯ , 90%, 95%.  
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A2.2. Model evaluation 
The data simulated from the QSP coagulation network model [31] agree 
reasonably well with the external data for factors II, VII, IX, X, and INR at the 
individual level. Plots of all 17 patients are shown in Figure A 2.1. The model 
was, on the whole, considered adequate in describing the warfarin-coagulation 
proteins-INR relationship for subsequent use in this simulation study.       
 
 
Figure A 2.1 Individual fits for the time course of factors II, VII, IX, X, and INR for 17 
patients following warfarin initiation. The black solid lines are prediction by the 
coagulation network model using parameters for a typical patient. The grey open circles 
are observations from the external test dataset [167, 181]. INR refers to the international 
normalised ratio and nM stands for nanomolar.     
 




Figure A 2.1 Continued.  
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A3.1. Modelling the time course of the derivative of SIVII  
Table A 3.1 Parameter estimates and goodness-of-fit of the individual model for the time 
course of dSIVII/dt at a specific Dref. At different Dref, the estimates for p obtained were 
largely similar (range 0.260 - 0.301) and fixing of p to 0.300 resulted in an almost 
identical model fit. Dref is the warfarin daily dose for a typical patient, h the upper 
horizontal asymptote, g the magnitude of horizontal shift, p the shape parameter, r2 the 
adjusted coefficient of determination, RSE the relative standard error, and SIVII the 
sensitivity index of INR to factor VII.   
𝑫𝒓𝒆𝒇 
(mg/day) 
Final estimate (%RSE) 
𝒓𝟐 
𝒉 (/%/day) 𝒈 (days) 𝒑 
1 0.00200 (6.44) -1.30 (21.3) 0.300 fixed 0.999 
4 0.00442 (1.48) 3.96 (2.48) 0.300 fixed 0.999 
7 0.00744 (1.35) 6.33 (1.76) 0.300 fixed 0.999 
10 0.0109 (1.10) 8.03 (1.31) 0.300 fixed 0.998 
13 0.0149 (0.883) 9.40 (1.00) 0.300 fixed 0.999 
a Observations for 𝑡 = 0.5 days were excluded from model-fitting. 
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A3.2. Determination of εSIVII  
In this study, Equation 4.12 that is based on 𝑆𝐼𝑉𝐼𝐼 is our approximation to 
Equation 4.5, which is an approximation to the theoretical gold standard of 






 described in Section 4.5.4 in Chapter 4). Based on Equation 4.12, 
a pre-requisite to the prediction of 𝑡𝑆𝑆,𝐼𝑁𝑅 is the choice of a suitable value of 𝜀𝑆𝐼𝑉𝐼𝐼. 
The choice of 𝜀𝑆𝐼𝑉𝐼𝐼 should correctly classify a given INR as non-steady-state (or 
steady-state) when the INR is truly non-steady-state (or steady-state). The choice 
of 𝜀𝑆𝐼𝑉𝐼𝐼 was based on optimising the receiver operating characteristic (ROC). The 
ROC curve analysis was conducted in Stata® Version 11.2 (StataCorp LLC, 
College Station, Texas, USA). Equation 4.2, which represents a practical solution 
to Equation 4.1, was used as the gold standard to determine the achievement of 
steady-state INR. Here, a value of 𝜀𝐼𝑁𝑅 was chosen to represent the target gold 
standard, in this case 𝜀𝐼𝑁𝑅 = 0.01, for defining the steady-state INR. 
 The resulting ROC curve for 
𝑑𝑆𝐼𝑉𝐼𝐼
𝑑𝑡
 is shown in Figure A 3.1. From the ROC 
analysis a choice of  𝜀𝑆𝐼𝑉𝐼𝐼 = 0.000150 as the tolerance for 
𝑑𝑆𝐼𝑉𝐼𝐼
𝑑𝑡
 (Equation 4.5 and 
Equation 4.12) corresponds to the steady-state INR. The associated sensitivity 
and specificity were 100.0% (56/56) and 93.6% (88/94), respectively. 
  




Figure A 3.1 ROC curve for εSIVII values to define the steady-state INR status in the 
dSIVII/dt domain compared to the presumed gold standard of dINR/dt≤εINR (where εINR 
= 0.01). The grey solid line represents the reference line for chance performance. SIVII is 
the sensitivity index of INR to factor VII.      
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A3.3. Modelling the derivative of INR as a function of the derivative of 
SIVII 
Table A 3.2 Parameter estimates and goodness-of-fit of the 2-parameter linear model for 
the dINR/dt versus dSIVII/dt data. Dref is the warfarin daily dose for a typical patient, k 
the slope, m the y-intercept, r2 the adjusted coefficient of determination, RSE the relative 
standard error, and SIVII the sensitivity index of INR to factor VII. 
𝑫𝒓𝒆𝒇 
(mg/day) 
Final estimate (%RSE) 
𝒓𝟐 
𝒌 (%) 𝒎 (/day) 
1 153 (2.65) 0.000770 (36.9) 0.984 
4 69.8 (1.55) 0.00195 (31.9) 0.994 
7 44.7 (1.45) 0.00290 (33.8) 0.995 
10 32.4 (1.36) 0.00376 (34.0) 0.996 
13 25.2 (1.28) 0.00446 (34.4) 0.996 
a Observations for 𝑡 = 0.5, 𝑡 = 1.5, 𝑡 = 2.5, 𝑡 = 3.5 and 𝑡 = 4.5 days were excluded from model-fitting. 
 
Table A 3.3 Parameter estimates and goodness-of-fit of the 3-parameter quadratic model 
for the dINR/dt versus dSIVII/dt data. Dref is the warfarin daily dose for a typical patient, 
k, m, and w are coefficients of the quadratic model, r2the adjusted coefficient of 




Final estimate (%RSE) 
𝒓𝟐 
𝒌 (%2×day) 𝒎 (%) 𝒘 (/day) 
1 -131000 (0.000000464) 176 (0.856) 0.000527 (41.9) 0.996 
4 -9990 (3.17) 83.6 (0.890) 0.000563 (41.7) 1.00 
7 -3070 (3.20) 55.1 (0.902) 0.0000830 (435) 1.00 
10 -1370 (2.88) 40.9 (0.816) -0.000695 (60.0) 1.00 
13 -735 (4.89) 32.2 (1.39) -0.00159 (53.2) 1.00 
a Observations for 𝑡 = 0.5 and 𝑡 = 1.5 days were excluded from model-fitting.     
 
Table A 3.4 Parameter estimates and goodness-of-fit of the 2-parameter quadratic model 
for the dINR/dt versus dSIVII/dt data. Dref is the warfarin daily dose for a typical patient, 
k and m are coefficients of the quadratic model, r2 the adjusted coefficient of 




Final estimate (%RSE) 
𝒓𝟐 
𝒌 (%2×day) 𝒎 (%) 
1 -141000 (8.00) 182 (2.43) 0.996 
4 -10300 (2.95) 84.7 (0.767) 1.00 
7 -3080 (2.71) 55.2 (0.685) 1.00 
10 -1340 (2.59) 40.5 (0.641) 1.00 
13 -698 (4.50) 31.6 (1.09) 0.999 
a Observations for 𝑡 = 0.5 and 𝑡 = 1.5 days were excluded from model-fitting.  




Figure A 3.2 Model fits of (a) a 2-parameter linear model, (b) a 3-parameter quadratic model and (c) a 2-parameter quadratic model for the dINR/dt 
versus dSIVII/dt data. The solid lines are the model predictions and the filled circles are the data that were derived based on simulations from the 
QSP coagulation network model [31]. SIVII is the sensitivity index of INR to factor VII. 
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A3.4. Symbolic solution for Equation 4.15 
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Equation A 3.1 Symbolic solution for the first definite integral in Equation 4.15. 
 




































Equation A 3.2 Symbolic solution for the second definite integral in Equation 4.15. 
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Then, the full expression for 𝐼𝑁𝑅𝑆𝑆 is given by substituting Equation A 3.1 and 
Equation A 3.2 into Equation 4.15: 
 














                  +𝑚(𝐷𝑟𝑒𝑓) ∙ [
ℎ(𝐷𝑟𝑒𝑓)
𝑝












ℎ(𝐷𝑟𝑒𝑓) = 𝑎0 + 𝑎1 ∙ 𝐷𝑟𝑒𝑓 
𝑔(𝐷𝑟𝑒𝑓) = 𝑏0 + 𝑏1 ∙ ln 𝐷𝑟𝑒𝑓 . 
Equation A 3.3 Symbolic solution for Equation 4.15. 
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A3.5. MATLAB® code for the implementation of the four-step algorithm 
for the prediction of tSS,INR and INRSS 
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A3.6. Patient data 
 
Figure A 3.3 Factor VII and INR profiles of the two patients, ID A and ID B, used to 
illustrate proof-of-concept of the proposed method [167, 181]. Solid black lines indicate 
observations corresponding to a warfarin dosing rate of 5 mg/day. Dashed grey lines 
indicate observations attributable to a likely dose adjustment according to the study 
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A4.1. Evaluation of assumptions underpinning the joint model for 
warfarin and vitamin K-dependent coagulation proteins  
A4.1.1. List of assumptions 
Chapter 2 describes the development of a joint model to quantify the 
influence of warfarin on all six vitamin K-dependent coagulation proteins 
simultaneously. The model and its development are underpinned by the 
following assumptions: 
 Assumption 1:  A one-compartment model with first-order absorption 
and elimination is appropriate to describe the pharmacokinetics (PK) of 
warfarin, 
 Assumption 2: The assumed value for the first-order absorption rate 
constant of warfarin, 𝑘𝑎 = 1.19 ℎ
−1, is appropriate,  
 Assumption 3: The assumed value for the volume of distribution of 
warfarin, 𝑉 = 8.06 𝐿, is appropriate,  
 Assumption 4: A hyperbolic model is appropriate to describe warfarin 
exposure and coagulation proteins response,  
 Assumption 5: The assumed value for the maximum inhibitory effect of 
warfarin on coagulation proteins production, 𝐼𝑚𝑎𝑥,𝑃 = 1.00 , is 
appropriate,  
 Assumption 6: The imputed daily dose time of 6 p.m. is appropriate and 
as a whole unbiased, 
 Assumption 7: The imputed blood sampling time of 1.30 p.m. (day 5) and 
11 a.m. (all other days) are appropriate and as a whole unbiased, 
 Assumption 8: All the patients enrolled were perfectly adherent, 
 Assumption 9: The last observation carried forward (LOCF) method is 
appropriate for dose imputation, 
 Assumption 10: For each coagulation protein, the errors, 𝜀 (𝑛 × 1), are 
normally distributed with a mean of zero and a variance of 𝜎2, and 
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 Assumption 11: For each coagulation protein, 𝜀 (𝑛 × 1), are independent 
and identically distributed (iid). 
A4.1.2. Evaluation methods and results 
Each of these assumptions was evaluated independently using the 
flowchart developed in Chapter 5. Here, an internal evaluation was conducted 
with the goal of assessing the influence of the aforementioned assumptions on 
the goodness-of-fit of the joint model. At this stage, where model development 
was of primary interest, an external evaluation was not carried out. It is 
important to note that only the reduced joint model, which is without the 
complex correlation structure for between-subject variability and random-
unexplained variability, was evaluated.    
The results of assumption evaluation are summarised in Table A 4.1 using 
the assumption table structure proposed in Chapter 5. Evaluation methods and 
results for each assumption are provided in greater details in the next following 
subsections. Briefly, for the majority of the assumptions, the impact of violation 
(𝐼) is significant but the probability of violation (𝑃) is low. Other remaining 
assumptions have insignificant 𝐼 and, as a result, the 𝑃 was not evaluated. The 
risk of assumption violation was considered on the whole to be minor thereby 
giving a go decision for model building.    
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Table A 4.1 Methods and results for internal evaluation of assumptions underpinning the warfarin-coagulation proteins model. I is the impact of 
assumption violation, NS means not significant, L means likely, P is the probability of assumption violation, S means significant, and U means 
unlikely. 
Assumption 
Impact (𝑰) Probability (𝑷) 
Decision 
Methods Results Rating Methods Results Rating 
1. A one-compartment 
model with first-order 
absorption and 
elimination is 
appropriate to describe 
the PK of warfarin  
Past experience and 
logical reasoning.  
It is possible that the joint 
model fit to 
pharmacodynamic data 
is robust to 
misspecification in the 
PK model but the 
parameter estimates may 
differ from its original 
meaning and therefore 
may be required to be 
interpreted differently.    





warfarin PK data well 
[99, 103, 140, 156, 157, 
165, 228-232].  
U Go for 
model 
building. 
2. The assumed value for 
the first-order absorption 
rate constant of warfarin, 
𝑘𝑎 = 1.19 ℎ
−1, is 
appropriate 
A sensitivity analysis 
was conducted. 𝑘𝑎 fixed 
to 0.01, 0.1, 1, 10 and 50 
ℎ−1 were tried. The 
overall model fit 
(objective function value 
(OFV)) and the 
parameter estimates were 
compared to the original 
model.   
The model fits appeared 
sensitive to the choice of 
𝑘𝑎 value. Smaller 𝑘𝑎 
value is associated with a 
better model fit. Lag 
time, 𝑡𝑙𝑎𝑔, and first-order 
degradation rate 
constant, 𝑘𝑜𝑢𝑡,𝐹, were also 
found sensitive to the 
choice of 𝑘𝑎 value.     
S Existing literature.  The 𝑘𝑎 value used 
resides well within the 
reported range of 𝑘𝑎 
(0.402 – 3.15 ℎ−1) [103, 
140, 152, 233]. 
 Go for 
model 
building. 
3. The assumed value for 
the volume of 
distribution of warfarin, 
𝑉 = 8.06 𝐿, is appropriate 
A structural 
identifiability analysis 
was conducted using 
popt_i® Version 1.0.  
In the absence of PK 
data, 𝑉 is not structurally 
identifiable. 𝑉 is unable 
to influence parameter 
estimates and model fits.  
NS NA NA NA Go for 
model 
building. 




Impact (𝑰) Probability (𝑷) 
Decision 
Methods Results Rating Methods Results Rating 
4. A hyperbolic model is 
appropriate to describe 
warfarin exposure and 
coagulation proteins 
response  
A sensitivity analysis 
was conducted. An 
empirical sigmoid 𝐸𝑚𝑎𝑥 
model was used. The 
overall model fit (OFV) 
and the parameter 
estimates were compared 
to the original model.  
Based on the likelihood-
ratio test, the sigmoid 
𝐸𝑚𝑎𝑥 model is associated 
with significantly better 
model fit compared to 
the original model 
(∆𝑂𝐹𝑉 = −59.1). 
Estimates of warfarin 
amount in the body that 
gives half the maximum 
effect, 𝐼𝐴50,𝐹, also differ 
between the two models.   
S Existing literature Warfarin inhibits vitamin 
K epoxide reductase 
(VKOR) thereby 
decreasing the formation 
of vitamin K 
hydroquinone, which is 
essential for the 
production of vitamin K-
dependent coagulation 
proteins. Enzymatic 
binding of warfarin to 
VKOR can be described 
by a hyperbolic model 
[43].   
U Go for 
model 
building. 
5. The assumed value for 
the maximum inhibitory 
effect of warfarin on 
coagulation proteins 
production, 𝐼𝑚𝑎𝑥,𝑃 =
1.00, is appropriate 
A sensitivity analysis 
was conducted. 𝐼𝑚𝑎𝑥,𝑃 
fixed to 0.800, 0.850, and 
0.900 was attempted. The 
overall model fit (OFV) 
and the parameter 
estimates were compared 
to the original model.      
The model fits appeared 
sensitive to the choice of 
𝐼𝑚𝑎𝑥,𝑃 value, with higher 
𝐼𝑚𝑎𝑥,𝑃 value associated 
with a better model fit. 
Of all the parameter 
estimates, 𝐼𝐴50,𝑃 is 
particularly sensitive to 
the 𝐼𝑚𝑎𝑥,𝑃 value used.    
S Existing literature.  Almost complete 
inhibition of coagulation 
proteins synthesis by 
warfarin had been 
reported [35, 144-146, 
167, 181, 234].  
U Go for 
model 
building. 
6. The imputed daily 
dose time of 6 p.m. is 
appropriate and as a 
whole unbiased  
A sensitivity analysis 
was conducted. Daily 
dose time of 8 a.m., 10 
a.m., 12 p.m., 2 p.m., 4 
p.m., 8 p.m., and 10 p.m. 
were attempted. The 
overall model fit (OFV) 
and the parameter 
estimates were compared 
to the original model.       
The same model fits and 
parameter estimates were 
obtained regardless of 
the daily dose time used 
for imputation.  
NS NA NA NA Go for 
model 
building. 




Impact (𝑰) Probability (𝑷) 
Decision 
Methods Results Rating Methods Results Rating 
7. The imputed blood 
sampling time of 1.30 
p.m. (day 5) and 11 a.m. 
(all other days) are 
appropriate and as a 
whole unbiased 
A sensitivity analysis 
was conducted. Blood 
sampling time of 8 a.m., 
10 a.m., 12 p.m., 2 p.m., 
and 4 p.m. were 
attempted. The overall 
model fit (OFV) and the 
parameter estimates were 
compared to the original 
model.       
The same model fits and 
parameter estimates were 
obtained regardless of 
the blood sampling time 
used for imputation. 
NS NA NA NA Go for 
model 
building. 
8. All the patients 
enrolled were perfectly 
adherent  
A published simulation 
study was referred. The 
study quantified the 
probability of therapeutic 




random missed doses, 
and drug holiday were 
simulated. [235]  
The probability of 
therapeutic success for 
perfect adherence was 
0.58 and for imperfect 
adherence was 0.52. The 
relative forgiveness index 
of warfarin was 0.78, 
which indicates that 
warfarin is forgiving to 
imperfect adherence.   
NS NA NA NA Go for 
model 
building. 
9. The last observation 
carried forward (LOCF) 
method is appropriate 
for dose imputation 
A sensitivity analysis 
was conducted. 
Observations following 
dose imputation were 
censored. The overall 
model fit (OFV adjusted 
for the number of 
observations) and the 
parameter estimates were 
compared to the original 
model.       
Almost identical adjusted 
OFV were obtained: 5.95 
(with LOCF) and 5.91 
(without LOCF). 
Parameter estimates for 
the model developed 
without LOCF reside 
well within the 95% 
confidence interval of the 
final estimates of the 
original LOCF model.   
NS NA NA NA Go for 
model 
building.  




Impact (𝑰) Probability (𝑷) 
Decision 
Methods Results Rating Methods Results Rating 
10. For each coagulation 
protein, the errors, 𝜀 (𝑛 ×
1), are normally 
distributed with a mean 
of zero and a variance of 
𝜎2 
Previous evaluation of 
impact of non-normality 
available in the literature 
[215]. 
Parameter estimation for 
maximum likelihood 
estimation is sensitive to 
specification of the 
residual error. 
Misspecification may 
result in biased 
parameter estimates and 
predictions. 
S The distribution 
of 𝐶𝑊𝑅𝐸𝑆 was 
compared to a 
standard normal 
distribution by 
using a Q-Q plot 
and a one-sample 
Kolmogorov-
Smirnov test.   
CWRES of all 
coagulation proteins do 
not have a distribution 
that is significantly 
different from a standard 
normal distribution. 
U Go for 
model 
building. 
11. For each coagulation 




Existing literature If autocorrelation is 
ignored, precision of 
parameter estimates [236, 
237] and random-effect 











resulting model fit 
(OFV and visual 
predictive checks 
(VPC)) were 
compared to the 
original model. 
Autocorrelation in 




time course for 
each patient.    
For independent models, 
modelling 
autocorrelation gives 
significantly better model 
fits in terms of OFV 
(Δ𝑂𝐹𝑉 > 3.84, 𝑑𝑓 = 1). 
However, improvement 
in model fits is not 
apparent from the VPC. 
For the (joint) reduced 
model, 𝐶𝑊𝑅𝐸𝑆 were 
found to be above or 
below zero in succession 
for consistent periods of 
time. 𝐶𝑊𝑅𝐸𝑆 are 
autocorrelated.    
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A4.1.2.1. Assumption 1:  A one-compartment model with first-order absorption 
and elimination is appropriate to describe the PK of warfarin 
Interpretation 
As above.  
Internal evaluation of 𝑰 
𝐼 = Significant. This was rated based on past experience and logical reasoning. 
There is a multitude of possibilities in the structural form that a PK model of a 
drug can take. However, it is difficult to judge with certainty the impact of a 
misspecification in the warfarin PK model on modelling the pharmacodynamic 
(PD) data using a kinetic-pharmacodynamic (KPD) model. From our experience, 
while it is possible that the KPD model fit to PD data is robust to misspecification 
in the PK model, parameter estimates may differ and may therefore require 
judicious interpretation. Here, when PK model is misspecified, PD parameter 
estimates may incorporate PK information that are otherwise not captured by 
the (misspecified) PK model. To minimise risk, 𝐼 was conservatively rated as 
significant.     
Internal evaluation of 𝑷 
𝑃 = Unlikely. Based on published warfarin PK models, a one-compartment 
model with first-order absorption and elimination is typically adequate to 
describe the concentration-time data arising from clinically-relevant warfarin 
doses [99, 103, 140, 156, 157, 165, 228-232]. 
Decision 
Decision = Go for model building. Even given the significant impact of violation 
of this assumption the probability of violation is low and hence the risk is 
considered to be negligible.  
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A4.1.2.2. Assumption 2: The assumed value 𝑘𝑎 = 1.19 ℎ
−1 is appropriate 
Interpretation 
𝑘𝑎 = 1.19 ℎ
−1 
Internal evaluation of 𝑰 
𝐼 = Significant. A sensitivity analysis was carried out to evaluate the impact of 
the choice of 𝑘𝑎  value on parameter estimations and model fits. Here, 𝑘𝑎  was 
fixed to arbitrarily chosen values of 0.0100 ℎ−1 , 0.100 ℎ−1 , 1.00 ℎ−1 , 10.0 ℎ−1 , 
and 50.0 ℎ−1. Estimation of 𝑘𝑎  was also attempted. The overall model fit was 
assessed using the objective function value (OFV) and the parameter estimates 
were also compared. From Table A 4.2, the overall model fits appeared sensitive 
to the choice of 𝑘𝑎 value, with smaller 𝑘𝑎 value associated with a better model fit 
(lower OFV). Correspondingly, the final parameter estimates, particularly, the 
lag time, 𝑡𝑙𝑎𝑔 , and the first-order degradation rate constant of coagulation 
protein, 𝑘𝑜𝑢𝑡,𝐹, were found sensitive to the changes in 𝑘𝑎 value (not shown). It is 
worth noting that estimation of 𝑘𝑎, despite resulting in a good model fit, is not 
sensible. This is because 𝑘𝑎 is not likely to be deterministically identifiable due 
to an absence of observations during the absorption phase of warfarin. 
 
Table A 4.2 Sensitivity of the overall model fits to the choice of ka value. ka is the first-
order absorption rate constant of warfarin and OFV is the objective function value.  
𝒌𝒂 (𝒉
−𝟏) OFV 
0.0100 (fixed) 5230.345 
0.0385 (estimated) 5196.816 
0.100 (fixed) 5213.868 
0.500 (fixed) 5296.159 
1.00 (fixed) 5297.467 
1.19 (fixed) 5297.628 
10.0 (fixed) 5298.110 
50.0 (fixed) 5298.130 
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Internal evaluation of 𝑷 
𝑃 =  Unlikely. Previously reported values of 𝑘𝑎  were 0.402 ℎ
−1  [103], 1.19 ℎ−1 
[152], 1.66 ℎ−1 [233], and 3.15 ℎ−1 [140]. The 𝑘𝑎 = 1.19 ℎ
−1 value chosen resides 
well within the range of reported values. Also noteworthy, within the reported 
range of 𝑘𝑎, dependence of the final model fit on the choice of 𝑘𝑎 was negligible 
(Table A 4.2).  
Decision 
Decision = Go for model building. Even given the significant impact of violation 
of this assumption the probability of violation is low and hence the risk is 
considered to be negligible.  
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A4.1.2.3. Assumption 3: The assumed value 𝑉 = 8.06 𝐿 is appropriate 
Interpretation 
𝑉 = 8.06 𝐿 
Internal evaluation of 𝑰 
𝐼 =  Insignificant. A formal structural identifiability analysis was conducted 
using popt_i® Version 1.0 (Duffull SB, Dunedin, New Zealand). In the absence of 
PK data, 𝑉  was found to be not structurally identifiable and therefore, by 
definition, is unable to influence parameter estimations and model fits.  
Internal evaluation of 𝑷 
NA.  
Decision 
Decision = Go for model building.  
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A4.1.2.4. Assumption 4: A hyperbolic model is appropriate to describe warfarin 
exposure and coagulation proteins response 
Interpretation 
As above.  
Internal evaluation of 𝑰 
𝐼 =  Significant. A sensitivity analysis was conducted. An empirical sigmoid 
𝐸𝑚𝑎𝑥  (non-hyperbolic) model was attempted. Other commonly adopted PD 
models such as the linear model and the log-linear model were not tested 
because they are models nested within the hyperbolic model. The overall model 
fit was assessed using the OFV and the parameter estimates were also compared. 
On the basis of the likelihood-ratio test, the sigmoid 𝐸𝑚𝑎𝑥 model is associated 
with significantly better model fit compared to the original model (∆𝑂𝐹𝑉 =
−59.1). The final estimate for the shape parameters, 𝛾𝐹, is as follows: 𝛾𝐼𝐼 = 1.58, 
𝛾𝑉𝐼𝐼 = 2.20, 𝛾𝐼𝑋 = 1.87, 𝛾𝑋 = 1.80, 𝛾𝑃𝐶 = 1.02, and 𝛾𝑃𝑆 = 1.45. The final estimates 
for warfarin amount in the body that gives half the maximum inhibitory effect, 
𝐼𝐴50,𝐹, also differ between the sigmoid 𝐸𝑚𝑎𝑥 model and the original model.   
Internal evaluation of 𝑷 
𝑃 =  Unlikely. This was rated based on prior knowledge. Warfarin exerts its 
anticoagulant effect by inhibiting the enzyme vitamin K epoxide reductase 
(VKOR). VKOR is responsible to reduce vitamin K epoxide to vitamin K quinone 
and to reduce vitamin K quinone to its active vitamin K hydroquinone form. By 
inhibiting vitamin K hydroquinone formation, warfarin decreases the 
production of vitamin K-dependent coagulation proteins – factors II, VII, IX, X, 
proteins C and S. Here, the inhibitory action of warfarin is underpinned by 
enzymatic binding and interactions with VKOR. The use of a hyperbolic model 
to describe warfarin-coagulation proteins relationship is reasonable [43].       
Decision 
Decision = Go for model building. Even given the significant impact of violation 
of this assumption the probability of violation is low and hence the risk is 
considered to be negligible.   
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A4.1.2.5. Assumption 5: The assumed value 𝐼𝑚𝑎𝑥,𝑃 = 1.00 is appropriate 
Interpretation 
𝐼𝑚𝑎𝑥,𝑃 = 1.00 
Internal evaluation of 𝑰 
𝐼 = Significant. A sensitivity analysis was carried out to evaluate the impact of 
the choice of 𝐼𝑚𝑎𝑥,𝑃 value on parameter estimations and model fits. 𝐼𝑚𝑎𝑥,𝑃 fixed 
to 0.800, 0.850, and 0.900 were attempted. Estimation of 𝐼𝑚𝑎𝑥,𝑃 was also tried. The 
overall fit of the model was evaluated based on the OFV and the parameter 
estimates were compared. From Table A 4.3, the overall model fits appeared 
sensitive to the choice of 𝐼𝑚𝑎𝑥,𝑃 value, with higher 𝐼𝑚𝑎𝑥,𝑃 value associated with a 
better model fit (lower OFV). Correspondingly, the final parameter estimates 
particularly 𝐼𝐴50,𝑃  were found sensitive to the changes in 𝐼𝑚𝑎𝑥,𝑃  value (not 
shown).  
Table A 4.3 Sensitivity of the overall model fits to the choice of Imax,P value. Imax,P is the 
maximum inhibitory effect of warfarin and OFV is the objective function value.  
𝑰𝒎𝒂𝒙,𝑭 OFV 
0.800 (fixed) 5437.406 
0.850 (fixed) 5380.181 
0.900 (fixed) 5340.714 
1.00 (fixed) 5297.628 
𝐼𝑚𝑎𝑥,𝐼𝐼 = 0.998 (estimated) 
5295.718 
𝐼𝑚𝑎𝑥,𝑉𝐼𝐼 = 0.998 (estimated) 
𝐼𝑚𝑎𝑥,𝐼𝑋 = 0.998 (estimated) 
𝐼𝑚𝑎𝑥,𝑋 = 0.998 (estimated) 
𝐼𝑚𝑎𝑥,𝑃𝐶 = 0.868 (estimated) 
𝐼𝑚𝑎𝑥,𝑃𝑆 = 0.998 (estimated) 
 
Internal evaluation of 𝑷 
𝑃 =  Unlikely. The extent of depression in the coagulation protein level is 
warfarin dose-dependent. Almost complete inhibition of coagulation proteins 
synthesis by warfarin had been observed and reported [35, 144-146, 167, 181, 
234]. An 𝐼𝑚𝑎𝑥,𝑃 = 1.00 is probable.      
 
  




Decision = Go for model building. Even given the significant impact of violation 
of this assumption the probability of violation is low and hence the risk is 
considered to be negligible.  
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A4.1.2.6. Assumption 6: The imputed daily dose time of 6 p.m. is appropriate 
and as a whole unbiased 
Interpretation 
As above.  
Internal evaluation of 𝑰 
𝐼 = Insignificant. A sensitivity analysis was carried out to evaluate the impact of 
departure from a daily dose time of 6 p.m. on parameter estimations and model 
fits. Daily dose time of 8 a.m., 10 a.m., 12 p.m., 2 p.m., 4 p.m., 8 p.m., and 10 p.m. 
were attempted. The overall fit of the model was evaluated based on the OFV 
and the parameter estimates were compared. Identical OFV (Table A 4.4) and 
final parameter estimates were obtained despite imputation of different daily 
dose times. Insensitivity of parameter estimations and model fitting process to 
the imputed daily dose time are attributable to the delayed time course of 
changes in coagulation proteins and sparse sampling (shortest sampling interval 
of 24 hours).   
 
Table A 4.4 Sensitivity of the overall model fits to the choice of daily dose time used for 
imputation. OFV is the objective function value.  
Daily dose time OFV 
8 a.m. 5297.628 
10 a.m. 5297.628 
12 p.m. 5297.628 
2 p.m. 5297.628 
4 p.m. 5297.628 
6 p.m. 5297.628 
8 p.m. 5297.628 
10 p.m. 5297.628 
 
Internal evaluation of 𝑷 
NA.  
Decision 
Decision = Go for model building.   
Appendix 4: Appendices to Chapter 5  
 276 
 
A4.1.2.7. Assumption 7: The imputed blood sampling time of 1.30 p.m. (day 5) 
and 11 a.m. (all other days) are appropriate and as a whole unbiased 
Interpretation 
As above. 
Internal evaluation of 𝑰 
𝐼 = Insignificant. A sensitivity analysis was carried out to evaluate the impact of 
departure from the above mentioned imputed blood sampling time on 
parameter estimations and model fits. Blood sampling time of 8 a.m., 10 a.m., 12 
p.m., 2 p.m., and 4 p.m. were attempted. The overall fit of the model was 
evaluated based on the OFV and the parameter estimates were compared. 
Identical OFV (Table A 4.5) and final parameter estimates were obtained despite 
imputation of different blood sampling times. Insensitivity of parameter 
estimations and model fitting process to the imputed blood sampling time are 
attributable to the delayed time course of changes in coagulation proteins and 
sparse sampling (shortest sampling interval of 24 hours).   
  
Table A 4.5 Sensitivity of the overall model fits to the choice of blood sampling time used 
for imputation. OFV is the objective function value.  
Blood sampling time OFV 
8 a.m. 5297.628 
10 a.m. 5297.628 
11 a.m. (all days) 
1.30 p.m. (day 5) 
5297.628 
12 p.m. 5297.628 
2 p.m. 5297.628 
4 p.m. 5297.628 
 
Internal evaluation of 𝑷 
NA.  
Decision 
Decision = Go for model building.  
  
Appendix 4: Appendices to Chapter 5 
277  
  
A4.1.2.8. Assumption 8: All the patients enrolled were perfectly adherent 
Interpretation 
All the patients enrolled took warfarin at the right time, had no random missed 
doses, and had no drug holidays.  
Internal evaluation of 𝑰 
𝐼 = Insignificant. This was rated based on the results of a published study [235]. 
In this work, adherence profile for 1000 patients were simulated. Imperfect 
adherence patterns including imperfect timing, random missed doses, and drug 
holiday were considered. The corresponding INR time course for these patients 
were simulated from a published model for warfarin and INR [54]. Here, 
therapeutic success was defined as where at least 55% of steady-state INR values 
are within the therapeutic range (INR 2 to 3.5). The simulation results showed 
that the probability of therapeutic success for perfect adherence was 0.58 and for 
imperfect adherence was 0.52. The relative forgiveness index of warfarin to 
imperfect adherence was 0.78. This indicates that warfarin is relatively forgiving 
to commonly-observed patterns of imperfect adherence. Here, the forgiving 
nature of warfarin suggests that imperfect adherence is likely to have minimal 
impact on the INR and as such it should have similarly minimal impact on 
parameter estimations and model fits of INR data.   
Internal evaluation of 𝑷 
NA.  
Decision 
Decision = Go for model building.  
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A4.1.2.9. Assumption 9: The LOCF method is appropriate for dose imputation 
Interpretation 
The dosing records for most individuals were missing after day 15. It is assumed 
that there is no change in warfarin dose from the last available dosing record.    
Internal evaluation of 𝑰 
𝐼 = Insignificant. A sensitivity analysis was carried out to evaluate the impact of 
dose imputation using LOCF method on parameter estimations and model fits. 
Here, observations (10.1%) following dose imputation were censored and the 
resulting model was compared to the original model with dose imputation using 
the LOCF method. The model fit was evaluated based on the OFV adjusted for 
the number of observations. The parameter estimates were also compared. With 
respect to model fit, almost identical adjusted OFV was resulted: 5.93 (with 
LOCF) and 5.91 (without LOCF). Differences in some final parameter estimates 
were observed (see Table A 4.6). However, this is unlikely of major importance 
because the final parameter estimates of the model developed without LOCF 
reside well within the 95% confidence interval of the final estimates of the 
original model (see Table A 4.6).        
Internal evaluation of 𝑷 
NA.  
Decision 
Decision = Go for model building.  
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Table A 4.6 Sensitivity of the final parameter estimates to imputation using the LOCF 
method. LOCF refers to the last observation carried forward method.     
Parameter 
With LOCF: 




% Change in 
final estimates 
𝐶𝐿 (L/h) 0.211 [0.136, 0.323] 0.170 -19.4 
𝐼𝐴50,𝐼𝐼 (mg) 1.83 [1.34, 2.41] 2.22 21.3 
𝐼𝐴50,𝑉𝐼𝐼 (mg) 1.86 [1.38, 2.43] 1.84 -1.08 
𝐼𝐴50,𝐼𝑋 (mg) 2.41 [1.79, 3.14] 2.57 6.64 
𝐼𝐴50,𝑋 (mg) 0.875 [0.631, 1.160] 1.10 25.7 
𝐼𝐴50,𝑃𝐶 (mg) 5.21 [3.93, 6.59] 5.90 13.2 
𝐼𝐴50,𝑃𝑆 (mg) 3.35 [2.46, 4.39] 3.96 18.2 
𝐼𝐼𝑡=0 (IU/dL) 115 [104, 125] 114 -0.870 
𝑉𝐼𝐼𝑡=0 (IU/dL) 115 [98, 134] 113 -1.74 
𝐼𝑋𝑡=0 (IU/dL) 141 [128, 155] 141 0.000 
𝑋𝑡=0 (IU/dL) 109 [99, 118] 108 -0.917 
𝑃𝐶𝑡=0 (IU/dL) 101 [92, 111] 102 0.990 
𝑃𝑆𝑡=0 (IU/dL) 105 [92, 118] 104 -0.952 
𝑘𝑜𝑢𝑡,𝐼𝐼 (h-1) 0.0135 [0.0108, 0.0171] 0.0141 4.44 
𝑘𝑜𝑢𝑡,𝑉𝐼𝐼 (h-1) 0.0570 [0.0358, 0.0946] 0.0534 -6.32 
𝑘𝑜𝑢𝑡,𝐼𝑋 (h-1) 0.0323 [0.0208, 0.0523] 0.0325 0.619 
𝑘𝑜𝑢𝑡,𝑋 (h-1) 0.0157 [0.0129, 0.0192] 0.0163 3.82 
𝑘𝑜𝑢𝑡,𝑃𝐶 (h-1) 0.0376 [0.0234, 0.0663] 0.0425 13.0 
𝑘𝑜𝑢𝑡,𝑃𝑆 (h-1) 0.0122 [0.0103, 0.0146] 0.0125 2.46 
𝐿𝐴𝐺 (h) 12.5 [10.4, 14.2] 12.7 1.60 
CV 𝐶𝐿 (%) 82.2 [55.9, 145.5] 92.5 12.5 
CV 𝐼𝐴50,𝑃𝐶 (%) 13.4 (0, 29.2] 18.9 41.0 
𝜔 𝐼𝐼𝑡=0 (IU/dL) 17.8 [10.6, 25.2] 17.6 -1.12 
𝜔 𝑉𝐼𝐼𝑡=0 (IU/dL) 26.9 [17.7, 42.3] 22.0 -18.2 
𝜔 𝐼𝑋𝑡=0 (IU/dL) 25.0 [16.2, 39.1] 24.1 -3.60 
𝜔 𝑋𝑡=0 (IU/dL) 17.5 [12.4, 26.0] 17.3 -1.14 
𝜔 𝑃𝐶𝑡=0 (IU/dL) 17.4 [12.2, 25.8] 17.3 -0.575 
𝜔 𝑃𝑆𝑡=0 (IU/dL) 24.4 [17.8, 35.8] 23.7 -2.87 
CV 𝑘𝑜𝑢𝑡,𝐼𝐼 (%) 41.4 [27.3, 66.7] 45.2 9.18 
CV 𝑘𝑜𝑢𝑡,𝑉𝐼𝐼 (%) 92.6 [54.4, 192.1] 121 30.7 
CV 𝑘𝑜𝑢𝑡,𝐼𝑋 (%) 89.6 [53.6, 182.0] 97.5 8.82 
CV 𝑘𝑜𝑢𝑡,𝑋 (%) 36.3 [24.6, 56.8] 38.8 6.89 
CV 𝑘𝑜𝑢𝑡,𝑃𝐶 (%) 91.2 [53.9, 194.4] 110 20.6 
CV 𝑘𝑜𝑢𝑡,𝑃𝑆 (%) 19.0 (0, 38.7] 31.0 63.2 
𝜎𝑎𝑑𝑑𝐼𝐼 (IU/dL) 7.11 [5.62, 8.56] 5.55 -21.9 
CVprop𝐼𝐼 (%)   3.69 (0, 7.56] 5.48 48.5 
𝜎𝑎𝑑𝑑𝑉𝐼𝐼 (IU/dL) 8.80 [5.34, 12.75] 8.06 -8.41 
CVprop𝑉𝐼𝐼 (%)   15.3 (0, 24.5] 14.6 -4.58 
𝜎𝑎𝑑𝑑𝐼𝑋 (IU/dL) 11.0 [7.1, 14.0] 9.21 -16.3 
CVprop𝐼𝑋 (%)   10.9 [1.5, 17.3] 12.7 16.5 
𝜎𝑎𝑑𝑑𝑋 (IU/dL) 5.41 [4.35, 6.64] 5.23 -3.33 
CVprop𝑋 (%)   5.96 [1.72, 8.93] 6.33 6.21 
𝜎𝑎𝑑𝑑𝑃𝐶 (IU/dL) 3.89 (0, 6.69] 1.20 -69.1 
CVprop𝑃𝐶 (%)   8.58 [2.99, 12.27] 8.96 4.43 
𝜎𝑎𝑑𝑑𝑃𝑆 (IU/dL) 3.33 (0, 5.97] 3.01 -9.61 
CVprop𝑃𝑆 (%)   10.6 [7.5, 13.5] 10.0 -5.66 
𝐿𝐴𝐺  lag. CI confidence interval. CV coefficient of variation. 𝐶𝐿 clearance of warfarin. 𝐼𝐴50,𝐹  warfarin 
amount in the body that gives half the maximum inhibitory effect. 𝑘𝑜𝑢𝑡,𝐹 first-order coagulation protein 
degradation rate constant. 𝜔 standard deviation of between subject variability in parameter. 𝜎𝑎𝑑𝑑 standard 
deviation for the additive error associated with model prediction. 𝐹𝑡=0 coagulation protein concentration at 
baseline.   
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A4.1.2.10. Assumption 10: For each coagulation protein, 𝜀 (𝑛 × 1) are normally 




Equation A 4.1 Normality assumption of error terms. 
 
Implicit to this assumption, (1) error terms have mean zero, (2) error terms 
have common variance 𝜎2 for all individuals and covariate values; and (3) error 
terms are normally distributed. Note that item (2) relates to the iid assumption 
and therefore will be addressed in section A4.1.2.11.    
 
𝐶𝑊𝑅𝐸𝑆~𝑁(0,1) 
Equation A 4.2 Normality assumption of conditional weighted residuals (CWRES). 
 
For each coagulation protein modelled, 𝐶𝑊𝑅𝐸𝑆 (𝑛 × 1) is the conditional 
weighted residuals associated with the first-order conditional estimation 
method implemented by NONMEM® Version 7.2 (ICON Development 
Solutions, Ellicott City, MD, USA). Here, note that 𝐶𝑊𝑅𝐸𝑆  represents a 
composite measure of additive and proportional error terms.  
Internal evaluation of 𝑰 
𝐼 = Significant. Parameter estimations in NONMEM® is reported to be sensitive 
to a misspecification in the residual error model. In particular, the estimation of 
random-effect parameters may be biased [215].            
Internal evaluation of 𝑷 
𝑃 = Unlikely.  The distribution of 𝐶𝑊𝑅𝐸𝑆 was visualised by using the histogram 
and the quantile-quantile (Q-Q) plot. In addition, 𝐶𝑊𝑅𝐸𝑆 was compared to a 
standard normal distribution by using a one-sample Kolmogorov-Smirnov 
goodness-of-fit test. The histogram of 𝐶𝑊𝑅𝐸𝑆 for different coagulation proteins 
is approximately bell-shaped with the greatest 𝐶𝑊𝑅𝐸𝑆  density observed at a 
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value of zero and all the 𝐶𝑊𝑅𝐸𝑆 are contained within boundaries of -4 and +4. 
The distribution of 𝐶𝑊𝑅𝐸𝑆  for factors VII, IX, and X is however slightly 
positively skewed. See Figure A 4.1. From the Q-Q plot, the large majority of the 
𝐶𝑊𝑅𝐸𝑆 quantiles fall on the reference line that corresponds to a standard normal 
distribution. Deviation of a small number of 𝐶𝑊𝑅𝐸𝑆 quantiles from the reference 
line was observed at high standard normal quantiles for factor IX and X. See 
Figure A 4.1. Finally, based on the Kolmogorov-Smirnov test, 𝐶𝑊𝑅𝐸𝑆 for factors 
II (𝑇 = 0.0315, 𝑝 = 0.998), IX (𝑇 = 0.0895, 𝑝 = 0.173), X (𝑇 = 0.0767, 𝑝 = 0.328), 
proteins C (𝑇 = 0.0588, 𝑝 = 0.660), and S (𝑇 = 0.0432, 𝑝 = 0.933) do not have a 
distribution that is significantly different from a standard normal distribution. 
An exception was the 𝐶𝑊𝑅𝐸𝑆 for factor VII (𝑇 = 0.111, 𝑝 = 0.0458). Based on 
these results, the 𝐶𝑊𝑅𝐸𝑆 as a whole are considered to have a standard normal 
distribution. 
Decision 
Decision = Go for model building. Even given the significant impact of violation 
of this assumption the probability of violation is low and hence the risk is 
considered to be negligible.  
 
 
Figure A 4.1 Histogram and Q-Q plot for the CWRES of the joint model. CWRES is the 
conditional weighted residuals, PC is protein C, PS is protein S, and Q-Q plot refers to 
quantile-quantile plot.    
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A4.1.2.11. Assumption 11: For the each coagulation protein, 𝜀 (𝑛 × 1) are iid 
Interpretation 
In modelling repeated measure data, assumption of independence of error terms 
is most typically conditioned on an absence of autocorrelation (serial correlation 
over time) in error terms. Here, it is assumed that error terms are not correlated 
regardless of the temporal proximity of the observations.   
Internal evaluation of 𝑰 
𝐼 = Significant. Based on published literature, if correlation in error terms is 
ignored, the precision of parameter estimates can be overestimated [236, 237] 
and the random-effect parameter estimates (e.g. between subject variability) may 
be upwardly biased [215]. A violation in this assumption may potentially 
mislead statistical inference.     
Internal evaluation of 𝑷 
𝑃 = Likely. In the first instance, autocorrelation in error terms was considered in 
independent model for factors II, VII, IX, X, proteins C, and S, respectively. The 
autocorrelation was modelled using an exponential function:  
 
𝜌 = 𝑒−𝑘𝑐𝑜𝑟𝑟×𝜏. 
Equation A 4.3 Exponential function to describe the autocorrelation in error terms. 
 
𝜌  is the correlation between two error terms, 𝜏  is the distance between time 
points, and 𝑘𝑐𝑜𝑟𝑟 is the rate constant for correlation decay. It is important to note 
that 𝜌 is inversely related to 𝜏. When 𝜏 = 0, 𝜌 = 1 and as 𝜏 approaches infinity, 
asymptotically, 𝜌 = 0. The resulting model fit, which was assessed based on the 
OFV and prediction-corrected visual predictive check (pcVPC), was compared 
to the original model. Modelling autocorrelation in error terms results in a better 
model fit (Δ𝑂𝐹𝑉 > 3.84, 𝑑𝑓 = 1) for all independent models except for protein S. 
𝜌 for the most commonly observed time distance in the dataset, 𝜏 = 24 ℎ, was 
calculated based on the estimated 𝑘𝑐𝑜𝑟𝑟 . Here, the positive autocorrelation in 
error terms appears to be substantial in magnitude (𝜌𝜏=24 > 0.600) (see Table A 
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4.7). However, the pcVPC for models with autocorrelation does not seem to be 
superior over that of the original model without autocorrelation (see Figure A 
4.2).  
        
Table A 4.7 Modelling autocorrelation in error terms in independent model of 
coagulation proteins. kcorr is the correlation decay rate constant, OFV is the objective 
function value, εadd is additive error, εprop is proportional error, and ρ is the correlation 








 (𝒉) 𝝆𝝉=𝟐𝟒 
II 𝜀𝑎𝑑𝑑 -12.3 0.0186 37.3 0.640 
VII 
𝜀𝑝𝑟𝑜𝑝 -57.8 0.00670 103 0.851 
𝜀𝑎𝑑𝑑 -53.0 0.00287 241 0.933 
IX 
𝜀𝑝𝑟𝑜𝑝 -33.2 0.0112 61.9 0.764 
𝜀𝑎𝑑𝑑 -32.1 0.00515 135 0.884 
X 𝜀𝑎𝑑𝑑 -8.61 0.0206 33.6 0.610 
PC 
𝜀𝑝𝑟𝑜𝑝 -34.4 0.0110 63.0 0.768 
𝜀𝑎𝑑𝑑 -27.1 0.00583 119 0.870 
PS 
𝜀𝑝𝑟𝑜𝑝 -0.320 0.0754 9.19 0.164 
𝜀𝑎𝑑𝑑 -5.14 0.000734 944 0.983 
 
 
Figure A 4.2 Prediction-corrected visual predictive check for independent model of factor 
VII without (a) and with (b) autocorrelation in error terms accounted for. The blue circle 
indicates observation. The black line indicates the 10th, 50th (median), or 90th percentile 
of simulated data. The red line indicates the 10th, 50th (median), or 90th percentile of 
observed data. The shaded area indicates the 95% confidence interval around the 
simulated percentiles.   
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Autocorrelation in error terms was also considered in the (joint) reduced model 
that quantifies warfarin influence on all six coagulation proteins simultaneously. 
However, the estimation process was unable to be initiated successfully when 
autocorrelation in error terms was considered for the reduced model. It was 
observed earlier that the estimation run time increase drastically with inclusion 
of each additional coagulation protein even if the autocorrelation structure is 
only included for one single coagulation protein. For the purpose of evaluating 
this assumption, a qualitative approach was used. 𝐶𝑊𝑅𝐸𝑆 time course for the 
(joint) reduced model was plotted. For the majority of patients, 𝐶𝑊𝑅𝐸𝑆 were 
found to be above or below zero in succession for consistent periods of time. This 
is suggestive of the presence of autocorrelation in 𝐶𝑊𝑅𝐸𝑆 (see Figure A 4.3). 
Taken together, these findings suggest that the possibility of autocorrelation in 
error terms cannot be excluded. Hence, 𝑃 was rated as likely.   
Decision 
Decision = No-go for model building. 
Note 
Despite the no-go decision, the autocorrelation was not accounted for in the final 
(joint) model. Despite a reduction in OFV, improvement in model fit is not 
evident in graphical diagnostics. More importantly, with numerical difficulties 
for parameter estimations that result in unacceptably long run time, it is not 
practically possible at this stage to obtain a final model that accounts for 
autocorrelation. It is important that this limitation should be made explicit and 
be appropriately addressed.        
 




Figure A 4.3 Conditional weighted residuals versus time plot for the (joint) reduced model. CWRES is conditional weighted residual, PC is protein 
C, and PS is protein S.   




Figure A 4.3 Continued. 




Figure A 4.3 Continued. 
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A4.2. Evaluation of assumptions underpinning the factor VII-based 
method for the prediction of the anticoagulant response to warfarin 
A4.2.1. List of assumptions 
Chapter 4 describes the development of a factor VII-based sensitivity index 
of the international normalised ratio (INR), 𝑆𝐼𝑉𝐼𝐼 , to predict the anticoagulant 
response to warfarin. The conceptual basis of 𝑆𝐼𝑉𝐼𝐼 to functionally approximate 
the INR and subsequently to provide a theoretical definition of the steady-state 
INR is built on the following key assumptions: 
 Assumption 1: Simultaneous reduction in factors II, VII, and X leads to 
less than additive increases in the INR, 
 Assumption 2: The most deficient coagulation protein drives the INR, 
 Assumption 3: Under non-steady-state INR conditions, factor VII is 
always the most deficient, 
 Assumption 4: Non-steady-state INR is the most sensitive to factor VII, 
 Assumption 5: The quantitative systems pharmacology (QSP) coagulation 
network model [31] is adequate in describing the warfarin-coagulation 
proteins-INR relationship, and 
 Assumption 6: The simulated coagulation proteins-INR time course is 
representative of that of typical patients initiated with warfarin.  
A4.2.2. Evaluation methods and results 
Each of these assumptions was evaluated independently using the 
flowchart developed in Chapter 5. Here, an internal evaluation was conducted 
with the goal of assessing the influence of the aforementioned assumptions on 
the ability of 𝑆𝐼𝑉𝐼𝐼  to approximate the INR. At this stage where model 
development is of primary interest, an external evaluation was not carried out. 
The results of assumption evaluation are summarised in Table A 4.8 using 
the assumption table structure proposed in Chapter 5. Evaluation methods and 
results for each assumption are provided in greater details in the next following 
subsections. To summarise, for all the assumptions, although given the high 𝐼, 
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the 𝑃 is low and hence the risk of assumption violation is considered on the 
whole to be minor. The use of these assumptions does not invalidate the use of 
𝑆𝐼𝑉𝐼𝐼 for determining steady-state INR (𝐼𝑁𝑅𝑆𝑆) after warfarin dosing. 
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Table A 4.8 Methods and results for internal evaluation of assumptions underpinning the factor VII-based method for INR prediction. I is the 
impact of assumption violation, P is the probability of assumption violation, S means significant, and U means unlikely. 
Assumption 
Impact (𝑰) Probability (𝑷) 
Decision 
Methods Results Rating Methods Results Rating 
1. Simultaneous 
reduction in factors II, 
VII, and X leads to 
less than additive 




Logical reasoning.  If the effects of II, VII, and 
X on the INR are additive 
or supra-additive, 
monitoring VII alone to 
inform the INR is unlikely 
to be adequate. 
S Isobologram analysis 
based on simulation 
of II, VII, X, and INR 
from the coagulation 
network model [31] 
was conducted.   
All simulated points 
fall above the 




between II, VII, and X 
on the INR.  
U Go for 
model 
building. 
2. The most deficient 
coagulation protein 
drives the INR 
Logical reasoning. If II, VII, and X all drive the 
INR considerably, 
monitoring VII alone to 
inform the INR is unlikely 
to be adequate.   
S Isobologram analysis 
based on simulation 
of II, VII, X, and INR 
from the coagulation 
network model [31] 
was conducted.   
At INR = 2.5 and INR 
= 4.5, vertical and 
horizontal segments 
were observed on the 
isobolograms. If 
either one of II, VII, 
and X is sufficiently 
deficient, the same 
INR will be resulted 
regardless of the 
concentration of other 
factors. 
U Go for 
model 
building. 




Impact (𝑰) Probability (𝑷) 
Decision 
Methods Results Rating Methods Results Rating 
3. Under non-steady-
state INR conditions, 
factor VII is always 
the most deficient 
A sensitivity analysis was 
conducted. The coagulation 
network model [31] with a 











was used for simulation. Then, 
sensitivity index of INR, 𝑆𝐼𝐼𝐼, 
𝑆𝐼𝑉𝐼𝐼, and 𝑆𝐼𝑋, were derived 
from the simulated data and 
compared to the INR.    
When X replaced VII as 
the most deficient 
coagulation protein, 
𝑆𝐼𝑉𝐼𝐼 fails to 
approximate the INR. 
Instead, 𝑆𝐼𝑋 provides 
the best approximation 











were simulated from 
the published 
warfarin-coagulation 
proteins model [181]. 











tested using the 
Wilcoxon-signed rank 















 (𝑍 = −27.4, 𝑝 <
0.001). At non-
steady-state INR, VII 
is likely to be the 
most deficient.    




INR is the most 
sensitive to factor VII 
A sensitivity analysis was 
conducted. The coagulation 












was used for simulation. Then, 
𝑆𝐼𝐼𝐼, 𝑆𝐼𝑉𝐼𝐼, and 𝑆𝐼𝑋 were 
derived from the simulated 
data and compared to the INR.    
When non-steady-state 
INR is more sensitive 
to X than to VII (i.e. 
𝑆𝐼𝑋 > 𝑆𝐼𝑉𝐼𝐼), INR is 
better approximated by 
𝑆𝐼𝑋 than 𝑆𝐼𝑉𝐼𝐼.   
S II, VII, X, and INR 
were simulated from 
the coagulation 




𝑆𝐼𝑉𝐼𝐼, and 𝑆𝐼𝑋 were 
derived from the 
simulated data. Their 
magnitudes were 
compared.    
It was observed that 
𝑆𝐼𝑉𝐼𝐼 is larger in 
magnitude compared 
to 𝑆𝐼𝐼𝐼 and 𝑆𝐼𝑋 at all 
time points during 
the non-steady-state 
INR. The non-steady-
state INR is the most 
sensitive to VII.   
U Go for 
model 
building. 
5. The coagulation 






Logical reasoning.  It is self-evident that if 
the coagulation 
network model is 
unable to describe the 
warfarin-coagulation 
proteins-INR 
relationship, the 𝑆𝐼𝑉𝐼𝐼 
derived is unlikely to 
be fit for purpose.       
S II, VII, X, and INR 
were simulated from 
the coagulation 
network model [31] 
using typical 
parameters. The 
simulated data were 
compared to external 
data (𝑛 = 17) [167, 
181].  
The simulated data 
agree well with the 
observed data for II, 
VII, X, and INR at the 
individual level.  
U Go for 
model 
building. 
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Assumption 
Impact (𝑰) Probability (𝑷) 
Decision 
Methods Results Rating Methods Results Rating 
6. The simulated 
coagulation proteins-
INR time course is 
representative of that 
of typical patients 
initiated with 
warfarin 
Logical reasoning.  It is self-evident that 
generalisability will be 
limited if the 
simulation results are 
unrepresentative.  
S II, VII, X, and INR 
were simulated from 
the coagulation 
network model [31] 
using typical 
parameters. The 
simulated data were 
compared to external 
data (𝑛 = 17) [167, 
181].  
The simulated data 
agree well with the 
observed data for II, 
VII, X, and INR at the 
individual level. 




Appendix 4: Appendices to Chapter 5 
293  
  
A4.2.2.1. Assumption 1: Simultaneous reduction in factors II, VII, and X leads 
to less than additive increases in the INR 
Interpretation 
 
∆𝐼𝑁𝑅↓𝑖∩↓𝑗 < (∆𝐼𝑁𝑅↓𝑖 + ∆𝐼𝑁𝑅↓𝑗);      𝑖, 𝑗 ∈ {𝐼𝐼, 𝑉𝐼𝐼, 𝑋}, 𝑖 ≠ 𝑗  
Equation A 4.4 The mathematical representation of sub-additive interactions between 
coagulation proteins with respect to the INR. 
 
Here, ∆𝐼𝑁𝑅↓𝑖∩↓𝑗 is the INR response to a simultaneous reduction in two different 
coagulation proteins. ∆𝐼𝑁𝑅↓𝑖  and ∆𝐼𝑁𝑅↓𝑗  represent the INR response to a 
reduction in a single coagulation protein. 
Internal evaluation of 𝑰 
𝐼 = Significant. This was rated based on logical reasoning. If the effects of factors 
II, VII, and X on the INR are additive or supra-additive, contribution of factors II 
and X to the INR will be significant then monitoring of factor VII alone to inform 
the INR is unlikely to be adequate.        
Internal evaluation of 𝑷 
𝑃 = Unlikely. Isobolograms of pairwise combinations of factors II, VII, and X 
with respect to the INR were constructed via simulation from the QSP 
coagulation network model [31]. All points on the same isobologram correspond 
to the same INR (e.g. INR=2.5). Points that fall below the additivity line indicate 
supra-additivity interactions whereas points that are located above the 
additivity line correspond to sub-additive interactions. The isobologram analysis 
indicates that simultaneous reduction in two coagulation proteins leads to less 
than additive increase in the INR (See Figure A 4.4). 
Decision 
Decision = Go for model building. Even given the significant impact of violation 
of this assumption the probability of violation is low and hence the risk is 
considered to be negligible. 
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Figure A 4.4 Isobolograms of pairwise combination of factors II, VII, and X for different 
INRs. The black circles correspond to pairwise combination of factors II, VII, or X that 
gives a predetermined INR. The diagonal solid line is the additivity line. INR is the 
international normalised ratio, RP,combi refers to the reduction in one coagulation protein 
when another coagulation protein is simultaneously reduced and RP the reduction in a 
single coagulation protein. 
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A4.2.2.2. Assumption 2: The most deficient coagulation protein drives the INR 
Interpretation 
Of factors II, VII, and X, the most deficient coagulation protein is the most 
important determinant of the INR. 
Internal evaluation of 𝑰 
𝐼 = Significant. This was rated based on logical reasoning. If factors II, VII, and 
X all drive the INR considerably, monitoring factor VII alone to inform the INR 
is unlikely to be adequate.   
Internal evaluation of 𝑷 
𝑃 = Unlikely. At high INR (e.g. INR=2.5 or INR=4.5), vertical and horizontal 
segments were observed on the isobolograms (see Figure A 4.4). This shows that 
if either one of the factors II, VII, and X is sufficiently deficient, then the same 
INR will occur regardless of the concentration of other coagulation proteins. 
Hence, the most deficient coagulation protein is likely the principal driving force 
behind the INR.    
Decision 
Decision = Go for model building. Even given the significant impact of violation 
of this assumption the probability of violation is low and hence the risk is 
considered to be negligible.  
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A4.2.2.3. Assumption 3: Under non-steady-state INR conditions, factor VII is 
always the most deficient 
Interpretation 
 












)) < 𝛼;      𝛼 = 0.05  
Equation A 4.5 Probability of factor VII having a degradation half-life significantly 





 represents the degradation half-life of factors II, VII, or X and 𝛼 is the 
overall significance level for hypothesis testing. 
Internal evaluation of 𝑰 
𝐼 = Significant. A sensitivity analysis was conducted. Here, the degradation rate 
constant of factor VII, 𝑘𝑜𝑢𝑡,𝑉𝐼𝐼, of the QSP coagulation network model [31] was 






. Then, 𝑆𝐼𝐼𝐼, 𝑆𝐼𝑉𝐼𝐼, and 𝑆𝐼𝑋, respectively, were derived 
from INR and coagulation proteins data simulated from the QSP coagulation 





| ;      𝑃 ∈ {𝐼𝐼, 𝑉𝐼𝐼, 𝑋}.  
Equation A 4.6 Local sensitivity of INR to changes in coagulation protein 
concentration. 
 
𝑆𝐼𝐼𝐼, 𝑆𝐼𝑉𝐼𝐼, and 𝑆𝐼𝑋 versus time were plotted and qualitatively compared to the 
INR versus time plot (see right-hand column of Figure A 4.5). When factor X 
replaced factor VII as the most deficient factor during the non-steady-state INR, 
the time course of 𝑆𝐼𝑉𝐼𝐼 no longer bears similarity to that of the INR. Instead, the 
time course of 𝑆𝐼𝑋 appears similar to that of the INR. It appears that what matters 
is that the 𝑆𝐼𝑃 for the coagulation protein with the shortest degradation half-life 
is used for prediction as it provides the best approximation to the INR.   




Figure A 4.5 The simulated time course of INR (panel a and b), and factors II, VII, and 
X (panel c and d), and SIII, SIVII, and SIX (panel e and f) following initiation of 4mg 
warfarin daily. The two columns of plots differ with respect to the t1/2,VII used for 
simulations. The left-hand column corresponds to t1/2,VII = 6 hours and the right-hand 
column refers to a hypothetical t1/2,VII = 80 hours. INR is the international normalised 
ratio, SIP is the sensitivity index of INR to a specific coagulation protein and t1/2,P the 
degradation half-life of a particular coagulation protein. 
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Internal evaluation of 𝑷 









 for 1000 individuals were simulated using 
relevant parameters (e.g. the 𝑘𝑜𝑢𝑡,𝐼𝐼 , 𝑘𝑜𝑢𝑡,𝑉𝐼𝐼 , 𝑘𝑜𝑢𝑡,𝑋  and the corresponding 
variance-covariance matrix of between subject variability in parameters) from 
the joint model for warfarin and coagulation proteins [181]. An overarching 




















Equation A 4.7 Hypotheses of the rank order of t1/2,VII  versus t1/2,II, and t1/2,X. 
 
Here, 𝐻0 is the null hypothesis and 𝐻𝐴 is the alternative hypothesis. Independent 












 were required. Each of these 
hypotheses was tested using a Wilcoxon-signed rank test at 𝛼 = 0.025  (one-






)  was found centred at 
median -35.0 (IQR -39.9, -30.8) hours. 𝑡1
2
,𝑉𝐼𝐼














 is significantly lower than 𝑡1
2
,𝐼𝐼
 (𝑍 = −27.4, 𝑝 < 0.001). Taken 
together, these results provide sufficient evidence to reject the 𝐻0. 
Decision 
Decision = Go for model building. Even given the significant impact of violation 
of this assumption the probability of violation is low and hence the risk is 
considered to be negligible.  
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A4.2.2.4. Assumption 4: Non-steady-state INR is the most sensitive to factor VII 
Interpretation 
𝑆𝐼𝑉𝐼𝐼  is greater in magnitude compared to both 𝑆𝐼𝐼𝐼  and 𝑆𝐼𝑋  at all time points 
during the non-steady-state INR. 
Internal evaluation of 𝑰 
𝐼 = Significant. A sensitivity analysis was conducted. Here, 𝑘𝑜𝑢𝑡,𝑉𝐼𝐼 of the QSP 






. Factors II, VII, 
X, and INR were simulated. 𝑆𝐼𝐼𝐼, 𝑆𝐼𝑉𝐼𝐼, and 𝑆𝐼𝑋 were derived from the simulated 
data. From the right column of Figure A 4.5, INR appears to be more sensitive to 
factor X than factor VII (i.e. 𝑆𝐼𝑋 > 𝑆𝐼𝑉𝐼𝐼) during the non-steady-state INR. Here, 
the time course of 𝑆𝐼𝑉𝐼𝐼 no longer bears similarity to that of the INR. Instead, the 
time course of 𝑆𝐼𝑋 mimics that of the INR.  
Internal evaluation of 𝑷 
𝑃 = Unlikely. Factors II, VII, X, and INR were simulated from the coagulation 
network model [31] using parameters for a typical individuals. Subsequently, 
𝑆𝐼𝐼𝐼, 𝑆𝐼𝑉𝐼𝐼, and 𝑆𝐼𝑋 were derived from the simulated data. From the left column 
of Figure A 4.5, it was observed that 𝑆𝐼𝑉𝐼𝐼 is larger in magnitude compared to 𝑆𝐼𝐼𝐼 
and 𝑆𝐼𝑋 at all time points during the non-steady-state INR. It is likely that the 
non-steady-state INR is the most sensitive to factor VII.   
Decision 
Decision = Go for model building. Even given the significant impact of violation 
of this assumption the probability of violation is low and hence the risk is 
considered to be negligible.  
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A4.2.2.5. Assumption 5: The QSP coagulation network model is adequate in 
describing the warfarin-coagulation proteins-INR relationship 
Interpretation 
The QSP coagulation network model is able to produce physiologically-sound 
simulated profiles for factors II, VII, X, and INR following warfarin initiation. 
Internal evaluation of 𝑰 
𝐼 = Significant. This was rated based on logical reasoning. It is self-evident that 
if the QSP model is unable to accurately describe the warfarin-coagulation 
proteins-INR relationship, the 𝑆𝐼𝑉𝐼𝐼 derived is unlikely to be fit for the intended 
purpose.  
Internal evaluation of 𝑷 
𝑃 =  Unlikely. Factors II, VII, X, and INR were simulated from the QSP 
coagulation network model [31]. The simulated data were compared to external 
data (𝑛 = 17) [167, 181]. Individual observed and simulated data versus time 
were plotted. It is however, not possible to validate the QSP model and hence it 
is not possible to fully test this assumption across the whole range of INR 
generating pathways. The simulated data agree reasonably well with the 
observed data for factors II, VII, X, and INR at the individual level. See Figure A 
4.6 for plots of five representative individuals. 
Decision 
Decision = Go for model building. Even given the significant impact of violation 
of this assumption the probability of violation is low and hence the risk is 
considered to be negligible.  
 




Figure A 4.6 Individual fits for the time course of factors II, VII, X, and INR for five 
representative individuals following warfarin initiation. The black solid lines are 
prediction by the coagulation network model. The grey open circles are observations from 
the external test dataset [167, 181]. INR refers to the international normalised ratio and 
nM stands for nanomolar.  
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A4.2.2.6. Assumption 6: The simulated coagulation proteins-INR time course is 
representative of that of typical patients initiated with warfarin 
Interpretation 
The simulated profiles for factors II, VII, X, and INR are representative of the 
majority of patients initiated with warfarin. 
Internal evaluation of 𝑰 
𝐼 = Significant. This was rated based on logical reasoning. It is self-evident that 
generalisability will be limited if the simulation results are unrepresentative.   
Internal evaluation of 𝑷 
𝑃 =  Unlikely. Factors II, VII, X, and INR were simulated from the QSP 
coagulation network model [31]. The simulated data were compared to external 
data (𝑛 = 17) [167, 181]. Individual observed and simulated data versus time 
were plotted. The data simulated from the QSP coagulation network model 
agree reasonably well with the observed data for factors II, VII, X, and INR at the 
individual level. See Figure A 4.6 above for plots of five representative 
individuals.  
Decision 
Decision = Go for model building. Even given the significant impact of violation 
of this assumption the probability of violation is low and hence the risk is 
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